(CONTINUED SEARCH)

STN SEARCH TRANSCRIPT

10/508,894

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623zct

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
NEWS  1          Web Page for STN Seminar Schedule - N. America
NEWS  2  MAR 15  WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS  3  MAR 16  CASREACT coverage extended
NEWS  4  MAR 20  MARPAT now updated daily
NEWS  5  MAR 22  LWPI reloaded
NEWS  6  MAR 30  RDISCLOSURE reloaded with enhancements
NEWS  7  APR 02  JICST-EPLUS removed from database clusters and STN
NEWS  8  APR 30  GENBANK reloaded and enhanced with Genome Project ID field
NEWS  9  APR 30  CHEMCATS enhanced with 1.2 million new records
NEWS 10  APR 30  CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 11  APR 30  INPADOC replaced by INPADOCDB on STN
NEWS 12  MAY 01  New CAS web site launched
NEWS 13  MAY 08  CA/CAplus Indian patent publication number format defined
NEWS 14  MAY 14  RDISCLOSURE on STN Easy enhanced with new search and display
                 fields
NEWS 15  MAY 21  BIOSIS reloaded and enhanced with archival data
NEWS 16  MAY 21  TOXCENTER enhanced with BIOSIS reload
NEWS 17  MAY 21  CA/CAplus enhanced with additional kind codes for German
                 patents
NEWS 18  MAY 22  CA/CAplus enhanced with IPC reclassification in Japanese
                 patents
NEWS 19  JUN 27  CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20  JUN 29  STN Viewer now available
NEWS 21  JUN 29  STN Express, Version 8.2, now available
NEWS 22  JUL 02  LEMBASE coverage updated
NEWS 23  JUL 02  LMEDLINE coverage updated
NEWS 24  JUL 02  SCISEARCH enhanced with complete author names
NEWS 25  JUL 02  CHEMCATS accession numbers revised
NEWS 26  JUL 02  CA/CAplus enhanced with utility model patents from China

NEWS EXPRESS  29 JUNE 2007:  CURRENT WINDOWS VERSION IS V8.2,
              CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS LOGIN    Welcome Banner and News Items
NEWS IPC8     For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

```
FILE 'HOME' ENTERED AT 14:45:30 ON 10 JUL 2007

=> FILE REG
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY      SESSION
FULL ESTIMATED COST                            0.21         0.21

FILE 'REGISTRY' ENTERED AT 14:45:39 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     9 JUL 2007  HIGHEST RN 941818-42-4
DICTIONARY FILE UPDATES:    9 JUL 2007  HIGHEST RN 941818-42-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\LXR  AGONISTS.str
```

```
chain nodes :
7  8  11  12  13  14  16  17  18  19  20  21  24
ring nodes :
1  2  3  4  5  6
chain bonds :
7-11  11-12  12-13  13-14  14-20  14-21  16-19  16-17  16-18  16-21  20-24
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
14-20  14-21  16-19  16-17  16-18  20-24

exact bonds :
7-11  11-12  12-13  13-14  16-21
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :

G1:Cy,Ak

G2:C,H,O,N

G3:C,H,O,S,N,X

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:Atom  10:Atom
11:CLASS  12:CLASS  13:CLASS  14:CLASS  16:CLASS  17:CLASS  18:CLASS  19:CLASS
20:CLASS  21:CLASS  24:Atom


L1      STRUCTURE UPLOADED

=> D L12
L12 NOT FOUND
The L-number entered has not been defined in this session, or it
has been deleted.  To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> D L1
L1 HAS NO ANSWERS
L1                STR
```




```
G1
G2 C,O,S,N
G3 C,N


Structure attributes must be viewed using STN Express query preparation.


=> S L1
SAMPLE SEARCH INITIATED 14:46:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    277322 TO ITERATE

  0.7% PROCESSED      2000 ITERATIONS                          1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **INCOMPLETE**
                        BATCH    **INCOMPLETE**
PROJECTED ITERATIONS:      5515813 TO  5577067
PROJECTED ANSWERS:            2067 TO     3479

L2             1 SEA SSS SAM L1

=>
=>
Uploading C:\Program Files\Stnexp\Queries\LXR  AGONISTS 2.str
```



```
chain nodes :
7  8  11  12  13  14  16  17  18  19  20  21  24
ring nodes :
1  2  3  4  5  6
chain bonds :
7-11  11-12  12-13  13-14  14-20  14-21  16-19  16-17  16-18  16-21  20-24
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
7-11  13-14  14-20  14-21  20-24
exact bonds :
11-12  12-13  16-19  16-17  16-18  16-21
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:Atom  10:Atom
11:CLASS  12:CLASS  13:CLASS  14:CLASS  16:CLASS  17:CLASS  18:CLASS  19:CLASS
20:CLASS  21:CLASS  24:Atom


L3      STRUCTURE UPLOADED

=> D L3
L3 HAS NO ANSWERS
L3                STR
```



Structure attributes must be viewed using STN Express query preparation.

=> S L3
SAMPLE SEARCH INITIATED 15:04:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 299 TO ITERATE

100.0% PROCESSED 299 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4943 TO 7017
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> S L3 SSS FULL
FULL SEARCH INITIATED 15:04:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6196 TO ITERATE

100.0% PROCESSED 6196 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L5 0 SEA SSS FUL L3

=>
Uploading C:\Program Files\Stnexp\Queries\LXR AGONISTS 2.str



chain nodes :
7 8 11 12 13 14 16 17 18 19 20 21 24
ring nodes :
1 2 3 4 5 6
chain bonds :
7-11 11-12 12-13 13-14 14-20 14-21 16-19 16-17 16-18 16-21 20-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-11 13-14 14-20 14-21 20-24
exact bonds :
11-12 12-13 16-19 16-17 16-18 16-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 24:Atom

L6 STRUCTURE UPLOADED

=> D L6
L6 HAS NO ANSWERS
L6 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L6
SAMPLE SEARCH INITIATED 15:06:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2868 TO ITERATE

69.7% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 54148 TO 60572
PROJECTED ANSWERS: 2 TO 158

L7 2 SEA SSS SAM L6

=> S L6 SSS FULL
FULL SEARCH INITIATED 15:06:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 55702 TO ITERATE

100.0% PROCESSED 55702 ITERATIONS 35 ANSWERS
SEARCH TIME: 00.00.01

L8 35 SEA SSS FUL L6

=> FILE CAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY 359.05 TOTAL SESSION 359.26

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:06:55 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 10 Jul 2007 VOL 147 ISS 3
FILE LAST UPDATED: 9 Jul 2007 (20070709/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L8
L9 10 L8

=> D 1-10 IBIB ABS HITSTR

L9 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:383697 CAPLUS
DOCUMENT NUMBER: 144:432552
TITLE: Preparation of substituted anilines as selective androgen receptor modulators
INVENTOR(S): Turnbull, Philip Stewart; Larkin, Andrew Lamont; Kaldor, Istvan; Cadilla, Rodolfo; Cowan, David John; Stewart, Eugene Lee
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044707	A1	20060427	WO 2005-US37094	20051013

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-618480P P 20041013
OTHER SOURCE(S): CASREACT 144:432552; MARPAT 144:432552
GI



I



II

AB This invention relates to non-steroidal compds. I [R1 = CN or NO2; R2 = independently CN, NO2, halo, etc.; R3 = H, (cyclo)alkyl, alkoxycarbonylalkyl, etc.; R4, R5 = independently H, (cyclo)alkyl, halo, etc., or R4R5 = (un)substituted (hetero)cyclyl; Y = (un)substituted methylene(oxy), methylenethio, carbonylamino, etc.; A = (hetero)aryl or heterocyclyl; m = 0-2; n = 0-5; R6 = independently (halo)alkyl, halo, hydroxy, etc.] which are or are believed to be modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compds. For example, II was provided in a multi-step synthesis starting from the reaction of 4-fluoro-2-(trifluoromethyl)benzonitrile with 1-cyclopropylmethanamine. The compds. I are claimed to be useful in the treatment or prophylaxis of conditions or disorders that respond to selective androgen receptor modulation (no data given).

IT 884854-39-1P, 4-[[3-[[4-(1,1-Dimethylethyl)phenyl]oxy]propyl](2,2-dimethylpropyl)amino]-2-(trifluoromethyl)benzonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted aniline derivs. as selective androgen receptor modulators)

RN 884854-39-1 CAPLUS
CN Benzonitrile, 4-[[3-[4-(1,1-dimethylethyl)phenoxy]propyl](2,2-dimethylpropyl)amino]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:99988 CAPLUS
DOCUMENT NUMBER: 144:192493

TITLE: Preparation of N-(benzoylphenyl)tyrosine derivatives as PPARγ modulators

INVENTOR(S): Serra Comas, Carmen; Fernandez Serrat, Anna; Balsa Lopez, Dolors; Masip Masip, Isabel; Catena Ruiz, Juan Lorenzo; Hidalgo Rodriguez, Jose; Lagunas Arnal, Carmen; Salcedo Roca, Carolina; Fernandez Garcia, Andres

PATENT ASSIGNEE(S): Laboratorios S.A.L.V.A.T., S.A., Spain

SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006010775	A1	20060202	WO 2005-EP53728	20050729
WO 2006010775	A8	20060615		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005266337	A1	20060202	AU 2005-266337	20050729
CA 2574021	A1	20060202	CA 2005-2574021	20050729
EP 1778624	A1	20070502	EP 2005-778004	20050729
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: ES 2004-1966 A 20040730
WO 2005-EP53728 W 20050729

OTHER SOURCE(S): MARPAT 144:192493

GI



AB The invention relates to tyrosine derivs. I [R is (CH2)2-3N(X-R1)-A-J-T, where X is null or CO; R1 is alkyl, haloalkyl, alkoxyalkyl, alkenyl, alkynyl, alk(en)(yn)ylene-Y (Y is a ring); A is alk(en)(yn)ylene or alk(en)(yn)ylene-Z (Z is a ring); J is a bond, (CH2)1-4, O, S, SO2, CO, etc.; T is H, alk(en)(yn)yl or Y], including stereoisomers and pharmaceutically-acceptable salts, which are PPARγ modulators and therefore are useful for the treatment or prevention of a condition or disease mediated by these receptors. Thus, (S)-2-(2-benzoylphenylamino)-3-[4-[3-[benzyl(3-phenylpropynoyl)amino]ethoxy]phenyl]propionic acid was prepared and Ki < 500 nM in the PPARγ affinity assay.

IT 875402-79-2P 875403-27-3P 875403-45-5P

RN 875403-89-7 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)(4-methylphenyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 875404-81-2 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 875406-09-0 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)phenylamino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 875407-42-4 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)(2-fluorophenyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

875403-89-7P 875404-81-2P 875406-09-0P
875407-42-4P 875407-44-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(benzoylphenyl)tyrosine derivs. as PPARγ modulators)

RN 875402-79-2 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)(2-methylphenyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 875403-27-3 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)[(3-methylphenyl)methyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 875403-45-5 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)(3-methylphenyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 875407-44-6 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)(3-fluorophenyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 875409-60-2P 875410-07-4P 875410-24-5P
875410-67-6P 875411-58-8P 875412-86-5P
875413-47-1P 875413-49-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(benzoylphenyl)tyrosine derivs. as PPARγ modulators)

RN 875409-60-2 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)(2-methylphenyl)amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 875410-07-4 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)[(3-methylphenyl)methyl]amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 875410-24-5 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)(3-methylphenyl)amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 875410-67-6 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)(4-methylphenyl)amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 875411-58-8 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)(phenylmethyl)amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:823574 CAPLUS
DOCUMENT NUMBER: 143:222476
TITLE: 4,4'-Bipiperidine derivative inhibitors of HER2 expression, and therapeutic use
INVENTOR(S): Uesugi, Motonari; Asada, Shinichi
PATENT ASSIGNEE(S): Baylor College of Medicine, USA
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005074933	A1	20050818	WO 2005-US3349	20050128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005283007	A1	20051222	US 2004-770303	20040202
PRIORITY APPLN. INFO.:			US 2004-770303	A 20040202
			US 2002-380481P	P 20020514
			US 2003-405387	A2 20030402

OTHER SOURCE(S): MARPAT 143:222476
GI

AB Peptide mimetic small mol. inhibitors of Sur-2 are provided. Compds. of the invention include I (R1 = indole, alkyl, cycloalkyl, etc.; R2 = H, OH, halo, etc.; R3 = halo, aryl, aralkyl, etc.; R4 = adamantane, alkyl, alkenyl, etc.). Compds. of the invention may be used to treat cancer,



RN 875412-86-5 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)phenylamino]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 875413-47-1 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)(2-fluorophenyl)amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 875413-49-3 CAPLUS
CN L-Tyrosine, N-(2-benzoylphenyl)-O-[3-[(2,2-dimethyl-1-oxopropyl)(3-fluorophenyl)amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

e.g. breast cancer. Compound preparation is included.
IT 862464-22-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bipiperidine derivative inhibitors of HER2 expression, and therapeutic use)
RN 862464-22-0 CAPLUS
CN [4,4'-Bipiperidine]-1-carboxamide, N-[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]-N-(1,1-dimethylethyl)-1'-(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1982:142884 CAPLUS
DOCUMENT NUMBER: 96:142884
TITLE: Etherified hydroxyquinazolone compounds
INVENTOR(S): Jaeggi, Knut A.; Ostermayer, Franz; Schroeter, Herbert
PATENT ASSIGNEE(S): Ciba-Geigy Corp., USA
SOURCE: U.S., 16 pp. Cont.-in-part of U.S. 4,140,789.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4310527	A	19820112	US 1979-18397	19790308
CH 624395	A5	19810731	CH 1976-161	19760108
US 4140789	A	19790220	US 1976-751233	19761216
CS 201041	B2	19801031	CS 1979-1289	19790226
CS 201042	B2	19801031	CS 1979-1290	19790226
CS 201043	B2	19801031	CS 1979-1291	19790226
AT 7901944	A	19790715	AT 1979-1944	19790315
AT 355038	B	19800211		
AT 7901945	A	19790715	AT 1979-1945	19790315
AT 355039	B	19800211		
AT 7901946	A	19790715	AT 1979-1946	19790315
AT 355040	B	19800211		
PRIORITY APPLN. INFO.:			CH 1976-161	A 19760108
			US 1976-751233	A2 19761216
			AT 1977-46	A 19770107
			CS 1977-117	19770107

OTHER SOURCE(S): MARPAT 96:142884
GI



I

AB Quinazolones I [X = O, H2; R = (un)substituted alkyl; R1 = H, acyl] were prepared for use as sympatholytics, cardiac stimulants, and antihypertensives (no data). Thus, I (X = H2, R = CMe3, R1 = H) was prepared from m-(O2N)2C6H4 in 7 steps via 3,2-H2N(H2NCH2)C6H3OCH2CH(OH)CH2NHCMe3.

IT 64208-58-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)

RN 64208-58-8 CAPLUS

CN Benzamide, 2-[(aminocarbonyl)amino]-6-[3-[(1,1-dimethylethyl)(phenylmethyl)amino]-2-hydroxypropoxy]- (9CI) (CA INDEX NAME)



IT 64208-48-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)

RN 64208-48-6 CAPLUS

CN Benzonitrile, 2-[3-[(1,1-dimethylethyl)(phenylmethyl)amino]-2-hydroxypropoxy]-6-nitro- (9CI) (CA INDEX NAME)



IT 64208-50-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with chloroformate)

RN 64208-50-0 CAPLUS

CN 2-Propanol, 1-[3-amino-2-(aminomethyl)phenoxy]-3-[(1,1-dimethylethyl)(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



IT 64208-49-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 64208-49-7 CAPLUS

CN Benzamide, 2-amino-6-[3-[(1,1-dimethylethyl)(phenylmethyl)amino]-2-hydroxypropoxy]- (9CI) (CA INDEX NAME)



IT 64208-50-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 64208-50-0 CAPLUS

CN 2-Propanol, 1-[3-amino-2-(aminomethyl)phenoxy]-3-[(1,1-dimethylethyl)(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L9 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1977:552206 CAPLUS

DOCUMENT NUMBER: 87:152206

TITLE: Etherified hydroxybenzo diheterocyclics

INVENTOR(S): Jaeggi, Knut A.; Ostermayer, Franz; Schroeter, Herbert

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Ger. Offen., 79 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2700193	A1	19770714	DE 1977-2700193	19770104
CH 624395	A5	19810731	CH 1976-161	19760108
GB 1549945	A	19790808	GB 1976-53633	19761222
SE 7700056	A	19770709	SE 1977-56	19770104
FI 7700036	A	19770709	FI 1977-36	19770106
FR 2337718	A1	19770805	FR 1977-232	19770106
FR 2337718	B1	19801107		
AU 7721105	A	19780713	AU 1977-21105	19770106
AU 507884	B2	19800228		
PL 110654	B1	19800731	PL 1977-195154	19770106
CA 1083150	A1	19800805	CA 1977-269205	19770106
PL 112491	B1	19801031	PL 1977-214708	19770106
PL 112441	B1	19801031	PL 1977-214709	19770106
PL 112442	B1	19801031	PL 1977-214710	19770106
IL 51222	A	19801231	IL 1977-51222	19770106
BE 850166	A1	19770707	BE 1977-173895	19770107
DK 7700061	A	19770709	DK 1977-61	19770107
NO 7700061	A	19770711	NO 1977-61	19770107
NL 7700141	A	19770712	NL 1977-141	19770107
SU 648091	A3	19790215	SU 1977-2435952	19770107
AT 7700046	A	19790815	AT 1977-46	19770107
AT 355564	B	19800310		
CS 201040	B2	19801031	CS 1977-117	19770107
JP 52085166	A	19770715	JP 1977-559	19770108
SU 645568	A3	19790130	SU 1977-2526202	19770929
SU 648092	A3	19790215	SU 1977-2525452	19770929
SU 651695	A3	19790305	SU 1977-2525901	19770929
CS 201041	B2	19801031	CS 1979-1289	19790226
CS 201042	B2	19801031	CS 1979-1290	19790226
CS 201043	B2	19801031	CS 1979-1291	19790226
AT 7901944	A	19790715	AT 1979-1944	19790315
AT 355038	B	19800211		
AT 7901945	A	19790715	AT 1979-1945	19790315
AT 355039	B	19800211		
AT 7901946	A	19790715	AT 1979-1946	19790315
AT 355040	B	19800211		

PRIORITY APPLN. INFO.:

CH 1976-161	A	19760108
AT 1977-46	A	19770107
CS 1977-117		19770107

OTHER SOURCE(S): CASREACT 87:152206

GI



I

AB Antiarrhythmic, cardiac stimulant, antihypertensive, and β-sympatholytic (no data) propanolamine derivs. I (R = CMe3, CHMe2, CHMeCH2Ph, 3,4-(MeO)2C6H3CH2CH2, methylenedioxyphenethyl; X = NH, OCH2, CH2NH, CONH, O, CH2O, NBu, NMe, NHCO) were prepared Thus 2,3-(MeO2C)2C6H3OH was treated with BrCH2CH:CH2, 2,3-(MeO2C)2C6H3OCH2CH:CH2 hydrolyzed, 2,3-(HO2C)2C6H3OCH2CH:CH2 converted to the anhydride and treated with Me3SiN3 to give 4-allyloxy-2-benzimidazolone, which was epoxidized and treated with Me3CNH2 to give I (R = CMe3, X = NH).

IT 64208-58-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)

RN 64208-58-8 CAPLUS

CN Benzamide, 2-[(aminocarbonyl)amino]-6-[3-[(1,1-dimethylethyl)(phenylmethyl)amino]-2-hydroxypropoxy]- (9CI) (CA INDEX NAME)



IT 64208-50-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of, with chloroformate)

RN 64208-50-0 CAPLUS

CN 2-Propanol, 1-[3-amino-2-(aminomethyl)phenoxy]-3-[(1,1-dimethylethyl)(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



IT 64208-48-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenolysis of)

RN 64208-48-6 CAPLUS

CN Benzonitrile, 2-[3-[(1,1-dimethylethyl)(phenylmethyl)amino]-2-hydroxypropoxy]-6-nitro- (9CI) (CA INDEX NAME)



IT 64208-49-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 64208-49-7 CAPLUS

CN Benzamide, 2-amino-6-[3-[(1,1-dimethylethyl)(phenylmethyl)amino]-2-hydroxypropoxy]- (9CI) (CA INDEX NAME)



IT 64208-28-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 64208-28-2 CAPLUS
CN 2-Propanol, 1-[3-amino-2-(aminomethyl)phenoxy]-3-[(1,1-dimethylethyl)(phenylmethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

L9 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1977:467965 CAPLUS
DOCUMENT NUMBER: 87:67965
TITLE: Amino alcohols and their acid adducts
INVENTOR(S): Suzuki, Yasuji; Tsukamoto, Kunio; Izumi, Akihiro; Hiramatsu, Yoshiro
PATENT ASSIGNEE(S): Teikoku Hormone Mfg. Co., Ltd., Japan
SOURCE: Jpn. Tokkyo Koho, 13 pp.
CODEN: JAXKAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 51041623	B	19761111	JP 1968-58272	19680817
PRIORITY APPLN. INFO.:			JP 1968-58272	19680817

GI



AB 2-Propanol derivs. I (R-R4 = C1-4 alkyl) and acid addition salts, useful as antiarrhythmic and β-adrenolytic agents, were prepared Thus, 5.34 g epoxide II was treated with 6 g Me3CNH2 at 80° for 5 h to give 5 g I (R-R4 = Me) (III), which showed β-adrenolytic activity 1.2 times that of propranolol in guinea pigs and 88.8% inhibition of arrhythmia in rats, compared to 41.5% inhibition with propranolol. Similarly prepared were III.HCl, III N-benzyl derivative and its HCl salt.

IT 62834-47-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debenzylation of)
RN 62834-47-3 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)(phenylmethyl)amino]-3-(2,3-dimethylphenoxy)- (9CI) (CA INDEX NAME)



IT 62834-48-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 62834-48-4 CAPLUS
CN 2-Propanol, 1-[(1,1-dimethylethyl)(phenylmethyl)amino]-3-(2,3-dimethylphenoxy)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1976:135479 CAPLUS
DOCUMENT NUMBER: 84:135479
TITLE: Cyclic substituted derivatives of 1-amino-2-propanol
INVENTOR(S): Jaeggi, Knut; Ostermayer, Franz; Schroeter, Herbert
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Ger. Offen., 131 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2520910	A1	19751204	DE 1975-2520910	19750510
CH 591448	A5	19770915	CH 1974-6582	19740514
CH 594626	A5	19780113	CH 1974-6618	19740514
SE 7504375	A	19751117	SE 1975-4375	19750416
NL 7504864	A	19751118	NL 1975-4864	19750424
GB 1493006	A	19771123	GB 1975-18491	19750502
US 4027027	A	19770531	US 1975-574785	19750505
FR 2270863	A1	19751212	FR 1975-14655	19750512
FR 2270863	B1	19790518		
AU 7581045	A	19761118	AU 1975-81045	19750512
CA 1067077	A1	19791127	CA 1975-226694	19750512
BE 828989	A1	19751113	BE 1975-156276	19750513
DK 7502098	A	19751115	DK 1975-2098	19750513
HU 172769	B	19781228	HU 1975-CI1575	19750513
JP 50154213	A	19751212	JP 1975-56214	19750514
CH 596182	A5	19780315	CH 1977-1454	19770207
US 4139623	A	19790213	US 1977-777222	19770314
PRIORITY APPLN. INFO.:			CH 1974-6582 A	19740514
			CH 1974-6618 A	19740514
			US 1975-574785 A3	19750505

OTHER SOURCE(S): MARPAT 84:135479
AB Twenty-eight title compds. RO2NHCH2CH(OH)CH2OR1 [I; R = Ph, substituted phenyl, or substituted or unsubstituted pyridyl, pyrimidinyl or pyrazinyl; R1 has same significance as R, but when R = Ph or substituted phenyl, R1 = heterocycloyl, and vice versa; Q = (CH2)2, (CH2)3, CH2CHMe, or CH2CMe2) and/or their hydrochloride or fumarate salts were prepared; I arrested isoprotenol-induced tachycardia in isolated dog hearts and lowered blood pressure in cats and rats. Thus, (PhCH2)2NCH2CH2OH with 6-chloronicotinamide gave 6-[2-(dibenzylamino)ethyl]nicotinamide, which was partially debenzylated, reacted with 1,2-epoxy-3-(o-tolyloxy)propane, then further debenzylated by hydrogenation to give I [R = 5-carbamoyl-2-pyridyl, R1 = 2-MeC6H4, Q = (CH2)2].

IT 58756-83-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debenzylation of)
RN 58756-83-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-[[2-hydroxy-3-(2-methylphenoxy)propyl](phenylmethyl)amino]-2-methylpropoxy]- (9CI) (CA INDEX NAME)



L9 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1976:4702 CAPLUS
DOCUMENT NUMBER: 84:4702
TITLE: Phenoxypropylamine derivatives
INVENTOR(S): Zoelss, Gerhard; Pittner, Heribert; Stormann-Menninger-Lerchenthal, Heimo
PATENT ASSIGNEE(S): Lentia G.m.b.H. Chem. und Pharm. Erzeugnisse-Industriebedarf, Ped. Rep. Ger.
SOURCE: Ger. Offen., 36 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2458624	A1	19750703	DE 1974-2458624	19741211
DE 2458624	C3	19790920		
DE 2458624	B2	19790125		
AT 334385	B	19760110	AT 1973-10666	19731220
AT 7310666	A	19760515		
AT 7409266	A	19760715	AT 1974-9266	19741119
AT 335464	B	19770310		
AT 7409308	A	19760715	AT 1974-9308	19741120
AT 335465	B	19770310		
AT 7409436	A	19760715	AT 1974-9436	19741125
AT 335467	B	19770310		
CH 615905	A5	19800229	CH 1975-13311	19751014
CH 615906	A5	19800229	CH 1975-13312	19751014
CH 617181	A5	19800514	CH 1975-13310	19751014
CS 181691	B2	19780331	CS 1975-7350	19751031
CS 181692	B2	19780331	CS 1975-7351	19751031
CS 183825	B2	19780731	CS 1975-7564	19751110
RO 72482	A1	19811104	RO 1975-83862	19751110
RO 70441	A1	19810130	RO 1975-83870	19751111
CA 1061341	A1	19790828	CA 1975-239398	19751112
CA 1061342	A1	19790828	CA 1975-239428	19751112
RO 72484	A1	19811124	RO 1975-83898	19751112
CA 1044236	A1	19781212	CA 1975-239750	19751113
DD 123320	A1	19761212	DD 1975-189501	19751117
PL 96050	B1	19771231	PL 1975-184783	19751117
SU 603333	A3	19780415	SU 1975-2189624	19751117
DD 122082	A1	19760912	DD 1975-189535	19751118
ES 442747	A1	19770416	ES 1975-442747	19751118
PL 96643	B1	19780131	PL 1975-184809	19751118
SU 613715	A3	19780630	SU 1975-2189816	19751118
JP 51125247	A	19761101	JP 1975-138273	19751119
JP 54009194	B	19790421		
ES 442813	A1	19770416	ES 1975-442813	19751119
JP 54009195	B	19790421	JP 1975-138274	19751119
DD 122081	A1	19760912	DD 1975-189614	19751121
JP 53012508	B	19780501	JP 1975-139371	19751121
PL 96061	B1	19771231	PL 1975-184945	19751122
ES 442895	A1	19770416	ES 1975-442895	19751124
PRIORITY APPLN. INFO.:			AT 1973-10666 A	19731220
			AT 1974-9266 A	19741119
			AT 1974-9308 A	19741120
			AT 1974-9436 A	19741125

AB Forty-two RR1NCONHC6H3(COR2)OCH2CH(OH)CH2NHR3-3,4 [I; R = H or C1-10 alkyl; R1 = H, C1-10 alkyl, cyclopentyl, cyclohexyl, Ph, or PhCH2 (or RR1N = a 4 to 7-membered heterocyclic ring); R2 = C1-6 alkyl, Ph, or PhCH2; R3 = branched C3-6 alkyl, cyanoalkyl, or C3-7 cycloalkyl] and/or their fumarate salts, useful as β-sympatholytics (no data), were prepared Thus, 1.0 g 4,3-(ClCH2CH(OH)CH2O](MeCO)C6H3NHCONEt2 treated with 8 ml Me3CNH2 and 8 ml H2O 17 hr at room temperature gave, after working up, 1.0 g (90.4% of theor.) I (R = R1 = Et, R2 = Me, R3 = Me3C).

IT 57470-86-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 57470-86-7 CAPLUS
CN Urea, [3-acetyl-4-[3-[(1,1-dimethylethyl)(phenylmethyl)amino]-2-hydroxypropoxy]phenyl]- (9CI) (CA INDEX NAME)



L9 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1972:488082 CAPLUS
DOCUMENT NUMBER: 77:88082
TITLE: Polysubstituted phenoxypropanolamine derivatives
INVENTOR(S): Blaha, Ludvik; Weichet, Jaroslav; Hodrova, Jarmila; Trcka, Vaclav
SOURCE: Czech., 6 pp.
CODEN: CZXXA9
DOCUMENT TYPE: Patent
LANGUAGE: Czech
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CS 143069		19711015	CS 1968-5515	19680729

GI For diagram(s), see printed CA Issue.
AB I (Y = OH, Z = NX1X2, NX1X2 = morpholino, piperidino, NCHMe2) were prepared by reaction of I (YZ = O) with NHX1X2. Thus, 2,3,5-trimethyl-4-acetoxyphenol, epichlorohydrin, and K2CO3 was refluxed in Me2CO 8 hr to give 3-(2,3,5-trimethyl-4-acetoxyphenoxy)-1,2-epoxypropane, which was heated with iso-PrNHCH2Ph in EtOH 3 hr at 70° to yield 1-(2,3,5-trimethyl-4-acetoxyphenoxy)-3-(benzylisopropylamino)-2 -propanol. Similarly prepared were 17 addnl. I, which were isolated as HCl salts, fumarates, or tartrates. Some I showed an antiarrhythmic effect.
IT 36593-10-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36593-10-9 CAPLUS
CN Phenol, 4-[3-[(1,1-dimethylethyl)(phenylmethyl)amino]-2-hydroxypropoxy]-2,3,6-trimethyl-, 1-acetate, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L9 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1969:403129 CAPLUS
DOCUMENT NUMBER: 71:3129
TITLE: Trimethyl hydroquinones β-adrenergic blockers
INVENTOR(S): Blaha, Ludvik; Weichet, Jaroslav; Hodrova, Jarmila; Trcka, Vaclav
SOURCE: Czech., 5 pp.
CODEN: CZXXA9
DOCUMENT TYPE: Patent
LANGUAGE: Czech
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CS 128471		19680715	CS	19670104

GI For diagram(s), see printed CA Issue.
AB Reaction of I with RNH2 gives II, which block or reverse the blood pressure response to isopropylnorepinephrine and affect the β-receptors of the adrenergic system. Thus, 7.8 g. I (X = AcO) and 6.6 g. phthalimide was refluxed in 70 ml. EtOH with 3 drops pyridine 6 hrs. and the phthalimido derivative [8.1 g., m. 155-6° (EtOH)] boiled 30 min. with 4.3 g. 50% N2H4.H2O in EtOH and worked up to give 4 g. II.HCl (X = R = R1 = H), m. 236-8° (H2O). Alternatively, I (X = AcO), m. 94-7° (EtOH), was prepared in an 80-g. yield by heating 82 g. 2,3,5,4-Me3(AcO)C6HOH with 125 g. epichlorohydrin and 0.9 ml. piperidine 6 hrs. at 95-100°, distilling excess reagent at 100°, and treating the residue (129 g.) in 700 ml. dry C6H6 with stirring at 30° in 70 min. with 2 63-g. portions of powdered NaOH. Heating I (X = AcO) with an EtOH solution of the resp. RNH2 3 hrs. at 70° in a closed vessel gave the following II (X, R, R1, and m.p. given): H, H, Me, - [HCl salt m. 225-9° (MeOH-AcOEt)], Ac, H, iso-Pr (III), 105-7° (cyclohexane); Ac, Ph, CMe3, - (b.0.001 181-3°) [acid tartrate m. 75-100° (decomposition)]; Ac, H, CHMeC11H23-n, 55-7° (petroleum ether); Bz, H, iso-Pr, 189-91° (MeOH-AcOEt); and palmitoyl, H, iso-Pr, 81-3° (MeOH). Alkaline hydrolysis of III by refluxing 2 g. in M alc. KOH 45 min. under N afforded 1.9 g. II.HCl (X = H, R = H, R1 = iso-Pr), m. 194-5.5° (1:5 MeOH-AcOEt).
IT 22664-56-8P 22664-57-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 22664-56-8 CAPLUS
CN 2-Propanol, 1-(N-tert-butylanilino)-3-(4-hydroxy-2,3,5-trimethylphenoxy)-, 4-acetate (8CI) (CA INDEX NAME)



RN 22664-57-9 CAPLUS
CN 2-Propanol, 1-(N-tert-butylanilino)-3-(4-hydroxy-2,3,5-trimethylphenoxy)-, 4-acetate, tartrate (1:1) (salt) (8CI) (CA INDEX NAME)

CM 1

CRN 22664-56-8
CMF C24 H33 N O4



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



=> D HIS

(FILE 'HOME' ENTERED AT 14:45:30 ON 10 JUL 2007)

FILE 'REGISTRY' ENTERED AT 14:45:39 ON 10 JUL 2007
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 STRUCTURE UPLOADED
L4 0 S L3
L5 0 S L3 SSS FULL
L6 STRUCTURE UPLOADED
L7 2 S L6
L8 35 S L6 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:06:55 ON 10 JUL 2007
L9 10 S L8

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	57.40	416.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.80	-7.80

FILE 'REGISTRY' ENTERED AT 15:13:00 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUL 2007 HIGHEST RN 941818-42-4
DICTIONARY FILE UPDATES: 9 JUL 2007 HIGHEST RN 941818-42-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> D L1
L1 HAS NO ANSWERS
L1 STR



G1
G2 C,O,S,N
G3 C,N

Structure attributes must be viewed using STN Express query preparation.

=> S L1 SSS FULL
FULL SEARCH INITIATED 15:13:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5525059 TO ITERATE

6.8% PROCESSED 376852 ITERATIONS 588 ANSWERS
17.6% PROCESSED 972340 ITERATIONS 1769 ANSWERS
18.1% PROCESSED 1000000 ITERATIONS 1788 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.40

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 5525059 TO 5525059
PROJECTED ANSWERS: 9580 TO 10176

L10 1788 SEA SSS FUL L1

=> S L10 NOT L8
L11 1788 L10 NOT L8

```
=> FILE CAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   172.55     589.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -7.80

FILE 'CAPLUS' ENTERED AT 15:14:24 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 10 Jul 2007  VOL 147 ISS 3
FILE LAST UPDATED: 9 Jul 2007  (20070709/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L11
L12          32 L11

=> D 1-5

L12  ANSWER 1 OF 32  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:505118  CAPLUS
DN   146:482074
TI   Preparation of azole heterocyclic compounds as G protein-coupled receptor
     kinase (GRK) inhibitors
IN   Kawamoto, Tetsuji; Okawa, Tomohiro; Hosono, Hiroshi; Ogino, Masaki
PA   Takeda Chemical Industries, Ltd., Japan
SO   Jpn. Kokai Tokkyo Koho, 175pp.
     CODEN: JKXXAF
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
PI   JP 2007112789       A      20070510    JP 2006-249474         20060914
PRAI JP 2005-276722      A      20050922
OS   MARPAT 146:482074

L12  ANSWER 2 OF 32  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:410768  CAPLUS
DN   146:421768
TI   Preparation of phenylalkyl carboxylic acid derivatives for cosmetic and
     pharmaceutical compns.
IN   Beumer, Raphael; Klock, Jochen; Stoeckli, Stefan Martin
PA   DSM IP Assets B.V., Neth.
SO   PCT Int. Appl., 37pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
PI   WO 2007039059       A1     20070412    WO 2006-EP8965         20060914
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
            KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
            MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
            RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
PRAI EP 2005-20446       A      20050920
OS   MARPAT 146:421768
RE.CNT  10     THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12  ANSWER 3 OF 32  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:410718  CAPLUS
DN   146:415131
TI   Identification of anticancer compounds and compounds for treating
     Huntington's disease, and methods of treatment thereof
IN   Stockwell, Brent R.; Smuksta, Inese
PA   The Trustees of Columbia University In the City of New York, USA
SO   PCT Int. Appl., 182pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
PI   WO 2007041341       A2     20070412    WO 2006-US38132        20060929
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
            KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
            MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
            RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
PRAI US 2005-721667P     P      20050929
     US 2006-771187P     P      20060207
OS   MARPAT 146:415131

L12  ANSWER 4 OF 32  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:405455  CAPLUS
DN   147:30904
TI   Stereoselective difluoromethylenation using Me3SiCF2SPh: synthesis of
     chiral 2,4-disubstituted 3,3-difluoropyrrolidines
AU   Li, Ya; Hu, Jinbo
CS   Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic
     Chemistry, Chinese Academy of Sciences, Shanghai, 200032, Peop. Rep. China
SO   Angewandte Chemie, International Edition (2007), 46(14), 2489-2492
     CODEN: ACIEF5; ISSN: 1433-7851
     PB   Wiley-VCH Verlag GmbH & Co. KGaA
     DT   Journal
     LA   English
     RE.CNT  37     THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
                    ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12  ANSWER 5 OF 32  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:359148  CAPLUS
DN   146:379692
TI   N-Acyl arenesulfonamides as apoptosis promoters and their preparation,
     pharmaceutical compositions and use in the treatment of diseases
IN   Bruncko, Milan; Ding, Hong; Elmore, Steven; Kunzer, Aaron; Lynch,
     Christopher L.; Mcclellan, William; Park, Cheol-Min; Petros, Andrew; Song,
     Xiaohong; Wang, Xilu; Tu, Noah; Wendt, Michael; Shoemaker, Alexander;
     Mitten, Michael
PA   USA
SO   U.S. Pat. Appl. Publ., 170pp., Cont.-in-part of U.S. Ser. No. 491,851.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 6
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
PI   US 2007072860       A1     20070329    US 2006-600445         20061116
     US 2006128706       A1     20060615    US 2005-127940         20050512
     US 2006258657       A1     20061116    US 2005-202827         20050812
     US 2007015787       A1     20070118    US 2006-491851         20060724
PRAI US 2005-127940      A2     20050512
     US 2005-202827      A2     20050812
     US 2006-491851      A2     20060724
     US 2003-519695P     P      20031113
     US 2004-988338      A2     20041112
OS   MARPAT 146:379692

=> D 6-10

L12  ANSWER 6 OF 32  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:342146  CAPLUS
DN   146:521449
TI   Stereoselective Synthesis of Di- and Monofluoromethylated Vicinal
     Ethylenediamines with Di- and Monofluoromethyl Sulfones
AU   Liu, Jun; Li, Ya; Hu, Jinbo
CS   Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic
     Chemistry, Chinese Academy of Sciences, Shanghai, 200032, Peop. Rep. China
SO   Journal of Organic Chemistry (2007), 72(8), 3119-3121
     CODEN: JOCEAH; ISSN: 0022-3263
     PB   American Chemical Society
     DT   Journal
     LA   English
     RE.CNT  35     THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
                    ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12  ANSWER 7 OF 32  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:301981  CAPLUS
DN   146:522052
TI   Extended peptoids: a new class of oligomers based on aromatic building
     blocks
AU   Combs, David J.; Lokey, R. Scott
CS   Department of Chemistry and Biochemistry, University of California Santa
     Cruz, Santa Cruz, CA, 95064, USA
SO   Tetrahedron Letters (2007), 48(15), 2679-2682
     CODEN: TELEAY; ISSN: 0040-4039
     PB   Elsevier Ltd.
     DT   Journal
     LA   English
     RE.CNT  19     THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
                    ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12  ANSWER 8 OF 32  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:259662  CAPLUS
DN   146:295935
TI   Preparation of 5-phenyl-1H-tetrazole and 5-phenyl-1,3-thiazolidine-2,4-
     dione derivatives as inhibitors for production of advanced glycation end
     products (AGEs)
IN   Kurokawa, Kiyoshi; Miyata, Toshio; Yanagisawa, Hiroaki
PA   Sankyo Company; Limited, Japan
SO   PCT Int. Appl., 167pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
PI   WO 2007026962       A1     20070308    WO 2006-JP317708       20060831
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
            KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
            MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
            RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
PRAI JP 2005-251826      A      20050831
OS   MARPAT 146:295935
RE.CNT  8      THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12  ANSWER 9 OF 32  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:87138  CAPLUS
DN   146:184244
TI   Preparation of benzenepropanamides as non-peptidic renin inhibitors
IN   Bayly, Christopher I.; Chen, Austin C.; Dube, Daniel; Dube, Laurence;
     Gallant, Michel; Lacombe, Patrick; MacDonald, Dwight; McKay, Daniel;
     Powell, David A.; Grimm, Erich L.
PA   Merck Frosst Canada Ltd., Can.
SO   PCT Int. Appl., 140pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
PI   WO 2007009250       A1     20070125    WO 2006-CA1196         20060720
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
            KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
            MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
            SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
            US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
```

PRAI US 2005-702026P P 20050722
OS MARPAT 146:184244
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:63622 CAPLUS
DN 146:163143
TI Preparation of N-acylsulfonamide apoptosis promoters
IN Bruncko, Milan; Ding, Hong; Elmore, Steven; Kunzer, Aaron; Lynch, Christopher L.; McClellan, William; Park, Cheol-Min; Petros, Andrew; Song, Xiaohong; Wang, Xilu; Tu, Noah; Wendt, Michael; Shoemaker, Alexander R.; Mitten, Michael J.
PA USA
SO U.S. Pat. Appl. Publ., 168pp., Cont.-in-part of U.S. Ser. No. 202,827.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007015787	A1	20070118	US 2006-491851	20060724
US 2005159427	A1	20050721	US 2004-988338	20041112
US 2006128706	A1	20060615	US 2005-127940	20050512
US 2006258657	A1	20061116	US 2005-202827	20050812
US 2007072860	A1	20070329	US 2006-600445	20061116
PRAI US 2003-519695P	P	20031113		
US 2004-988338	A2	20041112		
US 2005-127940	A2	20050512		
US 2005-202827	A2	20050812		
US 2006-491851	A2	20060724		

OS MARPAT 146:163143

=> D 11-15

L12 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1279948 CAPLUS
DN 146:45498
TI Process for preparation of optically active [[(benzoxazolylamino)alkyl]phenoxy]butyric acid derivatives
IN Yamazaki, Yukiyoshi; Araki, Takaaki; Koura, Minoru; Shibuya, Kimiyuki
PA Kowa Co., Ltd., Japan
SO PCT Int. Appl., 35pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006129649	A1	20061207	WO 2006-JP310755	20060530
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI JP 2005-159261	A	20050531		
JP 2005-176663	A	20050616		

PA Merck & Co., Inc., USA
SO PCT Int. Appl., 70pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006110626	A1	20061019	WO 2006-US13253	20060410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2005-670542P	P	20050412		
US 2005-718340P	P	20050919		

OS MARPAT 145:438603
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1070195 CAPLUS
DN 145:419146
TI Preparation of bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors
IN Michardy, Stanton Furst; Lowe, John Adams, III
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 103pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006106425	A1	20061012	WO 2006-IB947	20060327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006229455	A1	20061012	US 2006-399071	20060406
NL 1031539	A1	20061010	NL 2006-1031539	20060407
NL 1031539	C2	20070410		
PRAI US 2005-669472P	P	20050408		

OS MARPAT 145:419146
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D 16-20

OS MARPAT 146:45498
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1228693 CAPLUS
DN 146:505770
TI Preparation of pyrrolidinyl peptides that bind to BIR domains
IN Laurent, Alain; Jarvis, Scott; Boudreault, Alain; Bureau, Patrick; Jaquith, James; Labit, Delphine
PA Aegera Therapeutics Inc., Can.
SO PCT Int. Appl., 256pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006122408	A1	20061123	WO 2006-CA797	20060516
WO 2006122408	A9	20070125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006264379	A1	20061123	US 2006-434166	20060516
PRAI US 2005-682000P	P	20050518		
US 2005-716489P	P	20050914		
US 2005-725280P	P	20051012		

OS MARPAT 145:505770
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1122383 CAPLUS
DN 145:446253
TI Electrophotographic photoconductor containing fluororesin microparticle in protective layer, image-forming method, electrophotographic apparatus, and process cartridge
IN Ikegami, Takaaki; Sugino, Akihiro; Takada, Takeshi
PA Ricoh Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 47pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2006292983	A	20061026	JP 2005-113121	20050411
PRAI JP 2005-113121		20050411		

OS MARPAT 145:446253

L12 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1091061 CAPLUS
DN 145:438603
TI Preparation of amidopropoxyphenyl compounds as orexin receptor antagonists for treating neurological and psychiatric disorders
IN Coleman, Paul J.; Schreier, John

L12 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:917282 CAPLUS
DN 145:314658
TI Preparation of optically active benzaldehyde derivatives as intermediates for PPAR-activating compounds
IN Yamazaki, Yukiyoshi; Araki, Takaaki; Koura, Minoru; Shibuya, Kimiyuki
PA Kowa Co., Ltd., Japan
SO PCT Int. Appl., 22pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006093142	A1	20060908	WO 2006-JP303741	20060228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI JP 2005-55686	A	20050301		

OS MARPAT 145:314658
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:888399 CAPLUS
DN 145:271758
TI Process for production of optically active (R)-2-[3-[N-(benzoxazol-2-yl)-N-(3-(4-methoxyphenoxy)propyl)aminomethyl]phenoxy]butyric acid as peroxisome proliferator activated receptor (PPAR)-activating compound and intermediates of the same
IN Yamazaki, Yukiyoshi; Araki, Takaaki; Koura, Minoru; Shibuya, Kimiyuki
PA Kowa Co., Ltd., Japan
SO PCT Int. Appl., 26pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006090768	A1	20060831	WO 2006-JP303245	20060223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI JP 2005-47476	A	20050223		

OS MARPAT 145:271758
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:740600 CAPLUS
DN 145:145680
TI Preparation of heterocyclic benzoic acid derivatives as PPAR-activating compounds
IN Yamazaki, Yukiyoshi; Toma, Tsutomu; Nishikawa, Masahiro; Yamada, Hajime; Ozawa, Hidefumi; Okuda, Ayumu; Abe, Kazutoyo
PA Kowa Co., Ltd., Japan
SO U.S. Pat. Appl. Publ., 31 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006167058	A1	20060727	US 2006-335669	20060120
WO 2006080407	A1	20060803	WO 2006-JP301249	20060126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2005-647014P	P	20050127		

OS MARPAT 145:145680

L12 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:690195 CAPLUS
DN 145:231216
TI Uv-resistant flame-retardant polyolefin plastic
IN Shen, Liming
PA Shanghai Farm Garden Green Engineering Co., Ltd., Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 6pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1693351	A	20051109	CN 2005-10026445	20050603
PRAI CN 2005-10026445		20050603		

L12 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:634421 CAPLUS
DN 145:103533
TI Preparation of substituted pyrrolidines as renin inhibitors
IN Breitenstein, Werner; Cottens, Sylvain; Ehrhardt, Claus; Jacoby, Edgar; Lorthiois, Edwige Liliane Jeanne; Maibaum, Juergen Klaus; Ostermann, Nils; Sellner, Holger; Simic, Oliver
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SO PCT Int. Appl., 455 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006066896	A2	20060629	WO 2005-EP13786	20051221
WO 2006066896	A3	20060831		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI GB 2004-28250	A	20041223		

OS MARPAT 145:103533

=> D 21-32

L12 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:510615 CAPLUS
DN 145:27861
TI Preparation of (hetero)aromatic ether amides as inhibitors of Factor Xa and/or thrombin.
IN Argade, Ankush Baburao; Goodson, Theodore, Jr.; Herron, David Kent; Joseph, Sajan; Lepore, Salvatore Donato; Marquart, Angela Lynn; Masters, John Joseph; Mendel, David; Merritt, Leander; Ratz, Andrew Michael; Smith, Gerald Floyd, Tebbe, Anne Louise; Wiley, Michael Robert; Yee, Ying Kwong
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 348 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006057845	A1	20060601	WO 2005-US41161	20051110
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2004-630984P	P	20041124		

OS MARPAT 145:27861
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:494289 CAPLUS
DN 145:8472
TI Preparation of peptides as agonists and antagonists of the somatostatin receptor
IN Krawinkler, Karl Heinz; Meier, Peter; Faller, Bernard
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006049232	A1	20060511	WO 2005-JP20262	20051104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005301626	A1	20060511	AU 2005-301626	20051104
PRAI JP 2004-321347	A	20041104		
WO 2005-JP20262	W	20051104		

OS MARPAT 144:468151
RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:494266 CAPLUS
DN 145:8190
TI Preparation of N-[(piperazinylmethyl)biphenyl]benzamide derivatives as M3 muscarinic acetylcholine receptor antagonists
IN Budzik, Brian; Jin, Jian; Laine, Dramane; Mccleland, Brent; Palovich, Michael; Rivero, Ralph; Wang, Yonghui; Xie, Haibo; Zhu, Chongjie; Cooper, Anthony
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006055553	A2	20060526	WO 2005-US41346	20051115
WO 2006055553	A3	20060908		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2004-627986P	P	20041115		

OS MARPAT 145:8190

L12 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:436703 CAPLUS
DN 144:468151
TI Preparation of carboxylic acid derivatives containing thiazole moiety as PPARα agonists
IN Tozawa, Takashi; Tsuruta, Osamu; Kitajima, Hiroshi; Aoki, Yoshiyuki; Ando, Naoko; Tamakawa, Hiroki
PA Mitsubishi Pharma Corporation, Japan
SO PCT Int. Appl., 512 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006049232	A1	20060511	WO 2005-JP20262	20051104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2004-618480P	P	20041013		

OS CASREACT 144:432552; MARPAT 144:432552
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:383697 CAPLUS
DN 144:432552
TI Preparation of substituted anilines as selective androgen receptor modulators
IN Turnbull, Philip Stewart; Larkin, Andrew Lamont; Kaldor, Istvan; Cadilla, Rodolfo; Cowan, David John; Stewart, Eugene Lee
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006044707	A1	20060427	WO 2005-US37094	20051013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2004-618480P	P	20041013		

OS CASREACT 144:432552; MARPAT 144:432552
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:297618 CAPLUS
DN 145:7583
TI Regio- and stereospecific ring opening of 1,1-dialkyl-2-(aryloxymethyl)aziridinium salts by bromide

AU D'hooghe, Matthias; Van Speybroeck, Veronique; Waroquier, Michel; De Kimpe, Norbert
CS Department of Organic Chemistry, Faculty of Bioscience Engineering, Ghent University, Belg.
SO Chemical Communications (Cambridge, United Kingdom) (2006), (14), 1554-1556
CODEN: CHCOFS; ISSN: 1359-7345
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 145:7583
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:228532 CAPLUS
DN 144:425111
TI Synthesis and appetite suppressant activity of 1-aryloxy-2-substituted aminomethyltetrahydronaphthalenes as conformationally rigid analogues of fluoxetine
AU Bhandari, Kalpana; Srivastava, Shipra; Shankar, Girija; Nath, Chandishwar
CS Medicinal and Process Chemistry Division, Central Drug Research Institute, Lucknow, 226001, India
SO Bioorganic & Medicinal Chemistry (2006), 14(8), 2535-2544
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier B.V.
DT Journal
LA English
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:186883 CAPLUS
DN 144:412389
TI Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P'2-ligands
AU Ghosh, Arun K.; Schiltz, Gary; Perali, Ramu Sridhar; Leshchenko, Sofiya; Kay, Stephanie; Walters, D. Eric; Koh, Yasuhiro; Maeda, Kenji; Mitsuya, Hiroaki
CS Departments of Chemistry and Medicinal Chemistry, Purdue University, West Lafayette, IN, 47907, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(7), 1869-1873
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 144:412389
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:180147 CAPLUS
DN 144:390504
TI A new approach towards 2-amino-1-aryloxy-3-methoxypropanes from 1-arylmethyl-2-(bromomethyl)aziridines
AU D'hooghe, Matthias; Waterinckx, Alex; Vanlangendonck, Tim; De Kimpe, Norbert
CS Department of Organic Chemistry, Faculty of Bioscience Engineering, Ghent University, Ghent, B-9000, Belg.
SO Tetrahedron (2006), 62(10), 2295-2303
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 144:390504

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:159044 CAPLUS
DN 145:504993
TI Product subclass 15: α-sodio aldehydes, α-sodio ketones, and related compounds
AU Juaristi, E.; Melgar-Fernandez, R.
CS Departamento de Química, Centro de Investigacion y de Estudios Avanzados, IPN, Mexico, 07000, Mex.
SO Science of Synthesis (2006), Volume Date 2005, 8b, 1285-1296
CODEN: SSCYJ9
PB Georg Thieme Verlag
DT Journal; General Review
LA English
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:151663 CAPLUS
DN 145:210822
TI Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease
AU Specker, Edgar; Boettcher, Jark; Brass, Sascha; Heine, Andreas; Lilie, Hauke; Schoop, Andreas; Mueller, Gerhard; Griebenow, Nils; Klebe, Gerhard
CS Institut fuer Pharmazeutische Chemie, Philipps-Universitaet Marburg, Marburg, 35032, Germany
SO ChemMedChem (2006), 1(1), 106-117
CODEN: CHEMGX; ISSN: 1860-7179
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
OS CASREACT 145:210822
RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:589349 CAPLUS
DN 143:266632
TI Design, synthesis and evaluation of racemic 1-(4-hydroxyphenyl)-2-[3-(substituted phenoxy)-2-hydroxy-1-propyl]amino-1-propanol hydrochlorides as novel uterine relaxants
AU Viswanathan, C. L.; Kodgule, M. M.; Chaudhari, A. S.
CS Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Mumbai, 400 098, India
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(15), 3532-3535
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 143:266632
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D HITSTR

L12 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2007 ACS on STN
IT 935782-60-8P, 3-(Dibenzylamino)-1-[(4-chlorophenyl)amino]-1-[3-(morpholino)-1H-1,2,4-triazol-5-yl]propane dihydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azole heterocyclic compds. as G protein-coupled receptor kinase (GRK) inhibitors for prevention or treatment of circulatory diseases)
RN 935782-60-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



●2 HCl

=> FILE CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	45.84	635.05
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.80

FILE 'CAPLUS' ENTERED AT 15:21:30 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 10 Jul 2007 VOL 147 ISS 3
FILE LAST UPDATED: 9 Jul 2007 (20070709/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.47	635.52
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.80

FILE 'REGISTRY' ENTERED AT 15:21:50 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JUL 2007 HIGHEST RN 941818-42-4
DICTIONARY FILE UPDATES: 9 JUL 2007 HIGHEST RN 941818-42-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\LXR AGONISTS.str





chain nodes :
7 8 11 12 13 14 16 17 18 19 20 21 24
ring nodes :
1 2 3 4 5 6
chain bonds :
7-11 11-12 12-13 13-14 14-20 14-21 16-19 16-17 16-18 16-21 20-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
14-20 14-21 16-19 16-17 16-18 20-24
exact bonds :
7-11 11-12 12-13 13-14 16-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :

containing 1 :

G1:Cy,Ak

G2:C,H,O,N

G3:C,H,O,S,N,X

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 24:Atom

L13 STRUCTURE UPLOADED

=> D L13
L13 HAS NO ANSWERS
L13 STR



G1 Cy,Ak
G2 C,H,O,N
G3 C,H,O,S,N,X

Structure attributes must be viewed using STN Express query preparation.

=> S L13
SAMPLE SEARCH INITIATED 15:22:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 43446 TO ITERATE

4.6% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 856474 TO 881366
PROJECTED ANSWERS: 0 TO 0

L14 0 SEA SSS SAM L13

=> S L13 SSS FULL
FULL SEARCH INITIATED 15:22:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 869039 TO ITERATE

95.7% PROCESSED 831474 ITERATIONS 1162 ANSWERS

99.0% PROCESSED 860004 ITERATIONS 1162 ANSWERS

100.0% PROCESSED 869039 ITERATIONS 1163 ANSWERS
SEARCH TIME: 00.00.38

L15 1163 SEA SSS FUL L13

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY 184.25 TOTAL SESSION 819.77

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY 0.00 TOTAL SESSION -7.80

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 15:38:21 ON 10 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Jul 2007 VOL 147 ISS 3
FILE LAST UPDATED: 9 Jul 2007 (20070709/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s L15
L16 112 L15

=> d his

(FILE 'HOME' ENTERED AT 14:45:30 ON 10 JUL 2007)

FILE 'REGISTRY' ENTERED AT 14:45:39 ON 10 JUL 2007
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 STRUCTURE UPLOADED
L4 0 S L3
L5 0 S L3 SSS FULL
L6 STRUCTURE UPLOADED
L7 2 S L6
L8 35 S L6 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:06:55 ON 10 JUL 2007
L9 10 S L8

FILE 'REGISTRY' ENTERED AT 15:13:00 ON 10 JUL 2007
L10 1788 S L1 SSS FULL

L11 1788 S L10 NOT L8

FILE 'CAPLUS' ENTERED AT 15:14:24 ON 10 JUL 2007
L12 32 S L11

FILE 'CAPLUS' ENTERED AT 15:21:30 ON 10 JUL 2007

FILE 'REGISTRY' ENTERED AT 15:21:50 ON 10 JUL 2007
L13 STRUCTURE UPLOADED
L14 0 S L13
L15 1163 S L13 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:38:21 ON 10 JUL 2007
L16 112 S L15

=> s l16 not l12
L17 108 L16 NOT L12

=> s l17 not l9
L18 106 L17 NOT L9

=> d 1-5

L18 ANSWER 1 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:621963 CAPLUS
TI Selective activation of liver X receptors by acanthoic acid-related diterpenes
AU Traves, Paqui G.; Hortelano, Sonsoles; Zeini, Miriam; Chao, Ta-Hsiang; Lam, Thanh; Neuteboom, Saskia T.; Theodorakis, Emmanuel A.; Palladino, Michael A.; Castrillo, Antonio; Bosca, Lisardo
CS Centro Nacional de Investigaciones Cardiovasculares and Instituto de Investigaciones Biomedicas Alberto Sols, Madrid, Spain
SO Molecular Pharmacology (2007), 71(6), 1545-1553
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:449834 CAPLUS
TI T0901317 is a potent PXR ligand: Implications for the biology ascribed to LXR
AU Mitro, Nico; Vargas, Leo; Romeo, Russell; Koder, Alan; Saez, Enrique
CS The Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92037, USA
SO FEBS Letters (2007), 581(9), 1721-1726
CODEN: FEBLAL; ISSN: 0014-5793
PB Elsevier B.V.
DT Journal
LA English
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1272920 CAPLUS
DN 146:119538
TI A Nuclear Receptor Corepressor-Dependent Pathway Mediates Suppression of Cytokine-Induced C-Reactive Protein Gene Expression by Liver X Receptor
AU Blaschke, Florian; Takata, Yasunori; Caglayan, Evren; Collins, Alan; Tontonoz, Peter; Hsueh, Willa A.; Tangirala, Rajendra K.
CS Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine, University of California, Los Angeles, Germany
SO Circulation Research (2006), 99(12), e88-e99
CODEN: CIRUAL; ISSN: 0009-7330
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1207196 CAPLUS
DN 145:495700
TI Use of liver x receptor agonists
IN Husson, Bernadette
PA Laboratoires Fournier S. A., Fr.
SO PCT Int. Appl., 43pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006120213	A2	20061116	WO 2006-EP62208	20060510
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2005-679768P	P	20050510		

L18 ANSWER 5 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1206741 CAPLUS
DN 145:489228
TI Preparation of thiazole compounds for treating Hepatitis C virus infections
IN Zhang, Suoming; Phadke, Avinash; Liu, Cuixian; Wang, Xiangzhu; Quinn, Jesse; Chen, Dawei; Gadhachanda, Venkat; Li, Shouming; Deshpande, Milind
PA Achillion Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 254pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006122011	A2	20061116	WO 2006-US17692	20060509
WO 2006122011	A3	20070503		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 2007004711	A1	20070104	US 2006-431155	20060509

PRAI US 2005-679133P P 20050509
OS MARPAT 145:489228

=> d 6-10

L18 ANSWER 6 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1186597 CAPLUS
DN 146:243889
TI Liver X receptor agonists ameliorate TNFα-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression
AU Fernandez-Veledo, S.; Nieto-Vazquez, I.; Rondinone, C. M.; Lorenzo, M.
CS Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy, Complutense University, Madrid, 28040, Spain
SO Diabetologia (2006), 49(12), 3038-3048
CODEN: DBTGAJ; ISSN: 0012-186X
PB Springer GmbH
DT Journal
LA English
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 7 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:993850 CAPLUS
DN 145:431974
TI Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels
AU Brunham, Liam R.; Kruit, Janine K.; Pape, Terry D.; Parks, John S.; Kuipers, Folkert; Hayden, Michael R.
CS Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Can.
SO Circulation Research (2006), 99(7), 672-674
CODEN: CIRUAL; ISSN: 0009-7330
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:977514 CAPLUS
DN 145:328397
TI Method for inhibiting lipid absorption and lipid absorption inhibitor containing CETP inhibitors
IN Yonemori, Fumihiko; Takahashi, Daisuke; Furukawa, Noboru
PA Japan Tobacco Inc., Japan
SO PCT Int. Appl., 609pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006098394	A1	20060921	WO 2006-JP305188	20060309

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006270705	A1	20061130	US 2006-375357	20060314
PRAI JP 2005-70292	A	20050314		
US 2005-666252P	P	20050329		

OS MARPAT 145:328397
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:955660 CAPLUS
DN 146:287604
TI Flexible induced fit docking of ligands to enzyme active sites
AU Farid, Ramy; Rao, Shashidhar; Day, Tyler; Beard, Hege; Shelley, Mee; Perry, Jason; Weiser, Joerg
CS Schrodinger, New York, NY, 10036, USA
SO QSAR and Molecular Modelling in Rational Design of Bioactive Molecules, Proceedings of the European Symposium on Structure-Activity Relationships (QSAR) and Molecular Modelling, 15th, Istanbul, Turkey, Sept. 5-10, 2004 (2006), 288-290. Editor(s): Aki, Esin; Yalcin, Ismail. Publisher: Computer Aided Drug Design & Development Society in Turkey, Ankara, Turk.
CODEN: 69IKYT; ISBN: 975-00782-0-9
DT Conference
LA English
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 10 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:937658 CAPLUS
DN 145:410048
TI Discovery of Phenyl Acetic Acid Substituted Quinolines as Novel Liver X Receptor Agonists for the Treatment of Atherosclerosis
AU Hu, Baihua; Collini, Michael; Unwalla, Rayomand; Miller, Christopher; Singhaus, Robert; Quinet, Elaine; Savio, Dawn; Halpern, Anita; Basso, Michael; Keith, James; Clerin, Valerie; Chen, Liang; Resmini, Christine; Liu, Qiang-Yuan; Feingold, Irene; Huselton, Christine; Azam, Farooq; Farnegardh, Mathias; Enroth, Cristofer; Bonn, Tomas; Goos-Nilsson, Annika; Wilhelmsson, Anna; Nambi, Ponnal; Wrobel, Jay
CS Chemical and Screening Science, Cardiovascular and Metabolic Disease, and Bio Transformation and Disposition, Wyeth Research, Collegeville, PA, 19426, USA
SO Journal of Medicinal Chemistry (2006), 49(21), 6151-6154
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 145:410048
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 10-15

L18 ANSWER 10 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:937658 CAPLUS
DN 145:410048
TI Discovery of Phenyl Acetic Acid Substituted Quinolines as Novel Liver X Receptor Agonists for the Treatment of Atherosclerosis
AU Hu, Baihua; Collini, Michael; Unwalla, Rayomand; Miller, Christopher; Singhaus, Robert; Quinet, Elaine; Savio, Dawn; Halpern, Anita; Basso, Michael; Keith, James; Clerin, Valerie; Chen, Liang; Resmini, Christine; Liu, Qiang-Yuan; Feingold, Irene; Huselton, Christine; Azam, Farooq; Farnegardh, Mathias; Enroth, Cristofer; Bonn, Tomas; Goos-Nilsson, Annika; Wilhelmsson, Anna; Nambi, Ponnal; Wrobel, Jay
CS Chemical and Screening Science, Cardiovascular and Metabolic Disease, and Bio Transformation and Disposition, Wyeth Research, Collegeville, PA, 19426, USA
SO Journal of Medicinal Chemistry (2006), 49(21), 6151-6154
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 145:410048
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:733310 CAPLUS
DN 145:159814
TI Use of LXR ligands for the modulation of dendritic cells (DCS)
IN Belanger, Carole; Darteil, Raphael; Hum, Dean
PA Genfit S.A., Fr.
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006077012	A2	20060727	WO 2006-EP43	20060105
WO 2006077012	A3	20061102		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI EP 2005-688	A	20050118		

L18 ANSWER 12 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:656076 CAPLUS
DN 145:117357
TI Compounds that activate liver X receptor and retinoid X receptor and thereby prevent macrophage apoptosis during pathogen infection
IN Glass, Christopher K.; Valledor, Annabel F.; Karin, Michael; Hsu, Li-Chung
PA The Regents of the University of California, USA
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006071451	A2	20060706	WO 2005-US43616	20051202
WO 2006071451	A9	20060824		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-632905P	P	20041203		

L18 ANSWER 13 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:583211 CAPLUS
DN 145:117081
TI Assessing the effects of LXR agonists on cellular cholesterol handling: a stable isotope tracer study
AU Aravindhan, Karpagam; Webb, Christine L.; Jaye, Michael; Ghosh, Avijit; Willette, Robert N.; DiNardo, N. John; Jucker, Beat M.
CS Department of Applied Physics, College of Arts and Sciences, Drexel University, Philadelphia, PA, 19104, USA
SO Journal of Lipid Research (2006), 47(6), 1250-1260
CODEN: JLPRAW; ISSN: 0022-2275
PB American Society for Biochemistry and Molecular Biology, Inc.
DT Journal
LA English
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 14 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:398377 CAPLUS
DN 145:95757
TI SAR studies: Designing potent and selective LXR agonists
AU Szewczyk, Jason W.; Huang, Shaei; Chin, Jayne; Tian, Jenny; Mitnaul, Lyndon; Rosa, Raymond L.; Peterson, Larry; Sparrow, Carl P.; Adams, Alan D.
CS Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, 07065, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(11), 3055-3060
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 145:95757
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 15 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:172464 CAPLUS
DN 145:117301
TI Activation of the liver X receptor protects against hepatic injury in endotoxemia by suppressing Kupffer cell activation
AU Wang, Yun Yong; Dahle, Maria K.; Aagren, Joanna; Myhre, Anders E.; Reinholt, Finn P.; Foster, Simon J.; Collins, Jon L.; Thiemermann, Christoph; Aasen, Ansgar O.; Wang, Jacob E.
CS Faculty Division Rikshospitalet, Institute for Surgical Research, University of Oslo, Oslo, Norway
SO Shock (2006), 25(2), 141-146
CODEN: SAGUAI; ISSN: 1073-2322
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 15-20

L18 ANSWER 15 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:172464 CAPLUS
DN 145:117301

```
TI   Activation of the liver X receptor protects against hepatic injury in
     endotoxemia by suppressing Kupffer cell activation
AU   Wang, Yun Yong; Dahle, Maria K.; Aagren, Joanna; Myhre, Anders E.;
     Reinholt, Finn P.; Foster, Simon J.; Collins, Jon L.; Thiemermann,
     Christoph; Aasen, Ansgar O.; Wang, Jacob E.
CS   Faculty Division Rikshospitalet, Institute for Surgical Research,
     University of Oslo, Oslo, Norway
SO   Shock (2006), 25(2), 141-146
     CODEN: SAGUAI; ISSN: 1073-2322
PB   Lippincott Williams & Wilkins
DT   Journal
LA   English
RE.CNT  34    THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18  ANSWER 16 OF 106  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:163732  CAPLUS
DN   144:305276
TI   A Novel Principle for Partial Agonism of Liver X Receptor Ligands:
     competitive recruitment of activators and repressors
AU   Albers, Michael; Blume, Beatrix; Schlueter, Thomas; Wright, Matthew B.;
     Kober, Ingo; Kremoser, Claus; Deuschle, Ulrich; Koegl, Manfred
CS   PhenoX Pharmaceuticals AG, Ludwigshafen, 67056, Germany
SO   Journal of Biological Chemistry (2006), 281(8), 4920-4930
     CODEN: JBCHA3; ISSN: 0021-9258
PB   American Society for Biochemistry and Molecular Biology
DT   Journal
LA   English
RE.CNT  50    THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18  ANSWER 17 OF 106  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:37125  CAPLUS
DN   144:129005
TI   Preparation of aryl-substituted piperazine derivatives as MCH modulators
IN   Hutchinson, Alan J.; Chenard, Bertrand L.; Li, Guiying; Ghosh, Manuka;
     Tarrant, James G.; Yoon, Taeyoung; Luke, George P.; Lee, Kyungae;
     O'Donnell, Mary-Margaret E.; Pringle, Wallace C.; Peterson, John M.;
     Hodgetts, Kevin J.; Steenstra, Cheryl K.; Doller, Dario
PA   USA
SO   U.S. Pat. Appl. Publ., 255 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ------------------  ----   --------    --------------------   --------
PI   US 2006009456       A1     20060112    US 2005-154986         20050616
     AU 2005265051       A1     20060126    AU 2005-265051         20050616
     CA 2567604          A1     20060126    CA 2005-2567604        20050616
     WO 2006009789       A2     20060126    WO 2005-US21340        20050616
     WO 2006009789       A3     20061228
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
            NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
            SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
            ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
            CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
            KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
            KZ, MD, RU, TJ, TM
     EP 1756107          A2     20070228    EP 2005-760258         20050616
```

```
     R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
         IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
         HR, LV, MK, YU
     NO 2007000293       A      20070315    NO 2007-293            20070116
PRAI US 2004-580958P     P      20040617
     WO 2005-US21340     W      20050616
OS   MARPAT 144:129005

L18  ANSWER 18 OF 106  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:32063  CAPLUS
DN   144:121798
TI   Tissue factor production inhibitors containing LXR ligands
IN   Terasaka, Naoki; Hiroshima, Ayano
PA   Sankyo Company, Limited, Japan
SO   PCT Int. Appl., 261 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ------------------  ----   --------    --------------------   --------
PI   WO 2006004030       A1     20060112    WO 2005-JP12185        20050701
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
            NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
            SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
            ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
            GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM
     CA 2572872          A1     20060112    CA 2005-2572872        20050701
     EP 1764075          A1     20070321    EP 2005-755860         20050701
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
PRAI JP 2004-196468      A      20040702
     WO 2005-JP12185     W      20050701
OS   MARPAT 144:121798
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18  ANSWER 19 OF 106  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:30802  CAPLUS
DN   144:387479
TI   Oxysterols suppress inducible nitric oxide synthase expression in
     lipopolysaccharide-stimulated astrocytes through liver X receptor
AU   Lee, Chang Seok; Joe, Eun-hye; Jou, Ilo
CS   Department of Pharmacology, Ajou University School of Medicine, Suwon, S.
     Korea
SO   NeuroReport (2006), 17(2), 183-187
     CODEN: NERPEZ; ISSN: 0959-4965
PB   Lippincott Williams & Wilkins
DT   Journal
LA   English
RE.CNT  24    THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18  ANSWER 20 OF 106  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:15776  CAPLUS
DN   144:101077
TI   Methods and compositions to promote bone homeostasis
IN   Van Rompaey, Luc; Tomme, Peter Herwig Maria
```

```
PA   Galapagos Genomics N.V., Belg.
SO   PCT Int. Appl., 72 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ------------------  ----   --------    --------------------   --------
PI   WO 2006000577       A2     20060105    WO 2005-EP52971        20050624
     WO 2006000577       A9     20060420
     WO 2006000577       A3     20061109
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
            NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
            SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
            ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
            CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
            KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
            KZ, MD, RU, TJ, TM
     CA 2568857          A1     20060105    CA 2005-2568857        20050624
     US 2006014231       A1     20060119    US 2005-166412         20050624
     US 2006020036       A1     20060126    US 2005-166009         20050624
     EP 1758651          A2     20070307    EP 2005-754121         20050624
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
             HR, LV, MK, YU
PRAI US 2004-582704P     P      20040624
     US 2004-630449P     P      20041123
     US 2005-673206P     P      20050420
     WO 2005-EP52971     W      20050624


=> d 20-25

L18  ANSWER 20 OF 106  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:15776  CAPLUS
DN   144:101077
TI   Methods and compositions to promote bone homeostasis
IN   Van Rompaey, Luc; Tomme, Peter Herwig Maria
PA   Galapagos Genomics N.V., Belg.
SO   PCT Int. Appl., 72 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ------------------  ----   --------    --------------------   --------
PI   WO 2006000577       A2     20060105    WO 2005-EP52971        20050624
     WO 2006000577       A9     20060420
     WO 2006000577       A3     20061109
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
            NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
            SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
            ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
            CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
            KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
```

```
            KZ, MD, RU, TJ, TM
     CA 2568857          A1     20060105    CA 2005-2568857        20050624
     US 2006014231       A1     20060119    US 2005-166412         20050624
     US 2006020036       A1     20060126    US 2005-166009         20050624
     EP 1758651          A2     20070307    EP 2005-754121         20050624
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
             HR, LV, MK, YU
PRAI US 2004-582704P     P      20040624
     US 2004-630449P     P      20041123
     US 2005-673206P     P      20050420
     WO 2005-EP52971     W      20050624

L18  ANSWER 21 OF 106  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:15775  CAPLUS
DN   144:101076
TI   Methods for identifying modulators of bone homeostasis and osteoblast
     differentiation, for treatment of human bone disorders
IN   Van Rompaey, Luc; Tomme, Peter Herwig Maria
PA   Galapagos Genomics N.V., Belg.
SO   PCT Int. Appl., 104 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ------------------  ----   --------    --------------------   --------
PI   WO 2006000576       A2     20060105    WO 2005-EP52970        20050624
     WO 2006000576       A3     20060810
     WO 2006000576       B1     20060928
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
            NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
            SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
            ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
            CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
            KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
            KZ, MD, RU, TJ, TM
     CA 2570496          A1     20060105    CA 2005-2570496        20050624
     US 2006014231       A1     20060119    US 2005-166412         20050624
     US 2006020036       A1     20060126    US 2005-166009         20050624
     EP 1766414          A2     20070328    EP 2005-758691         20050624
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
PRAI US 2004-582704P     P      20040624
     US 2004-630449P     P      20041123
     US 2005-673206P     P      20050420
     WO 2005-EP52970     W      20050624

L18  ANSWER 22 OF 106  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:7566  CAPLUS
DN   144:285109
TI   Tetranuclear iron(III) complexes of an octadentate pyridine-carboxylate
     ligand and their catalytic activity in alkane oxidation by hydrogen
     peroxide
AU   Gutkina, Elena A.; Trukhan, Vladimir M.; Pierpont, Cortlandt G.; Mkoyan,
     Shaen; Strelets, Vladimir V.; Nordlander, Ebbe; Shteinman, Albert A.
CS   Institute of Problems of Chemical Physics, Chernogolovka, 142432, Russia
SO   Dalton Transactions (2006), (3), 492-501
     CODEN: DTARAF; ISSN: 1477-9226
PB   Royal Society of Chemistry
```

DT Journal
LA English
OS CASREACT 144:285109
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 23 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1348778 CAPLUS
DN 144:480701
TI Pharmacological Activation of Liver X Receptors Promotes Reverse Cholesterol Transport In Vivo
AU Naik, Snehal U.; Wang, Xun; Da Silva, Jaqueline S.; Jaye, Michael; Macphee, Colin H.; Reilly, Muredach P.; Billheimer, Jeffrey T.; Rothblat, George H.; Rader, Daniel J.
CS Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
SO Circulation (2006), 113(1), 90-97
CODEN: CIRCAZ; ISSN: 0009-7322
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 24 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1244494 CAPLUS
DN 144:16893
TI Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice
AU Grefhorst, Aldo; van Dijk, Theo H.; Hammer, Anke; van der Sluijs, Fjodor H.; Havinga, Rick; Havekes, Louis M.; Romijn, Johannes A.; Groot, Pieter H.; Reijngoud, Dirk-Jan; Kuipers, Folkert
CS Center for Liver, Digestive, and Metabolic Diseases, Laboratory of Pediatrics, University Medical Center Groningen, Groningen, Neth.
SO American Journal of Physiology (2005), 289(5, Pt. 1), E829-E838
CODEN: AJPHAP; ISSN: 0002-9513
PB American Physiological Society
DT Journal
LA English
RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 25 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1083027 CAPLUS
DN 144:32097
TI Synthetic LXR agonists increase LDL in CETP species
AU Groot, Pieter H. E.; Pearce, Nigel J.; Yates, John W.; Stocker, Claire; Sauermelch, Charles; Doe, Christopher P.; Willette, Robert N.; Olzinski, Alan; Peters, Tambra; d'Epagnier, Denise; Morasco, Kathleen O.; Krawiec, John A.; Webb, Christine L.; Aravindhan, Karpagam; Jucker, Beat; Burgert, Mark; Ma, Chun; Marino, Joseph P.; Collins, Jon L.; Macphee, Colin H.; Thompson, Scott K.; Jaye, Michael
CS Cardiovascular Center for Excellence in Drug Discovery, GlaxoSmithKline, King of Prussia, PA, 19406-0939, USA
SO Journal of Lipid Research (2005), 46(10), 2182-2191
CODEN: JLPRAW; ISSN: 0022-2275
PB American Society for Biochemistry and Molecular Biology, Inc.
DT Journal
LA English
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 26-30

L18 ANSWER 26 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:703800 CAPLUS
DN 143:221837
TI Discovery of Substituted Maleimides as Liver X Receptor Agonists and Determination of a Ligand-Bound Crystal Structure
AU Jaye, Michael C.; Krawiec, John A.; Campobasso, Nino; Smallwood, Angela; Qiu, Chunyan; Lu, Quinn; Kerrigan, John J.; De Los Frailes Alvaro, Maite; Laffitte, Bryan; Liu, Wu-Schyong; Marino, Joseph P., Jr.; Meyer, Craig R.; Nichols, Jason A.; Parks, Derek J.; Perez, Paloma; Sarov-Blat, Lea; Seepersaud, Sheila D.; Steplewski, Klaudia M.; Thompson, Scott K.; Wang, Ping; Watson, Mike A.; Webb, Christine L.; Haigh, David; Caravella, Justin A.; Macphee, Colin H.; Willson, Timothy M.; Collins, Jon L.
CS GlaxoSmithKline Research and Development, Research Triangle Park, NC, 27709, USA
SO Journal of Medicinal Chemistry (2005), 48(17), 5419-5422
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 143:221837
RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 27 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:540481 CAPLUS
DN 143:71761
TI Methods of treatment with LXR agonists
IN Kikkawa, Hideo; Kinoshita, Mine; Kurusu, Osamu
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005055998	A1	20050623	WO 2004-US40440	20041203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI US 2003-526770P	P	20031204		
OS MARPAT 143:71761				

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 28 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:527397 CAPLUS
DN 143:78096
TI Preparation of quinolines useful in treating LXR (liver X receptor)-mediated diseases
IN Collini, Michael D.; Singhaus, Robert R.; Hu, Baihua; Jetter, James W.; Morris, Robert L.; Kaufman, David H.; Miller, Christopher P.; Ullrich, John W.; Unwalla, Rayomand J.; Wrobel, Jay E.; Quinet, Elaine; Nambi, Ponnal; Bernotas, Ronald C.; Elloso, Merle
PA Wyeth, John, and Brother Ltd., USA
SO U.S. Pat. Appl. Publ., 169 pp.
CODEN: USXXCO

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005030185	A2	20050407	WO 2004-JP14428	20040924
WO 2005030185	A3	20050811		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004275637	A1	20050407	AU 2004-275637	20040924
CA 2554982	A1	20050407	CA 2004-2554982	20040924
EP 1670446	A2	20060621	EP 2004-773516	20040924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004014822	A	20061114	BR 2004-14822	20040924
CN 1886124	A	20061227	CN 2004-80034573	20040924
JP 2007506646	T	20070322	JP 2006-515401	20040924
US 2007054839	A1	20070308	US 2006-389542	20060324
NO 2006001818	A	20060626	NO 2006-1818	20060425
PRAI JP 2003-373453	A	20030926		
US 2004-590811P	P	20040723		
WO 2004-JP14428	W	20040924		
OS MARPAT 142:349078				

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005131014	A1	20050616	US 2004-10236	20041210
AU 2004298486	A1	20050630	AU 2004-298486	20041210
CA 2547518	A1	20050630	CA 2004-2547518	20041210
WO 2005058834	A2	20050630	WO 2004-US41399	20041210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1692111	A2	20060823	EP 2004-813688	20041210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1914173	A	20070214	CN 2004-80041595	20041210
BR 2004017543	A	20070327	BR 2004-17543	20041210
JP 2007516258	T	20070621	JP 2006-544016	20041210
IN 2006KN01443	A	20070504	IN 2006-KN1443	20060529
NO 2006002561	A	20060908	NO 2006-2561	20060602
PRAI US 2003-529009P	P	20031212		
US 2004-600296P	P	20040810		
WO 2004-US41399	W	20041210		
OS MARPAT 143:78096				

L18 ANSWER 29 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:301489 CAPLUS
DN 143:935
TI Liver X Receptor Agonists Inhibit Cytokine-Induced Osteopontin Expression in Macrophages Through Interference With Activator Protein-1 Signaling Pathways
AU Ogawa, Daisuke; Stone, Jeffrey F.; Takata, Yasunori; Blaschke, Florian; Chu, Van H.; Towler, Dwight A.; Law, Ronald E.; Hsueh, Willa A.; Bruemmer, Dennis
CS Division of Endocrinology and Molecular Medicine, University of Kentucky College of Medicine, Lexington, KY, USA
SO Circulation Research (2005), 96(7), e59-e67
CODEN: CIRUAL; ISSN: 0009-7330
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 30 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:300235 CAPLUS
DN 142:349078
TI Method using cholesteryl ester transfer protein (CETP) inhibitors for inhibiting remnant lipoprotein production
IN Okamoto, Hiroshi; Furukawa, Noboru; Sasase, Tomohiko
PA Japan Tobacco Inc., Japan
SO PCT Int. Appl., 578 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

=> d 31-40

L18 ANSWER 31 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:273322 CAPLUS
DN 142:385558
TI Liver X receptor agonists inhibit tissue factor expression in macrophages
AU Terasaka, Naoki; Hiroshima, Ayano; Ariga, Akiko; Honzumi, Shoko; Koieyama, Tadashi; Inaba, Toshimori; Fujiwara, Toshihiko
CS Pharmacology and Molecular Biology Research Laboratories, Sankyo Co. Ltd, Tokyo, 140-8710, Japan
SO FEBS Journal (2005), 272(6), 1546-1556
CODEN: FJEOAC; ISSN: 1742-464X
PB Blackwell Publishing Ltd.
DT Journal
LA English
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 32 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:238962 CAPLUS
DN 142:316838
TI Preparation of azole compounds as PPARα agonists
IN Yamazaki, Yukiyoshi; Toma, Tsutomu; Nishikawa, Masahiro; Ozawa, Hidefumi; Okuda, Ayumu; Araki, Takaaki; Abe, Kazutoyo; Oda, Soichi
PA Kowa Co., Ltd., Japan
SO PCT Int. Appl., 184 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005023777	A1	20050317	WO 2004-JP12750	20040902
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

	AU 2004270538	A1	20050317	AU 2004-270538		20040902
	CA 2535749	A1	20050317	CA 2004-2535749		20040902
	EP 1661890	A1	20060531	EP 2004-772699		20040902
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
	CN 1845905	A	20061011	CN 2004-80025146		20040902
	BR 2004013991	A	20061107	BR 2004-13991		20040902
	US 2005101636	A1	20050512	US 2004-933467		20040903
	US 7109226	B2	20060919			
	NO 2006000654	A	20060426	NO 2006-654		20060209
	US 2006189667	A1	20060824	US 2006-407076		20060420
	US 7183295	B2	20070227			
PRAI	US 2003-499357P	P	20030903			
	JP 2003-317353	A	20030909			
	JP 2003-364817	A	20031024			
	WO 2004-JP12750	W	20040902			
	US 2004-933467	A3	20040903			

OS MARPAT 142:316836
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 33 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:158622 CAPLUS
DN 142:279952
TI Preparation of aralkanoates as inhibitors of prostaglandin and leukotriene production.
IN Shoda, Motoshi; Kuriyama, Hiroshi
PA Asahi Kasei Pharma Corporation, Japan
SO PCT Int. Appl., 687 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016862	A1	20050224	WO 2004-JP11952	20040813
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004265191	A1	20050224	AU 2004-265191	20040813
	CA 2535665	A1	20050224	CA 2004-2535665	20040813
	WO 2005016862	A1	20050224	WO 2004-XA11952	20040813
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	EP 1653938	A2	20060510	EP 2004-763551		20040727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR					
	JP 2007500158	T	20070111	JP 2006-521514		20040727
	US 2006205819	A1	20060914	US 2006-566637		20060127
PRAI	US 2003-490614P	P	20030728			
	WO 2004-EP8426	W	20040727			

OS MARPAT 142:212365

L18 ANSWER 35 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:120698 CAPLUS
DN 142:225773
TI Controlled release dosage forms containing cholesteryl ester transfer protein inhibitors and immediate release of HMG-CoA reductase inhibitors
IN Curatolo, William John; Friesen, Dwayne Thomas; Sutton, Steven C.
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005011634	A1	20050210	WO 2004-IB2457	20040721
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004261058	A1	20050210	AU 2004-261058		20040721
	CA 2534371	A1	20050210	CA 2004-2534371		20040721
	EP 1653926	A1	20060510	EP 2004-744109		20040721
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
	BR 2004013363	A	20061010	BR 2004-13363		20040721
	CN 1863511	A	20061115	CN 2004-80029003		20040721
	JP 2007501217	T	20070125	JP 2006-522426		20040721
	US 2005038007	A1	20050217	US 2004-903433		20040730
	NO 2006001072	A	20060504	NO 2006-1072		20060306
PRAI	US 2003-492407P	P	20030804			
	WO 2004-IB2457	W	20040721			

OS MARPAT 142:225773
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 36 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:99330 CAPLUS
DN 142:191262
TI Methods of cardiovascular disease treatment with LXR agonists
IN Barone, Frank C.; Costney, Robert M.; Legos, Jeffrey J.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2005016862	A1	20050224	WO 2004-XB11952	20040813
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2005016862	A1	20050224	WO 2004-XC11952	20040813
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1660427	A1	20060531	EP 2004-771913	20040813
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	JP 2003-293590	A	20030814		
	US 2003-495734P	P	20030818		
	WO 2004-JP11952	W	20040813		

OS MARPAT 142:279952
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 34 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:136527 CAPLUS
DN 142:212365
TI Use of LXR agonists to treat inflammatory bowel diseases
IN Goto, Yukio; Kikkawa, Hideo; Kinoshita, Mine
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005013946	A2	20050217	WO 2004-EP8426	20040727
	WO 2005013946	A3	20050407		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PI WO 2005009383 A2 20050203 WO 2004-US23658 20040722
WO 2005009383 A3 20051208
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	EP 1646394	A2	20060419	EP 2004-778949		20040722
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
	JP 2006528200	T	20061214	JP 2006-521249		20040722
	US 2006189693	A1	20060824	US 2006-565495		20060120
PRAI	US 2003-489202P	P	20030722			
	WO 2004-US23658	W	20040722			

OS MARPAT 142:191262

L18 ANSWER 37 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1127103 CAPLUS
DN 142:69217
TI Reciprocal regulation of inflammation and lipid metabolism by liver x receptors
IN Tontonoz, Peter; Joseph, Sean B.; Castrillo, Antonio
PA USA
SO U.S. Pat. Appl. Publ., 32 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004259948	A1	20041223	US 2004-755720	20040112
	WO 2005070072	A2	20050804	WO 2005-US442	20050107
	WO 2005070072	A3	20051019		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-439570P	P	20030110		
	US 2004-755720	A	20040112		

L18 ANSWER 38 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1124587 CAPLUS
DN 142:69188
TI Combination therapy for the treatment of diabetes
IN Brondu, Ngozi E.; Fong, Tung M.; MacNeil, Douglas J.; Van Der Ploeg, Leonardus H. T.; Kanatani, Akio
PA Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110375	A2	20041223	WO 2004-US17291	20040602
	WO 2004110375	A3	20050512		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1635832	A2	20060322	EP 2004-753999	20040602
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 2007099884	A1	20070503	US 2005-559206	20051202
PRAI	US 2003-476386P	P	20030606		
	WO 2004-US17291	W	20040602		
OS	MARPAT 142:69188				

L18 ANSWER 39 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1124581 CAPLUS
DN 142:69181
TI Combination therapy for the treatment of hypertension
IN Fong, Tung M.; Erondu, Ngozi E.; Macneil, Douglas J.; Mcintyre, James H.; Van Der Ploeg, Leonardus H. T.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110368	A2	20041223	WO 2004-US17090	20040602
	WO 2004110368	A3	20060720		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1635773	A2	20060322	EP 2004-753832	20040602
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	US 2006160834	A1	20060720	US 2005-559111	20051202
PRAI	US 2003-476390P	P	20030606		
	WO 2004-US17090	W	20040602		
OS	MARPAT 142:69181				

L18 ANSWER 40 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:927179 CAPLUS
DN 141:395430
TI Preparation of isoquinoline-5-sulfonic acid amides as inhibitors of Akt (Protein kinase B) for treating neoplasms and viral infections
IN Al Awar, Rima Salim; Barda, David Anthony; Henry, Kenneth James, Jr.; Joseph, Sajan; Lin, Ho-Shen; Lopez, Jose Eduardo; Richett, Michael Enrico; Somoza, Carmen
PA Eli Lilly and Company, USA; Dee, Albert Gerard
SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004094386	A1	20041104	WO 2004-US6093	20040325
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004231554	A1	20041104	AU 2004-231554	20040407
	CA 2520908	A1	20041104	CA 2004-2520908	20040407
	US 2005070532	A1	20050331	US 2004-820647	20040407
	EP 1613326	A1	20060111	EP 2004-759820	20040407
	EP 1613326	B1	20060913		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004009763	A	20060509	BR 2004-9763	20040407
	CN 1791409	A	20060621	CN 2004-80010350	20040407
	AT 339205	T	20061015	AT 2004-759820	20040407
	JP 2006523698	T	20061019	JP 2006-509849	20040407
	IN 2005KN01963	A	20061222	IN 2005-KN1963	20051004
PRAI	US 2003-464581P	P	20030417		
	WO 2004-US10970	W	20040407		
OS	MARPAT 141:379940				

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 41 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:927049 CAPLUS
DN 141:379940
TI A preparation of hydroxypropylamine derivatives, useful as modulators of peroxisome proliferator activated receptors (PPARs)
IN Liu, Kevin; Zhao, Cunxiang
PA Kalypsys, Inc., USA
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004093879	A1	20041104	WO 2004-US10970	20040407
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004231554	A1	20041104	AU 2004-231554	20040407
	CA 2520908	A1	20041104	CA 2004-2520908	20040407
	US 2005070532	A1	20050331	US 2004-820647	20040407
	EP 1613326	A1	20060111	EP 2004-759820	20040407
	EP 1613326	B1	20060913		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004009763	A	20060509	BR 2004-9763	20040407
	CN 1791409	A	20060621	CN 2004-80010350	20040407
	AT 339205	T	20061015	AT 2004-759820	20040407
	JP 2006523698	T	20061019	JP 2006-509849	20040407
	IN 2005KN01963	A	20061222	IN 2005-KN1963	20051004
PRAI	US 2003-464581P	P	20030417		
	WO 2004-US10970	W	20040407		
OS	MARPAT 141:379940				

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 42 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:835972 CAPLUS
DN 142:254275
TI Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor
AU Quinet, Elaine M.; Savio, Dawn A.; Halpern, Anita R.; Chen, Liang; Miller, Christopher P.; Nambi, Ponnal
CS Departments of Cardiovascular/Metabolic Diseases, Wyeth Research, Collegeville, PA, 19246, USA
SO Journal of Lipid Research (2004), 45(10), 1929-1942
CODEN: JLPRAW; ISSN: 0022-2275
PB American Society for Biochemistry and Molecular Biology, Inc.
DT Journal
LA English
RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 43 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:653996 CAPLUS
DN 141:199923
TI Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator
AU Miao, Bowman; Zondlo, Susan; Gibbs, Sandy; Cromley, Debra; Hosagrahara, Vinayak P.; Kirchgessner, Todd G.; Billheimer, Jeffrey; Mukherjee, Ranjan
CS Cardiovascular Biology, Experimental Station, Bristol-Myers Squibb Company, Wilmington, DE, 19880, USA
SO Journal of Lipid Research (2004), 45(8), 1410-1417
CODEN: JLPRAW; ISSN: 0022-2275
PB American Society for Biochemistry and Molecular Biology, Inc.
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 44 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:571227 CAPLUS
DN 141:117718
TI The effect of LXR activators on AP-1 proteins in keratinocytes
AU Schmuth, Matthias; Elias, Peter M.; Hanley, Karen; Lau, Peggy; Moser, A.; Willson, Timothy M.; Bikle, Daniel D.; Feingold, Kenneth R.
CS Department of Medicine, University of California, San Francisco, CA, USA
SO Journal of Investigative Dermatology (2004), 123(1), 41-48
CODEN: JIDEAB; ISSN: 0022-202X
PB Blackwell Publishing, Inc.
DT Journal
LA English
RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 45 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:566658 CAPLUS
DN 141:119046
TI Crystal structure of a ligand-binding domain of human LXRβ and applications in drug discovery
IN Farnegardh, Mathias; Bonn, Tomas; Sun, Sherry; Ljunggren, Jan; Ahola, Harri; Carlquist, Mats
PA Karo Bio Ab, Swed.
SO PCT Int. Appl., 378 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058819	A2	20040715	WO 2003-IB6412	20031224
	WO 2004058819	A3	20041202		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2511357	A1	20040715	CA 2003-2511357	20031224
	AU 2003296851	A1	20040722	AU 2003-296851	20031224
	EP 1583776	A2	20051012	EP 2003-813966	20031224
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003017744	A	20051122	BR 2003-17744	20031224
	CN 1753910	A	20060329	CN 2003-80109950	20031224
	US 2007060740	A1	20070315	US 2006-540612	20060724
PRAI	GB 2002-30177	A	20021224		
	WO 2003-IB6412	W	20031224		

L18 ANSWER 46 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:566548 CAPLUS
DN 141:117168
TI Novel use of liver x receptor agonists to treat diabetes and related diseases
IN Saez, Enrique; Tontonoz, Peter; Laffitte, Bryan A.; Li, Jing
PA IRM Llc, Bermuda; The Regents of the University of California
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058175	A2	20040715	WO 2003-US40906	20031222
	WO 2004058175	A3	20040910		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2003301216	A1	20040722	AU 2003-301216	20031222
US	2005036992	A1	20050217	US 2003-745334	20031222
PRAI US	2002-436112P	P	20021223		
WO	2003-US40906	W	20031222		

L18 ANSWER 47 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:430788 CAPLUS
DN 141:6921
TI Preparation of substituted phenyl amides as LXRα and LXRβ agonists
IN Thompson, Scott K.; Frazee, James S.; Kallander, Lara S.; Ma, Chun; Marino, Joseph P.; Neeb, Michael J.; Wang, Ning
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004043939	A1	20040527	WO 2003-US9461	20030326

W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2003220558	A1	20040603	AU 2003-220558	20030326
EP	1497270	A1	20050119	EP 2003-716872	20030326
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US	2005107444	A1	20050519	US 2003-508791	20030326
JP	2006514925	T	20060518	JP 2004-551393	20030326
PRAI US	2002-368427P	P	20020327		
WO	2003-US9461	W	20030326		

OS MARPAT 141:6921
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 48 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:308396 CAPLUS
DN 140:339072
TI Preparation of benzamide derivatives as LPA receptor antagonists
IN Terakado, Masahiko; Nakade, Shinji; Seko, Takuya; Takaoka, Yoshikazu
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 304 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004031118	A1	20040415	WO 2003-JP6680	20030528

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2003241836	A1	20040423	AU 2003-241836	20030528
EP	1553075	A1	20050713	EP 2003-733131	20030528
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US	2006148830	A1	20060706	US 2005-530249	20050404
PRAI JP	2002-291137	A	20021003		
WO	2003-JP6680	W	20030528		

OS MARPAT 140:339072
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 49 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:182896 CAPLUS
DN 140:236000
TI Preparation of 4-benzylpyrazolyl glucopyranosides and galactopyranoside derivatives as sodium-glucose cotransporter (SGLT1) inhibitors, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
IN Fushimi, Nobuhiko; Shimizu, Kazuo; Yonekubo, Shigeru; Teranishi, Hirotaka; Tomae, Masaki; Isaji, Masayuki
PA Kissei Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 270 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004018491	A1	20040304	WO 2003-JP10551	20030821

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP	2004137245	A	20040513	JP 2002-324076	20021107
CA	2496329	A1	20040304	CA 2003-2496329	20030821
AU	2003262263	A1	20040311	AU 2003-262263	20030821
EP	1546024	A1	20050629	EP 2003-792760	20030821
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR	2003013694	A	20050705	BR 2003-13694	20030821
CN	1698597	A	20051026	CN 2003-824499	20030821
NZ	538423	A	20070223	NZ 2003-538423	20030821
US	2005272669	A1	20051208	US 2005-525197	20050222
NO	2005001411	A	20050426	NO 2005-1411	20050317
PRAI JP	2002-244381	A	20020823		
JP	2002-324076	A	20021107		
WO	2003-JP10551	W	20030821		

OS MARPAT 140:236000
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 50 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:971723 CAPLUS
DN 140:23272
TI Treatments for age-related macular degeneration (AMD)that increase reverse cholesterol transport using a hormone receptor ligand or a lipid transporter
IN Schwartz, Daniel M.; Duncan, Keith G.; Bailey, Kathy R.; Kane, John P.; Ishida, Brian Y.
PA The Regents of the University of California, USA
SO U.S. Pat. Appl. Publ., 64 pp., Cont.-in-part of U.S. Pat. Appl. 2003 162,758.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003229062	A1	20031211	US 2003-428551	20030502
US 2003162758	A1	20030828	US 2002-313641	20021206
US 2004266663	A1	20041230	US 2004-794198	20040305
WO 2004098506	A2	20041118	WO 2004-US13332	20040430
WO 2004098506	A3	20060112		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US	2005282750	A1	20051222	US 2005-55309	20050210
PRAI US	2001-340498P	P	20011207		
US	2002-415864P	P	20021003		
US	2002-313641	A2	20021206		
US	2003-428551	A2	20030502		
US	2004-794198	A3	20040305		

=> d 51-60

L18 ANSWER 51 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:796645 CAPLUS
DN 139:307687
TI Preparation of (hetero)arylalkanoic acids and esters as LXR agonists
IN Thompson, Scott K.; Kallander, Lara S.; Ma, Chun; Marino, Joseph P.; Lee, Dennis
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003082802	A1	20031009	WO 2003-US9278	20030326

W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2003222083	A1	20031013	AU 2003-222083	20030326
EP	1487776	A1	20041222	EP 2003-718068	20030326
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP	2005521721	T	20050721	JP 2003-580271	20030326
US	2006041164	A1	20060223	US 2005-508893	20050126
PRAI US	2002-368426P	P	20020327		
WO	2003-US9278	W	20030326		

OS MARPAT 139:307687
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 52 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:796427 CAPLUS
DN 139:323535
TI Preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivatives as modulating agents for liver X receptors (LXR)
IN Thompson, Scott K.; Frazee, James S.; Kallander, Lara S.; Ma, Chun; Marino, Joseph P.; Neeb, Michael J.; Bhat, Ajita; Mcatee, John Jeffrey; Stavenger, Robert A.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003082205	A2	20031009	WO 2003-US9450	20030326

W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2003226094	A1	20031013	AU 2003-226094	20030326
US	2005113580	A1	20050526	US 2003-508894	20030326
EP	1575495	A2	20050921	EP 2003-745638	20030326
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP	2006512280	T	20060413	JP 2003-579748	20030326
PRAI US	2002-368425P	P	20020327		
WO	2003-US9450	W	20030326		

OS MARPAT 139:323535

L18 ANSWER 53 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:796421 CAPLUS
DN 139:302072
TI Methods of treatment with LXR modulators
IN Cairns, William J.; Irving, Elaine A.; Parsons, Andrew A.; Soden, Peter E.; Richardson, Jill C.; Burbidge, Stephen A.; Vinson, Mary; Watson, Mike A.; Whitney, Karl
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003082198	A2	20031009	WO 2003-US9225	20030326
WO 2003082198	A3	20041223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2003220521	A1	20031013	AU 2003-220521	20030326
EP	1511483	A2	20050309	EP 2003-716832	20030326
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US	2005171084	A1	20050804	US 2003-509197	20030326
JP	2005533007	T	20051104	JP 2003-579741	20030326
PRAI US	2002-368424P	P	20020327		
WO	2003-US9225	W	20030326		

OS MARPAT 139:302072

L18 ANSWER 54 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:771030 CAPLUS
DN 139:334533
TI The Three-dimensional Structure of the Liver X Receptor β Reveals a Flexible Ligand-binding Pocket That Can Accommodate Fundamentally Different Ligands
AU Faernegardh, Mathias; Bonn, Tomas; Sun, Sherry; Ljunggren, Jan; Ahola, Harri; Wilhelmsson, Anna; Gustafsson, Jan-Ake; Carlquist, Mats
CS Karolinska Institute, Huddinge University Hospital, NOVUM, Karo Bio AB, Huddinge, SE-141 57, Swed.
SO Journal of Biological Chemistry (2003), 278(40), 38821-38828
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 55 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:719439 CAPLUS
DN 139:245783
TI Preparation of arylamidine derivatives as fungicides
IN Hayashi, Kazuya; Ojima, Katsuji; Hori, Kozo; Okujo, Hiroyuki; Mitsuyama, Junichi; Kunitani, Kazuto; Tohdo, Keisuke
PA Toyama Chemical Co., Ltd., Japan
SO PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003074476	A1	20030912	WO 2003-JP2506	20030304
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2477212	A1	20030912	CA 2003-2477212	20030304
	AU 2003211692	A1	20030916	AU 2003-211692	20030304
	EP 1481966	A1	20041201	EP 2003-743600	20030304
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008207	A	20041221	BR 2003-8207	20030304
	US 2005113424	A1	20050526	US 2003-506422	20030304
	CN 1642906	A	20050720	CN 2003-807452	20030304
	NZ 534962	A	20050729	NZ 2003-534962	20030304
	RU 2299195	C2	20070520	RU 2004-129725	20030304
	IN 2004KN01208	A	20060512	IN 2004-KN1208	20040819
	ZA 2004006717	A	20050824	ZA 2004-6717	20040824
	NO 2004003914	A	20040920	NO 2004-3914	20040920
PRAI	JP 2002-60618	A	20020306		
	WO 2003-JP2506	W	20030304		

OS MARPAT 139:245783
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 56 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:643137 CAPLUS
DN 140:266251
TI Molecular determinants of LXRα agonism
AU Wang, Minmin; Thomas, Jeffrey; Burris, Thomas P.; Schkeryantz, Jeffrey; Michael, Laura F.
CS Lilly Research Laboratories, Department of Discovery Chemistry Research and Technologies, Eli Lilly & Company, Indianapolis, IN, 46285, USA
SO Journal of Molecular Graphics & Modelling (2003), 22(2), 173-181
CODEN: JMGMFI; ISSN: 1093-3263
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 57 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:633275 CAPLUS
DN 139:169333
TI Novel anticholesterol compositions and method for using same
IN Dudley, Robert; Liao, Shutsung; Song, Ching
PA USA
SO U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 137,695.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003153541	A1	20030814	US 2002-174934	20020619
	WO 9922728	A1	19990514	WO 1998-US23041	19981030
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6576660	B1	20030610	US 2000-530443	20000428
	US 6645955	B1	20031111	US 2000-560236	20000428
	ZA 2001009793	A	20030228	ZA 2001-9793	20011128
	CA 2438221	A1	20020815	CA 2002-2438221	20020207
	AU 2002238093	A1	20020819	AU 2002-238093	20020207
	EP 1385868	A2	20040204	EP 2002-704407	20020207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2005508281	T	20050331	JP 2002-562310	20020207
	US 2002107233	A1	20020808	US 2002-72128	20020208
	US 2002193357	A1	20021219	US 2002-137695	20020502
	US 7012069	B2	20060314		
	CA 2489702	A1	20031231	CA 2003-2489702	20030619
	WO 2004001002	A2	20031231	WO 2003-US19515	20030619
	WO 2004001002	A3	20040506		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003245605	A1	20040106	AU 2003-245605	20030619
	EP 1534298	A2	20050601	EP 2003-739234	20030619
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005533810	T	20051110	JP 2004-516031	20030619
PRAI	US 1997-63770P	P	19971031		
	WO 1998-US23041	W	19981030		
	US 1999-131728P	P	19990430		
	US 2000-530443	A2	20000428		
	US 2000-560236	A2	20000428		
	US 2001-267493P	P	20010208		
	US 2001-288643P	P	20010503		
	US 2001-348020P	P	20011108		
	US 2002-72128	A2	20020208		
	US 2002-137695	A2	20020502		
	US 2000-191864P	P	20000324		
	WO 2002-US3626	W	20020207		
	US 2002-174934	A	20020619		
	WO 2003-US19515	W	20030619		

OS MARPAT 139:169333

L18 ANSWER 58 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:472342 CAPLUS
DN 139:47197
TI Treatment for age-related macular degeneration
IN Schwartz, Daniel M.; Duncan, Keith; Bailey, Kathy; Kane, John; Ishida, Brian
PA Regents of the University of California, USA
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003049685	A2	20030619	WO 2002-US38856	20021206
	WO 2003049685	A3	20040708		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2468989	A1	20030619	CA 2002-2468989	20021206
	AU 2002360489	A1	20030623	AU 2002-360489	20021206
	EP 1461028	A2	20040929	EP 2002-795748	20021206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005511713	T	20050428	JP 2003-550736	20021206
PRAI	US 2001-340498P	P	20011207		
	US 2002-415864P	P	20021003		
	WO 2002-US38856	W	20021206		

L18 ANSWER 59 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:101818 CAPLUS
DN 139:47079
TI Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: Liver-X-receptor-specific inhibition of inflammation and primary cytokine production
AU Fowler, Ashley J.; Sheu, Mary Y.; Schmuth, Matthias; Kao, Jack; Fluhr, Joachim W.; Rhein, Linda; Collins, Jon L.; Willson, Timothy M.; Mangelsdorf, David J.; Elias, Peter M.; Feingold, Kenneth R.
CS Department of Dermatology, University of California, San Francisco, USA
SO Journal of Investigative Dermatology (2003), 120(2), 246-255
CODEN: JIDEAE; ISSN: 0022-202X
PB Blackwell Publishing, Inc.
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 60 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:434801 CAPLUS
DN 137:362768
TI Synthetic LXR ligand inhibits the development of atherosclerosis in mice
AU Joseph, Sean B.; McKilligin, Elaine; Pei, Liming; Watson, Michael A.; Collins, Alan R.; Laffitte, Bryan A.; Chen, Mingyi; Noh, Grace; Goodman, Joanne; Hagger, Graham N.; Tran, Jonathan; Tippin, Tim K.; Wang, Xuping; Lusis, Aldons J.; Hsueh, Wila A.; Law, Ronald E.; Collins, Jon L.; Willson, Timothy M.; Tontonoz, Peter
CS Departments of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, 90095-1662, USA
SO Proceedings of the National Academy of Sciences of the United States of America (2002), 99(11), 7604-7609
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 51-106 ibib abs hitstr

L18 ANSWER 51 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:796645 CAPLUS
DOCUMENT NUMBER: 139:307687
TITLE: Preparation of (hetero)arylalkanoic acids and esters as LXR agonists
INVENTOR(S): Thompson, Scott K.; Kallander, Lara S.; Ma, Chun; Marino, Joseph P.; Lee, Dennis
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003082802		A1	20031009	WO 2003-US9278	20030326
	W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003222083		A1	20031013	AU 2003-222083	20030326
EP 1487776		A1	20041222	EP 2003-718068	20030326
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005521721		T	20050721	JP 2003-580271	20030326
US 2006041164		A1	20060223	US 2005-508893	20050126
PRIORITY APPLN. INFO.:				US 2002-368426P	P 20020327
				WO 2003-US9278	W 20030326

OTHER SOURCE(S): MARPAT 139:307687

GI



I

AB Title compds. I [X, X2 = bond, alkylene; X1 = alkylene; Q = (un)substituted cycloalkyl, Ph, heterocyclic; W1, W2 = cycloalkyl, aryl; R = H, alkyl, alkenyl, alkynyl, aralkyl, heterocyclylalkyl, cycloalkylalkyl; R1, R2 = H, alkyl; R3 = halo, CN, NO2, (un)substituted alkyl, alkenyl, alkynyl; Z = (un)substituted CH, N; when Z = (un)substituted CH, n = 0-4; when Z = N, n = 0-3] were prepared for use as LXR agonists in treatment of cardiovascular disease, atherosclerosis, or inflammation (no data). Thus, 3-HOC6H4CH2CO2H was converted to 3-HOC6H4CH2CO2Me and treated with (S)-BrCH2CHMeCH2OH, followed by Ph2CHCH2NH2 and 2,3-Cl(F3C)C6H3CHO to give (S)-3-MeO2CC6H4OCH2CHMeCH2N(CH2CHPh2)CH2C6H3(CF3)Cl-3,2.

IT 610319-04-5P 610319-12-5P 610319-13-6P
610319-16-9P 610319-17-0P 610319-18-1P
610319-21-6P 610319-22-7P 610319-26-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (hetero)arylalkanoic acids and esters as LXR agonists)

RN 610319-04-5 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 610319-12-5 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2,2-bis(4-fluorophenyl)ethyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 610319-13-6 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2,2-bis(3-fluorophenyl)ethyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 610319-16-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(2-chlorophenyl)-2-phenylethyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 610319-17-0 CAPLUS
CN Benzoic acid, 2-bromo-5-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 610319-18-1 CAPLUS
CN Benzeneacetic acid, 2-bromo-5-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 610319-21-6 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-cyclopentyl-2-phenylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 610319-22-7 CAPLUS
CN Benzoic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 610319-26-1 CAPLUS
CN Benzenepropanoic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α,α-dimethyl-, methyl ester (9CI) (CA INDEX NAME)



IT 610318-36-0P 610318-39-3P 610318-46-2P
610318-90-6P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (hetero)arylalkanoic acids and esters as LXR agonists)

RN 610318-36-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α,α-diethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 610318-39-3 CAPLUS
CN Benzoic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-46-2 CAPLUS
CN Benzeneacetic acid, 3-chloro-4-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 610318-90-6 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α,α-diethyl- (9CI) (CA INDEX NAME)



IT 610318-05-3P 610318-29-1P 610318-30-4P
610318-31-5P 610318-32-6P 610318-33-7P
610318-34-8P 610318-35-9P 610318-37-1P
610318-40-6P 610318-41-7P 610318-42-8P
610318-43-9P 610318-44-0P 610318-47-3P
610318-48-4P 610318-49-5P 610318-82-6P
610318-83-7P 610318-84-8P 610318-85-9P
610318-86-0P 610318-87-1P 610318-88-2P
610318-89-3P 610318-91-7P 610318-92-8P
610318-93-9P 610318-94-0P 610318-95-1P
610318-96-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hetero)arylalkanoic acids and esters as LXR agonists)

RN 610318-05-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-29-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2,2-bis(4-fluorophenyl)ethyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-30-4 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2,2-bis(3-fluorophenyl)ethyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-31-5 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(2-chlorophenyl)-2-phenylethyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-32-6 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α-ethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-33-7 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α-propyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-34-8 CAPLUS
CN Benzeneacetic acid, α-butyl-3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-35-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-37-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α,α-diethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-40-6 CAPLUS
CN Benzoic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-41-7 CAPLUS
CN Benzoic acid, 2-bromo-5-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-42-8 CAPLUS
CN Benzeneacetic acid, 2-bromo-5-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-48-4 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-49-5 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610318-82-6 CAPLUS
CN Benzoic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-4-methyl- (9CI) (CA INDEX NAME)



RN 610318-83-7 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2,2-bis(4-fluorophenyl)ethyl][[2-chloro-3-



● HCl

RN 610318-43-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-cyclopentyl-2-phenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 610318-44-0 CAPLUS
CN Benzenepropanoic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α,α-dimethyl- (9CI) (CA INDEX NAME)



RN 610318-47-3 CAPLUS
CN Benzeneacetic acid, 3-chloro-4-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)

(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 610318-84-8 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2,2-bis(3-fluorophenyl)ethyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 610318-85-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(2-chlorophenyl)-2-phenylethyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 610318-86-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α-ethyl- (9CI) (CA INDEX NAME)



RN 610318-87-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α-propyl- (9CI) (CA INDEX NAME)



RN 610318-88-2 CAPLUS
CN Benzeneacetic acid, α-butyl-3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 610318-89-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 610318-91-7 CAPLUS
CN Benzoic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 610318-96-2 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α-methyl- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 52 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:796427 CAPLUS
DOCUMENT NUMBER: 139:323535
TITLE: Preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivatives as modulating agents for liver X receptors (LXR)
INVENTOR(S): Thompson, Scott K.; Frazee, James S.; Kallander, Lara S.; Ma, Chun; Marino, Joseph P.; Neeb, Michael J.; Bhat, Ajita; Mcatee, John Jeffrey; Stavenger, Robert A.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082205	A2	20031009	WO 2003-US9450	20030326
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003226094	A1	20031013	AU 2003-226094	20030326
US 2005113580	A1	20050526	US 2003-508894	20030326
EP 1575495	A2	20050921	EP 2003-745638	20030326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006512280	T	20060413	JP 2003-579748	20030326
PRIORITY APPLN. INFO.:			US 2002-368425P	P 20020327
			WO 2003-US9450	W 20030326

OTHER SOURCE(S): MARPAT 139:323535
GI



RN 610318-92-8 CAPLUS
CN Benzoic acid, 2-bromo-5-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 610318-93-9 CAPLUS
CN Benzeneacetic acid, 2-bromo-5-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 610318-94-0 CAPLUS
CN Benzeneacetic acid, 3-chloro-4-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 610318-95-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-α,α-dimethyl- (9CI) (CA INDEX NAME)





AB The title compds. (I) [X = C1-8 alkyl, halo, each (un)substituted OH, NH2, NHCONH2, SO2NH2, CO2H, or C(:NH)NH2; 5 or 6-membered heterocyclyl, etc.; or X and R3 together with their bonded atoms form alkylenedioxy; Z = (un)substituted CH or N; when Z = (un)substituted CH, p1 = 0-4 and q1 = 0-1; when Z = N, p1 = 0-3 and q1 = 0; Y = O, S, each (un)substituted NH or CH2; W1 = C1-6 alkyl, C3-8 cycloalkyl, aryl, heterocyclyl, etc.; W2 = H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, each N, S, or O-(un)substituted C0-6 alkyl-NH2, C0-C6 alkyl-SH, C0-6 alkyl-OH, C0-6 alkyl-CO2H, etc.; W3 = H, halo, C1-6 alkyl, each N, S, or O-(un)substituted C0-6 alkyl-NH2, C0-6 alkyl-SH, C0-6 alkyl-OH, or C0-6 alkyl-CO2H, etc.; p = 0-8; n = 2-8; m, q, q1 = 0, 1; R1, R2 = H, halo, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, each N-, O-, or S-(un)substituted C0-6 alkyl-NH2 C0-6 alkyl-OH, or C0-6 alkyl-SH, heterocyclyl-C1-C6 alkyl, aryl-C1-6 alkyl, C3-7 cycloalkyl-C1-C6 alkyl, etc.; or CR1R2 forms a 3-5 membered carbocyclic or heterocyclic ring; R3 = halo, cyano, nitro, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, aryl-C0-6 alkyl, heterocyclyl-C0-6 alkyl etc.; R4, R5 = H, halo, C1-6 alkyl, heterocyclyl-C0-6 alkyl, aryl-C0-6 alkyl, C3-7 cycloalkyl-C0-6 alkyl; R6, R7, R8, R9 = H, halo, C1-6 alkyl, heterocyclyl-C0-6 alkyl, aryl-C0-6 alkyl, C3-7 cycloalkyl-C0-6 alkyl, etc.] or pharmaceutically acceptable salts or solvates thereof are prepared. Many specific compds. are claimed. Also disclosed are pharmaceutical compns. containing the compds. I. The compds. I, salts and solvates of this invention are useful as LXR agonists for the prevention or treatment of LXR-mediated diseases such as cardiovascular disease, atherosclerosis, inflammation or as a medicament for increasing reverse cholesterol transport or inhibiting cholesterol absorption.

IT 609772-11-4P 612498-41-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine deriva. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

RN 609772-11-4 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[[2-(ethoxymethyl)-2H-tetrazol-5-yl]methyl]phenoxy]propyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612498-41-6 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[[1-(ethoxymethyl)-1H-tetrazol-5-yl]methyl]phenoxy]propyl]- β-phenyl- (9CI) (CA INDEX NAME)



IT 405910-78-3P 405911-17-3P 405911-26-4P
609772-14-7P 610318-44-0P 610319-22-7P
610319-26-1P 612498-34-7P 612498-35-8P
612498-36-9P 612498-44-9P, (2-Chloro-3-trifluoromethylbenzyl)(2-cyclohexyl-2-phenylethyl)[3-[3-[(1-ethoxymethyl-1H-1,2,3,4-tetrazol-5-yl)methyl]phenoxy]propyl]amine 612498-45-0P, (2-Chloro-3-trifluoromethylbenzyl)(2-cyclohexyl-2-phenylethyl)[3-[3-[(2-ethoxymethyl-2H-1,2,3,4-tetrazol-5-yl)methyl]phenoxy]propyl]amine
612498-47-2P 612498-50-7P 612498-54-1P
612498-79-0P 612498-80-3P 612498-82-5P
612498-83-6P 612498-84-7P 612498-86-9P
612498-89-2P 612498-93-8P 612498-96-1P
612498-98-3P 612498-99-4P 612499-00-0P
612499-01-1P 612499-02-2P 612499-03-3P
612499-05-5P 612499-06-6P, 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl][2,2-diphenylethyl]amino]propoxy]phenyl]-N-ethylacetamide hydrochloride 612499-07-7P 612499-08-8P
612499-13-5P 612499-14-6P 612499-15-7P
612499-30-6P 612499-31-7P 612499-34-0P
612499-37-3P 612499-39-5P 612499-44-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

RN 405910-78-3 CAPLUS
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-17-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 612498-34-7 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[[1-(ethoxymethyl)-1H-1,2,4-triazol-3-yl]methyl]phenoxy]propyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612498-35-8 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[[1-(ethoxymethyl)-1H-1,2,4-triazol-5-yl]methyl]phenoxy]propyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612498-36-9 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[[4-(ethoxymethyl)-4H-1,2,4-triazol-3-yl]methyl]phenoxy]propyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612498-44-9 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-cyclohexyl-N-[3-[3-[[1-(ethoxymethyl)-1H-tetrazol-5-yl]methyl]phenoxy]propyl]- (9CI) (CA INDEX NAME)

RN 405911-26-4 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 609772-14-7 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 610318-44-0 CAPLUS
CN Benzenepropanoic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- α,α-dimethyl- (9CI) (CA INDEX NAME)



RN 610319-22-7 CAPLUS
CN Benzoic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 610319-26-1 CAPLUS
CN Benzenepropanoic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- α,α-dimethyl-, methyl ester (9CI) (CA INDEX NAME)



RN 612498-45-0 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-cyclohexyl-N-[3-[3-[[2-(ethoxymethyl)-2H-tetrazol-5-yl]methyl]phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 612498-47-2 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-hydroxy-2-phenylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 612498-50-7 CAPLUS
CN Propanedioic acid, [3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]-, monomethyl ester (9CI) (CA INDEX NAME)



RN 612498-54-1 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-(2-methyl-3-nitrophenoxy)propyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612498-79-0 CAPLUS
CN Carbamic acid, [[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 612498-80-3 CAPLUS
CN Benzeneethanamine, N-[3-[3-(aminomethyl)phenoxy]propyl]-N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-β-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 612498-82-5 CAPLUS
CN Benzaldehyde, 4-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612498-83-6 CAPLUS
CN Benzaldehyde, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612498-96-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-(3-thienyl)propyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 612498-98-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-(2-thienyl)propyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 612498-99-4 CAPLUS
CN Morpholine, 4-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA



RN 612498-84-7 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[5-nitro-2-(trifluoromethyl)phenoxy]propyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612498-86-9 CAPLUS
CN Carbamic acid, [3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-4-methylphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 612498-89-2 CAPLUS
CN Morpholine, 4-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612498-93-8 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]-α,α-dimethyl-, methyl ester

INDEX NAME)



● HCl

RN 612499-00-0 CAPLUS
CN Piperazine, 1-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612499-01-1 CAPLUS
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612499-02-2 CAPLUS
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(1H-imidazol-2-ylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612499-03-3 CAPLUS
CN Benzeneacetamide, N-[(5-bromo-2-thienyl)methyl]-3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612499-05-5 CAPLUS
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-(2-thienylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612499-06-6 CAPLUS
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 612499-14-6 CAPLUS
CN Benzeneacetaldehyde, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612499-15-7 CAPLUS
CN Glycine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 612499-30-6 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(2-chlorophenyl)propyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 612499-31-7 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(3-chlorophenyl)propyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



● HCl

RN 612499-07-7 CAPLUS
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612499-08-8 CAPLUS
CN Pyrrolidine, 1-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612499-13-5 CAPLUS
CN Thiomorpholine, 4-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 612499-34-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(4-chlorophenyl)propyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 612499-37-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(2-methoxyphenyl)propyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 612499-39-5 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(4-methoxyphenyl)propyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX

NAME)



RN 612499-44-2 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](4-methyl-2-phenylpentyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT 612499-46-4P 612499-48-6P 612499-50-0P
612499-52-2P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

RN 612499-46-4 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-4-methyl-2-phenylpentyl]amino]propoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612499-45-3
CMF C31 H35 Cl F3 N O3

Absolute stereochemistry.

RN 612499-50-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-phenylbutyl]amino]propoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612499-49-7
CMF C29 H31 Cl F3 N O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 612499-52-2 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylbutyl]amino]propoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612499-51-1
CMF C29 H31 Cl F3 N O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 612499-48-6 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-4-methyl-2-phenylpentyl]amino]propoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 612499-47-5
CMF C31 H35 Cl F3 N O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 612495-65-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

RN 612495-65-5 CAPLUS
CN Cyclopropanecarboxamide, N-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT 217098-62-9P 217098-65-2P 609772-06-7P
609772-15-8P 609772-16-9P 612494-88-9P
612494-89-0P 612494-92-5P 612494-93-6P
612494-94-7P 612494-95-8P 612494-96-9P
612494-97-0P 612494-98-1P 612494-99-2P
612495-00-8P 612495-01-9P 612495-02-0P
612495-03-1P 612495-04-2P 612495-05-3P
612495-07-5P 612495-08-6P 612495-09-7P
612495-10-0P 612495-11-1P 612495-12-2P
612495-13-3P 612495-14-4P 612495-15-5P
612495-31-5P 612495-32-6P 612495-48-4P
612495-49-5P 612495-50-8P 612495-66-6P
612495-67-7P 612495-68-8P 612495-69-9P
612495-70-2P 612495-71-3P 612495-72-4P
612495-77-9P 612495-81-5P 612495-82-6P
612495-85-9P 612495-87-1P 612495-88-2P

612495-89-3P 612495-90-6P 612495-91-7P
612495-92-8P 612495-93-9P 612495-94-0P
612495-95-1P 612495-96-2P 612495-97-3P
612495-98-4P 612495-99-5P 612496-00-1P
612496-01-2P 612496-02-3P 612496-03-4P
612496-04-5P 612496-06-7P 612496-07-8P
612496-08-9P 612496-20-5P 612496-21-6P
612496-24-9P 612496-25-0P 612496-26-1P
612496-27-2P 612496-28-3P 612496-29-4P
612496-30-7P 612496-31-8P 612496-32-9P
612496-33-0P 612496-34-1P 612496-35-2P
612496-36-3P 612496-37-4P 612496-38-5P
612496-39-6P 612496-40-9P 612496-42-1P
612496-45-4P 612496-46-5P 612496-47-6P
612496-48-7P 612496-49-8P 612496-50-1P
612496-51-2P 612496-53-4P 612496-54-5P
612496-55-6P 612496-56-7P 612496-57-8P
612496-58-9P 612496-76-1P 612496-77-2P
612496-78-3P 612496-80-7P 612496-81-8P
612496-82-9P 612496-83-0P 612496-84-1P
612496-85-2P 612496-86-3P 612496-87-4P
612496-88-5P 612496-89-6P 612496-90-9P
612496-91-0P 612496-92-1P 612496-93-2P
612496-94-3P 612496-99-8P 612497-00-4P
612497-01-5P 612497-02-6P 612497-03-7P
612497-04-8P 612497-05-9P 612497-06-0P
612497-07-1P 612497-08-2P 612497-09-3P
612497-10-6P 612497-45-7P 612497-46-8P
612497-49-1P 612497-50-4P 612497-51-5P
612497-52-6P 612497-53-7P 612497-54-8P
612497-55-9P 612497-56-0P 612497-57-1P
612497-58-2P 612497-59-3P 612497-60-6P
612497-61-7P 612497-62-8P 612497-63-9P
612497-64-0P 612497-65-1P 612497-66-2P
612497-69-5P 612497-70-8P 612497-71-9P
612497-72-0P 612497-73-1P 612497-74-2P
612497-75-3P 612497-77-5P 612497-78-6P
612497-79-7P 612497-80-0P 612497-81-1P
612497-82-2P 612497-97-9P, N-(2,2-Diphenylethyl)-N-(2-chloro-3-trifluoromethylbenzyl)[3-[3-(2-methyl-2-aminopropyl)phenoxy]propyl]amine 612497-98-0P
612498-00-7P 612498-01-8P 612498-02-9P
612498-03-0P 612498-04-1P 612498-05-2P
612498-06-3P 612498-08-5P 612498-09-6P
612498-10-9P 612498-11-0P 612498-12-1P
612498-46-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

RN 217098-62-9 CAPLUS
CN 1,2-Benzenedicarboxylic acid, 5-[3-[[(3,4-dichlorophenyl)methyl][2-(2-naphthalenyl)ethyl]amino]propoxy]-3-methoxy-, dimethyl ester (9CI) (CA INDEX NAME)



RN 217098-65-2 CAPLUS
CN 1,2-Benzenedicarboxylic acid, 5-[3-[[(3,4-dichlorophenyl)methyl][2-(2-naphthalenyl)ethyl]amino]propoxy]-3-methoxy-, (9CI) (CA INDEX NAME)



RN 609772-06-7 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-phenyl-N-[3-[3-(1H-tetrazol-5-ylmethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 609772-15-8 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 609772-16-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 612494-88-9 CAPLUS
CN Benzeneethanol, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612494-89-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)oxidoamino]propoxy]- (9CI) (CA INDEX NAME)



RN 612494-92-5 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-phenyl-N-[3-[3-(1H-1,2,4-triazol-3-ylmethyl)phenoxy]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612494-93-6 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-cyclohexyl-N-[3-[3-(1H-tetrazol-5-ylmethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 612494-94-7 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-methyl-N-[3-[3-(2H-tetrazol-2-ylmethyl)phenoxy]propyl]-, monohydrochloride, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 612494-95-8 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-methyl-N-[3-[3-(2H-tetrazol-2-ylmethyl)phenoxy]propyl]-, monohydrochloride, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 612494-96-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-phenylpropyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 612494-97-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](1-naphthalenylmethyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl



● HCl

RN 612495-02-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-phenoxy-2-phenylethyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612495-03-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(benzoyloxy)-2-phenylethyl][2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612495-04-2 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(acetyloxy)-2-phenylethyl][2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)

RN 612494-98-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](phenylmethyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612494-99-2 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-phenylethyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612495-00-8 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-hydroxy-2-phenylethyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612495-01-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(acetyloxy)-2-phenylethyl][2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



RN 612495-05-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(benzoyloxy)-2-phenylethyl][2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 612495-07-5 CAPLUS
CN Benzeneacetic acid, 3-[3-[[(4-fluoro-3-methylphenyl)methyl][(2R)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612495-08-6 CAPLUS
CN Benzeneacetic acid, 3-[3-[(1,3-benzodioxol-5-ylmethyl)[(2R)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612495-09-7 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[4-(1,1-dimethylethyl)phenyl]methyl][(2R)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612495-10-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl][(2R)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612495-11-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[4-(methylthio)phenyl]methyl][(2R)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612495-15-5 CAPLUS
CN 1,3-Propanediol, 2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612495-31-5 CAPLUS
CN 1-Propanesulfonamide, N-[5-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 612495-32-6 CAPLUS
CN Benzeneethanamine, N-[3-(3-amino-2-methylphenoxy)propyl]-N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-48-4 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](3,3,3-trifluoro-2-phenylpropyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612495-12-2 CAPLUS
CN Benzeneacetic acid, 3-[3-[[(2R)-2-phenylpropyl][2,4,5-trifluorophenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612495-13-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[(2R)-2-phenylpropyl][5-(1-piperidinyl)-2-furanyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612495-14-4 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[4-(1-methylethyl)phenyl]methyl][(2R)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612495-49-5 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(dimethylamino)-2-phenylethyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612495-50-8 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(4-morpholinyl)-2-phenylethyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612495-66-6 CAPLUS
CN Propanamide, N-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 612495-67-7 CAPLUS
CN Acetamide, 2-(acetyloxy)-N-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 612495-68-8 CAPLUS
CN Propanamide, N-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 612495-69-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]methyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 612495-70-2 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-(2-methylphenoxy)propyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-71-3 CAPLUS
CN Benzonitrile, 2-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612495-72-4 CAPLUS

CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-(2-methylpropyl)phenoxy]propyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-88-2 CAPLUS
CN Benzeneethanamine, N-[3-(3-butylphenoxy)propyl]-N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-89-3 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-(2,2-dimethylpropyl)phenoxy]propyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-90-6 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[4-[(methylamino)methyl]phenoxy]propyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-91-7 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[4-[(dimethylamino)methyl]phenoxy]propyl]-β-phenyl- (9CI) (CA INDEX NAME)



CN Benzonitrile, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612495-77-9 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-(1-methylethyl)phenoxy]propyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-81-5 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-β-phenyl-N-[3-[3-(trifluoromethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 612495-82-6 CAPLUS
CN Ethanone, 1-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 612495-85-9 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-(3-methylphenoxy)propyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-87-1 CAPLUS

RN 612495-92-8 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[4-(4-morpholinylmethyl)phenoxy]propyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-93-9 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[4-[(4-methyl-1-piperazinyl)methyl]phenoxy]propyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-94-0 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[(methylamino)methyl]phenoxy]propyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-95-1 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[(dimethylamino)methyl]phenoxy]propyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-96-2 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-(4-morpholinylmethyl)phenoxy]propyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-97-3 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[(4-methyl-1-piperazinyl)methyl]phenoxy]propyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-98-4 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[[(1-methylethyl)amino]methyl]phenoxy]propyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612495-99-5 CAPLUS
CN Benzeneethanamine, N-[3-[5-amino-2-(trifluoromethyl)phenoxy]propyl]-N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612496-00-1 CAPLUS
CN Benzeneethanamine, N-[3-(5-amino-2-methylphenoxy)propyl]-N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612496-03-4 CAPLUS
CN 2-Propanesulfonamide, N-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-4-methylphenyl]- (9CI) (CA INDEX NAME)

RN 612496-04-5 CAPLUS
CN 2-Propanesulfonamide, N-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-4-methylphenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612496-03-4
CMF C35 H38 Cl F3 N2 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 612496-06-7 CAPLUS
CN Methanesulfonamide, N-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-4-methylphenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612496-05-6
CMF C33 H34 Cl F3 N2 O3 S



RN 612496-01-2 CAPLUS
CN Ethanesulfonamide, N-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-4-methylphenyl]- (9CI) (CA INDEX NAME)



RN 612496-02-3 CAPLUS
CN Ethanesulfonamide, N-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-4-methylphenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612496-01-2
CMF C34 H36 Cl F3 N2 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 612496-07-8 CAPLUS
CN Ethanesulfonamide, N-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-4-methylphenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 612496-08-9 CAPLUS
CN Ethanesulfonamide, N-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-4-methylphenyl]-2,2,2-trifluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612496-07-8
CMF C34 H33 Cl F6 N2 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 612496-20-5 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-methyl-N-[3-[3-[2-(4-morpholinyl)ethyl]phenoxy]propyl]-, monohydrochloride, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 612496-21-6 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[2-(ethylamino)ethyl]phenoxy]propyl]- β-methyl-, monohydrochloride, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 612496-24-9 CAPLUS
CN Benzeneethanol, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 612496-25-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]- α,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 612496-26-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-phenylpropyl]amino]propoxy]- α,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 612496-27-2 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(3-thienyl)propyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-28-3 CAPLUS
CN Benzeneethanol, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(3-thienyl)propyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-29-4 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(2-thienyl)propyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-30-7 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(2-pyridinyl)propyl]amino]propoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-31-8 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(4-methyl-2-pyridinyl)propyl]amino]propoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-32-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][3,3,3-trifluoro-2-(1H-pyrrol-2-yl)propyl]amino]propoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-36-3 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[2-(ethylamino)ethyl]phenoxy]propyl]- β-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-37-4 CAPLUS
CN 2-Thiophenemethanamine, 5-bromo-N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B

RN 612496-38-5 CAPLUS
CN 2-Thiophenemethanamine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-33-0 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[2-(4-methyl-1-piperazinyl)ethyl]phenoxy]propyl]- β-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-34-1 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[2-(methylamino)ethyl]phenoxy]propyl]- β-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-35-2 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-39-6 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[2-(dimethylamino)ethyl]phenoxy]propyl]- β-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-40-9 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-phenyl-N-[3-[3-[2-(1-pyrrolidinyl)ethyl]phenoxy]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-42-1 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[2-(4-morpholinyl)ethyl]phenoxy]propyl]- β-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-45-4 CAPLUS
CN Benzeneethanamine, N-[3-[3-(2-aminoethyl)phenoxy]propyl]-N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-46-5 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[2-[(1-methylethyl)amino]ethyl]phenoxy]propyl]- β-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-47-6 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-phenyl-N-[3-[3-[2-(propylamino)ethyl]phenoxy]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-51-2 CAPLUS
CN Glycine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-53-4 CAPLUS
CN Glycine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-54-5 CAPLUS
CN Alanine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-48-7 CAPLUS
CN Ethanol, 2-[[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-49-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-50-1 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-phenyl-N-[3-[3-[2-(4-thiomorpholinyl)ethyl]phenoxy]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-55-6 CAPLUS
CN L-Alanine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 612496-56-7 CAPLUS
CN D-Proline, 1-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 612496-57-8 CAPLUS
CN L-Proline, 1-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 612496-58-9 CAPLUS
CN 2-Pyrimidinamine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-76-1 CAPLUS
CN Benzeneethanamine, N-[3-[3-(2-amino-2-methylpropyl)phenoxy]propyl]-N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 612496-77-2 CAPLUS
CN Benzenemethanol, 2-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-78-3 CAPLUS
CN Benzeneethanol, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- α,α-dimethyl- (9CI) (CA INDEX NAME)



RN 612496-80-7 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(2-chlorophenyl)propyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-81-8 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(3-chlorophenyl)propyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-82-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(4-chlorophenyl)propyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-83-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(2-methoxyphenyl)propyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-84-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(4-methoxyphenyl)propyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-85-2 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](4-methyl-2-phenylpentyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-86-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-phenylbutyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-87-4 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-methyl-2-phenylpropyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-88-5 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](3-methyl-2-phenylbutyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-89-6 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-phenylhexyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-93-2 CAPLUS
CN Benzeneethanol, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-methoxy-2-phenylethyl]amino]propoxy]- α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612496-94-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-methylpropyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 612496-99-8 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-phenyl-N-[3-[3-(1H-1,2,4-triazol-3-ylmethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



● HCl

RN 612496-90-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-phenyl-3-butynyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612496-91-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-methoxy-2-phenylethyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 612496-92-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-methoxy-2-phenylethyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612497-00-4 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-methyl-N-[3-[3-(2H-tetrazol-2-ylmethyl)phenoxy]propyl]-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612497-01-5 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-methyl-N-[3-[3-(2H-tetrazol-2-ylmethyl)phenoxy]propyl]-, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612497-02-6 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612497-03-7 CAPLUS
CN Benzeneacetic acid, 2-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](1-naphthalenylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612497-04-8 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](phenylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612497-05-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-phenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612497-06-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-hydroxy-2-phenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612497-45-7 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-methyl-N-[3-[3-[2-(4-morpholinyl)ethyl]phenoxy]propyl]-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612497-46-8 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[2-(ethylamino)ethyl]phenoxy]propyl]- β-methyl-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612497-49-1 CAPLUS
CN Benzeneethanol, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612497-07-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(acetyloxy)-2-phenylethyl][2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612497-08-2 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-phenoxy-2-phenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612497-09-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(benzoyloxy)-2-phenylethyl][2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612497-10-6 CAPLUS
CN 1,3-Propanediol, 2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 612497-50-4 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]- α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612497-51-5 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-phenylpropyl]amino]propoxy]- α,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612497-52-6 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-(3-thienyl)propyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612497-53-7 CAPLUS
CN Benzeneethanol, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(3-thienyl)propyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612497-54-8 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(2-thienyl)propyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612497-55-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(2-pyridinyl)propyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612497-56-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(4-methyl-2-pyridinyl)propyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612497-57-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][3,3,3-trifluoro-2-(1H-pyrrol-2-yl)propyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612497-58-2 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[2-(4-methyl-1-piperazinyl)ethyl]phenoxy]propyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612497-59-3 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[2-(methylamino)ethyl]phenoxy]propyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612497-60-6 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 612497-61-7 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[2-(ethylamino)ethyl]phenoxy]propyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612497-62-8 CAPLUS
CN 2-Thiophenemethanamine, 5-bromo-N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 612497-63-9 CAPLUS
CN 2-Thiophenemethanamine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 612497-64-0 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[2-(dimethylamino)ethyl]phenoxy]propyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612497-65-1 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-phenyl-N-[3-[3-[2-(1-pyrrolidinyl)ethyl]phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 612497-66-2 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[2-(4-morpholinyl)ethyl]phenoxy]propyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612497-69-5 CAPLUS
CN Benzeneethanamine, N-[3-[3-(2-aminoethyl)phenoxy]propyl]-N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612497-70-8 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[2-[(1-methylethyl)amino]ethyl]phenoxy]propyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612497-71-9 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-β-phenyl-N-[3-[3-[2-(propylamino)ethyl]phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 612497-72-0 CAPLUS
CN Ethanol, 2-[[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 612497-73-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]eth



yl]-1-methyl- (9CI) (CA INDEX NAME)

RN 612497-74-2 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-β-phenyl-N-[3-[3-[2-(4-thiomorpholinyl)ethyl]phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 612497-75-3 CAPLUS
CN Glycine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 612497-77-5 CAPLUS
CN Glycine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 612497-78-6 CAPLUS
CN Alanine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 612497-79-7 CAPLUS
CN L-Alanine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612497-80-0 CAPLUS
CN D-Proline, 1-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612497-81-1 CAPLUS
CN L-Proline, 1-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612497-82-2 CAPLUS
CN 2-Pyrimidinamine, N-[2-[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 612497-97-9 CAPLUS
CN Benzeneethanamine, N-[3-[3-(2-amino-2-methylpropyl)phenoxy]propyl]-N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-β-phenyl- (9CI) (CA INDEX NAME)



RN 612497-98-0 CAPLUS
CN Benzenemethanol, 2-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612498-00-7 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(2-chlorophenyl)propyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612498-01-8 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(3-chlorophenyl)propyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612498-02-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[2-(4-chlorophenyl)propyl][[2-chloro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612498-03-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(2-methoxyphenyl)propyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612498-08-5 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](3-methyl-2-phenylbutyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612498-09-6 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-phenylhexyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612498-10-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-methoxy-2-phenylethyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 612498-11-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-methoxy-2-phenylethyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612498-04-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2-(4-methoxyphenyl)propyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612498-05-2 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](4-methyl-2-phenylpentyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612498-06-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-phenylbutyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612498-12-1 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2-methylpropyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 612498-46-1 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-methyl-N-[3-[3-(1H-tetrazol-5-ylmethyl)phenoxy]propyl]-, monohydrochloride, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 405911-09-3 612498-81-4 612499-11-3
612499-12-4 612499-24-8 612499-54-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of N-[3-(2-pyridyloxy or phenoxy)propyl]benzylamine derivs. as modulating agents for liver X receptors (LXR) for prevention or treatment of LXR-mediated diseases)

RN 405911-09-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (CA INDEX NAME)



RN 612498-81-4 CAPLUS
CN Benzeneethanamine, N-[3-[3-(aminomethyl)phenoxy]propyl]-N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 612499-11-3 CAPLUS
CN Piperazine, 1-[[3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 612499-12-4 CAPLUS
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 612499-24-8 CAPLUS
CN Benzenepropanoic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- α,α-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)

EP 1511483	A2	20050309	EP 2003-716832		20030326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 2005171084	A1	20050804	US 2003-509197		20030326
JP 2005533007	T	20051104	JP 2003-579741		20030326
PRIORITY APPLN. INFO.:			US 2002-368424P	P	20020327
			WO 2003-US9225	W	20030326

OTHER SOURCE(S): MARPAT 139:302072

AB In one aspect, the present invention provides the use of an LXR receptor agonist in the manufacture of medicaments for the treatment and/or prevention of diseases or conditions characterized by neuron degeneration, inflammation in the CNS, injury or impaired plasticity. In another aspect, the present invention provides a method for treating a patient suffering from a disease selected from the group consisting of: stroke, Alzheimer's disease, fronto-temporal dementias, peripheral neuropathy, Parkinson's disease, dementia with Lewy bodies, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis, said method comprising the step of administering to said patient an effective amount of an LXR receptor modulator in combination with a carrier. In yet another aspect, the present invention provides a method for promoting cholesterol efflux in at least one astroglial cell, said method comprising the step of: contacting said at least one astroglial cell with a cholesterol-efflux-promoting effective amount of an LXR receptor modulator in combination with a carrier.

IT 405911-09-3P 609772-06-7P 609772-12-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

RN 405911-09-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (CA INDEX NAME)



RN 609772-06-7 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]- β-phenyl-N-[3-[3-(1H-tetrazol-5-ylmethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 609772-12-5 CAPLUS
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 612499-54-4 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2R)-2-methoxy-2-phenylethyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 53 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2003:796421 CAPLUS
DOCUMENT NUMBER:	139:302072
TITLE:	Methods of treatment with LXR modulators
INVENTOR(S):	Cairns, William J.; Irving, Elaine A.; Parsons, Andrew A.; Soden, Peter E.; Richardson, Jill C.; Burbidge, Stephen A.; Vinson, Mary; Watson, Mike A.; Whitney, Karl
PATENT ASSIGNEE(S):	Smithkline Beecham Corporation, USA
SOURCE:	PCT Int. Appl., 100 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082198	A2	20031009	WO 2003-US9225	20030326
WO 2003082198	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003220521	A1	20031013	AU 2003-220521	20030326



IT 609772-11-4P 609772-14-7P 609772-15-8P
609772-16-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(methods of treatment of neuron degeneration and inflammation in the CNS or impaired plasticity with LXR modulators in relation to promoting cholesterol efflux in astroglial cells)

RN 609772-11-4 CAPLUS
CN Benzeneethanamine, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N-[3-[3-[[2-(ethoxymethyl)-2H-tetrazol-5-yl]methyl]phenoxy]propyl]- β-phenyl- (9CI) (CA INDEX NAME)



RN 609772-14-7 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 609772-15-8 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 609772-16-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][(2S)-2-phenylpropyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L18 ANSWER 54 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:771030 CAPLUS
DOCUMENT NUMBER: 139:334533
TITLE: The Three-dimensional Structure of the Liver X Receptor β Reveals a Flexible Ligand-binding Pocket That Can Accommodate Fundamentally Different Ligands
AUTHOR(S): Faernegardh, Mathias; Bonn, Tomas; Sun, Sherry; Ljunggren, Jan; Ahola, Harri; Wilhelmsson, Anna; Gustafsson, Jan-Ake; Carlquist, Mats
CORPORATE SOURCE: Karolinska Institute, Huddinge University Hospital, NOVUM, Karo Bio AB, Huddinge, SE-141 57, Swed.
SOURCE: Journal of Biological Chemistry (2003), 278(40), 38821-38828
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The structures of the liver X receptor LXRβ (NR1H2) have been determined in complexes with two synthetic ligands, T0901317 and GW3965, to 2.1 and 2.4 Å, resp. Together with its isoform LXRα (NR1H3) it regulates target genes involved in metabolism and transport of cholesterol and fatty acids. The two LXRβ structures reveal a flexible ligand-binding pocket that can adjust to accommodate fundamentally different ligands. The ligand-binding pocket is hydrophobic but with polar or charged residues at the two ends of the cavity. T0901317 takes advantage of this by binding to His-435 close to H12 while GW3965 orients itself with its charged group in the opposite direction. Both ligands induce a fixed "agonist conformation" of helix H12 (also called the AF-2 domain), resulting in a transcriptionally active receptor.

IT 405911-09-3D, GW3965, complex with liver X receptor β
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(three-dimensional structure of human liver X receptor β reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands)

RN 405911-09-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl][2,2-diphenylethyl]amino]propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 55 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:719439 CAPLUS
DOCUMENT NUMBER: 139:245783
TITLE: Preparation of arylamidine derivatives as fungicides
INVENTOR(S): Hayashi, Kazuya; Ojima, Katsuji; Hori, Kozo; Okujo, Hiroyuki; Mitsuyama, Junichi; Kunitani, Kazuto; Tohdo, Keisuke
PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074476	A1	20030912	WO 2003-JP2506	20030304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477212	A1	20030912	CA 2003-2477212	20030304
AU 2003211692	A1	20030916	AU 2003-211692	20030304
EP 1481966	A1	20041201	EP 2003-743600	20030304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008207	A	20041221	BR 2003-8207	20030304
US 20051134 24	A1	20050526	US 2003-506422	20030304
CN 1642906	A	20050720	CN 2003-807452	20030304
NZ 534962	A	20050729	NZ 2003-534962	20030304
RU 2299195	C2	20070520	RU 2004-129725	20030304
IN 2004KN01208	A	20060512	IN 2004-KN1208	20040819
ZA 2004006717	A	20050824	ZA 2004-6717	20040824
NO 2004003914	A	20040920	NO 2004-3914	20040920

PRIORITY APPLN. INFO.: JP 2002-60618 A 20020306
WO 2003-JP2506 W 20030304

OTHER SOURCE(S): MARPAT 139:245783
GI



AB The title arylamidine derivs. with general formula of I [wherein X = (un)substituted alkylene or alkenylene; G1 = O, S, or imino; G2 = CH or N; Ra = H, halo, (un)substituted alkyl, cycloalkyl, or alkoxy; R1 = (un)substituted amidino; R2 = (un)substituted NH2, etc.] and salts thereof are prepared as fungicides. For example, the compound II•xHCl was prepared in a multi-step synthesis. II showed IC50 of 0.0039 μg/mL against synthetic amino acid medium fungal (SAAMF) in agar.

IT 596809-18-6P 596809-34-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of arylamidine derivs. as fungicides)

RN 596809-18-6 CAPLUS
CN Hexanoic acid, 6-[[3-[4-(aminoiminomethyl)phenoxy]propyl][1-[3-[4-(aminoiminomethyl)phenoxy]propyl]-4-piperidinyl]amino]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 596809-34-6 CAPLUS
CN Hexanoic acid, 6-[[3-[4-(aminoiminomethyl)phenoxy]propyl][1-[3-[4-(aminoiminomethyl)phenoxy]propyl]-4-piperidinyl]amino]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

IT 596810-39-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of arylamidine derivs. as fungicides)

RN 596810-39-8 CAPLUS
CN Hexanoic acid, 6-[[3-(4-cyanophenoxy)propyl][1-[3-(4-cyanophenoxy)propyl]-4-piperidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 56 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:643137 CAPLUS
DOCUMENT NUMBER: 140:266251
TITLE: Molecular determinants of LXRα agonism
AUTHOR(S): Wang, Minmin; Thomas, Jeffrey; Burris, Thomas P.; Schkeryantz, Jeffrey; Michael, Laura F.
CORPORATE SOURCE: Lilly Research Laboratories, Department of Discovery Chemistry Research and Technologies, Eli Lilly & Company, Indianapolis, IN, 46285, USA
SOURCE: Journal of Molecular Graphics & Modelling (2003), 22(2), 173-181
CODEN: JMGMFI; ISSN: 1093-3263
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Liver X receptors (LXRs) are nuclear receptors that participate in the regulation of cholesterol, bile acid, and glucose metabolism Despite the identification of the natural oxysterol and nonsteroidal ligands for LXRα, little is known about the structure of the LXRα ligand-binding domain (LBD). We constructed a 3-dimensional (3D) homol. model of the LBD of LXRα based on the crystal structure of the

retinoic acid receptor γ (RARγ) and all-trans retinoic acid complex. We combined mol. modeling and classical structure-function techniques to define the interactions between the LBD and 3 structurally diverse ligands, 22(R)-hydroxycholesterol (22RHC), N-(2,2,2-trifluoroethyl)-N-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide (T0901317) and (3-{3-[(2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-amino]-propoxy}-phenyl)-acetic acid (GW3965). Sixteen individual amino acid point mutations were made in the predicted ligand-binding cavity of the LBD, and each of these mutant receptors was assessed for their ability to be activated by these 3 ligands. The majority of individual mutations resulted in lack of activation by all 3 ligands. Two residues were identified that resulted in a significant increase in basal activity while retaining responsiveness to the ligands. Interestingly, a number of residues were identified that appear to be selective in their response to a particular ligand, indicating that these 3 ligands recognize distinct structural components within the ligand-binding cavity. These data, together with our docking study, enable us to identify the amino acids that coordinate the interaction of both steroidal and non-steroidal ligands in the ligand-binding pocket of LXRα.

IT 405911-09-3, GW 3965
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(GW 3965; mol. determinants of liver X receptor α agonism)

RN 405911-09-3 CAPLUS

CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 57 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:633275 CAPLUS
DOCUMENT NUMBER: 139:169333
TITLE: Novel anticholesterol compositions and method for using same
INVENTOR(S): Dudley, Robert; Liao, Shutsung; Song, Ching
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 137,695.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003153541	A1	20030814	US 2002-174934	20020619
WO 9922728	A1	19990514	WO 1998-US23041	19981030
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6576660	B1	20030610	US 2000-530443	20000428
US 6645955	B1	20031111	US 2000-560236	20000428
ZA 2001009793	A	20030228	ZA 2001-9793	20011128
CA 2438221	A1	20020815	CA 2002-2438221	20020207
AU 2002238093	A1	20020819	AU 2002-238093	20020207
EP 1385868	A2	20040204	EP 2002-704407	20020207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005508281	T	20050331	JP 2002-562310	20020207
US 2002107233	A1	20020808	US 2002-72128	20020208
US 2002193357	A1	20021219	US 2002-137695	20020502
US 7012069	B2	20060314		
CA 2489702	A1	20031231	CA 2003-2489702	20030619
WO 2004001002	A2	20031231	WO 2003-US19515	20030619
WO 2004001002	A3	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003245605	A1	20040106	AU 2003-245605	20030619
EP 1534298	A2	20050601	EP 2003-739234	20030619
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005533810	T	20051110	JP 2004-516031	20030619

PRIORITY APPLN. INFO.:
US 1997-63770P P 19971031
WO 1998-US23041 W 19981030
US 1999-131728P P 19990430
US 2000-530443 A2 20000428
US 2000-560236 A2 20000428
US 2001-267493P P 20010208
US 2001-288643P P 20010503
US 2001-348020P P 20011108
US 2002-72128 A2 20020208
US 2002-137695 A2 20020502
US 2000-191864P P 20000324
WO 2002-US3826 W 20020207
US 2002-174934 A 20020619
WO 2003-US19515 W 20030619

OTHER SOURCE(S): MARPAT 139:169333

AB Disclosed are compns., methods, combinations, and kits for treating a disorder related to elevated serum cholesterol concentration, for example, atherosclerosis, elevated LDL plasma levels, low HDL plasma levels, hypertriglyceridemia, hyperlipidemia, hypertension, hypercholesterolemia, cholesterol gallstones, lipid storage diseases, obesity, and diabetes. The compns., methods, combinations, and kits of the present invention are pharmaceutical compns. comprising at least two of an LXR receptor modulator, a therapeutically effective amount of a catechin, and/or a therapeutically effective amount of a lipid regulating agent, such as a HMG-CoA reductase inhibitor, a fibric acid derivative, niacin, a bile-acid sequestrant, an absorption inhibitor, probucol, raloxifene and its derivs., an azetidinone compound, and an unsatd. omega-3 fatty acid.

IT 405911-09-3, GW3965
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticholesterol compns. containing LXR modulators and lipid regulating agents)

RN 405911-09-3 CAPLUS

CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (CA INDEX NAME)



L18 ANSWER 58 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:472342 CAPLUS
DOCUMENT NUMBER: 139:47197
TITLE: Treatment for age-related macular degeneration
INVENTOR(S): Schwartz, Daniel M.; Duncan, Keith; Bailey, Kathy; Kane, John; Ishida, Brian
PATENT ASSIGNEE(S): Regents of the University of California, USA
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003049685	A2	20030619	WO 2002-US38856	20021206
WO 2003049685	A3	20040708		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2468989	A1	20030619	CA 2002-2468989	20021206
AU 2002360489	A1	20030623	AU 2002-360489	20021206
EP 1461028	A2	20040929	EP 2002-795748	20021206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005511713	T	20050428	JP 2003-550736	20021206

PRIORITY APPLN. INFO.:
US 2001-340498P P 20011207
US 2002-415864P P 20021003
WO 2002-US38856 W 20021206

AB The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.

IT 405911-09-3, GW3965
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment for age-related macular degeneration)

RN 405911-09-3 CAPLUS

CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (CA INDEX NAME)



L18 ANSWER 59 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:101818 CAPLUS
DOCUMENT NUMBER: 139:47079
TITLE: Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: Liver-X-receptor-specific inhibition of inflammation and primary cytokine production
AUTHOR(S): Fowler, Ashley J.; Sheu, Mary Y.; Schmuth, Matthias; Kao, Jack; Fluhr, Joachim W.; Rhein, Linda; Collins, Jon L.; Willson, Timothy M.; Mangelsdorf, David J.; Elias, Peter M.; Feingold, Kenneth R.
CORPORATE SOURCE: Department of Dermatology, University of California, San Francisco, USA
SOURCE: Journal of Investigative Dermatology (2003), 120(2), 246-255
CODEN: JIDEAE; ISSN: 0022-202X
PUBLISHER: Blackwell Publishing, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Activators of liver X receptors (LXR) stimulate epidermal differentiation and development, but inhibit keratinocyte proliferation. In this study, the anti-inflammatory effects of two oxysterols, 22(R)-hydroxycholesterol (22ROH) and 25-hydroxycholesterol (25OH), and a nonsteroid activator of LXR, GW3965, were examined utilizing models of irritant and allergic contact dermatitis. Irritant dermatitis was induced by applying phorbol 12-myristate-13-acetate(TPA) to the surface of the ears of CD1 mice, followed by treatment with 22ROH, 25OH, GW3965, or vehicle alone. Whereas TPA treatment alone induced an ≈2-fold increase in ear weight and thickness, 22ROH, 25OH, or GW3965 markedly suppressed the increase (greater than 50% decrease), and to an extent comparable to that observed with 0.05% clobetasol treatment. Histol. also revealed a marked decrease in TPA-induced cutaneous inflammation in oxysterol-treated animals. As topical treatment with cholesterol did not reduce the TPA-induced inflammation, and the nonsteroid LXR activator (GW3965) inhibited inflammation, the anti-inflammatory effects of oxysterols cannot be ascribed to a non-specific sterol effect. In addition, 22ROH did not reduce inflammation in LXRβ -/- or LXRαβ -/- animals, indicating that LXRβ is required for this anti-inflammatory effect. 22ROH also caused a partial reduction in ear thickness in LXRα -/- animals, however (≈50% of that observed in wild-type mice), suggesting that this receptor also mediates the anti-inflammatory effects of oxysterols. Both ear thickness and weight increased (≈1.5-fold) in the oxazolone-induced allergic dermatitis model, and 22ROH and GW3965 reduced inflammation by ≈50% and ≈30%, resp. Finally, immunohistochem. demonstrated an inhibition in the production of the pro-inflammatory cytokines interleukin-1α and tumor necrosis factor α in the oxysterol-treated sites from both TPA- and oxazolone-treated animals. These studies demonstrate that activators of LXR display potent anti-inflammatory activity in both irritant and allergic contact models of dermatitis, requiring the participation of both LXRα and LXRβ. LXR activators could provide a new class of therapeutic agents for the treatment of cutaneous inflammatory disorders.

IT 405911-09-3, GW3965
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(liver-X-receptor-specific inhibition of inflammation and primary cytokine production in irritant and allergic contact dermatitis)

RN 405911-09-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 60 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:434801 CAPLUS
DOCUMENT NUMBER: 137:362768
TITLE: Synthetic LXR ligand inhibits the development of atherosclerosis in mice
AUTHOR(S): Joseph, Sean B.; McKilligin, Elaine; Pei, Liming; Watson, Michael A.; Collins, Alan R.; Laffitte, Bryan A.; Chen, Mingyi; Noh, Grace; Goodman, Joanne; Hagger, Graham N.; Tran, Jonathan; Tippin, Tim K.; Wang, Xuping; Lusis, Aldons J.; Hsueh, Wila A.; Law, Ronald E.; Collins, Jon L.; Willson, Timothy M.; Tontonoz, Peter
CORPORATE SOURCE: Departments of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, 90095-1662, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2002), 99(11), 7604-7609
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The nuclear receptors LXRα and LXRβ have been implicated in the control of cholesterol and fatty acid metabolism in multiple cell types. Activation of these receptors stimulates cholesterol efflux in macrophages, promotes bile acid synthesis in liver, and inhibits intestinal cholesterol absorption, actions that would collectively be expected to reduce atherosclerotic risk. However, synthetic LXR ligands have also been shown to induce lipogenesis and hypertriglyceridemia in mice, raising questions as to the net effects of these compds. on the development of cardiovascular disease. We demonstrate here that the nonsteroidal LXR agonist GW3965 has potent antiatherogenic activity in two different murine models. In LDLR-/- mice, GW3965 reduced lesion area by 53% in males and 34% in females. A similar reduction of 47% was observed in male apoE-/- mice. Long-term (12-wk) treatment with LXR agonist had differential effects on plasma lipid profiles in LDLR-/- and apoE-/- mice. GW3965 induced expression of ATP-binding cassettes A1 and G1 in modified low-d. lipoprotein-loaded macrophages in vitro as well as in the aortas of hyperlipidemic mice, suggesting that direct actions of LXR ligands on vascular gene expression are likely to contribute to their antiatherogenic effects. These observations provide direct evidence for an atheroprotective effect of LXR agonists and support their further evaluation as potential modulators of human cardiovascular disease.

IT 405911-09-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthetic LXR ligand inhibits the development of atherosclerosis in mice)

RN 405911-09-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 61 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:287592 CAPLUS
DOCUMENT NUMBER: 137:41546
TITLE: Identification of a Nonsteroidal Liver X Receptor Agonist through Parallel Array Synthesis of Tertiary Amines
AUTHOR(S): Collins, Jon L.; Fivush, Adam M.; Watson, Michael A.; Galardi, Cristin M.; Lewis, Michael C.; Moore, Linda B.; Parks, Derek J.; Wilson, Joan G.; Tippin, Tim K.; Binz, Jane G.; Plunket, Kelli D.; Morgan, Daniel G.; Beaudet, Elizabeth J.; Whitney, Karl D.; Kliewer, Steven A.; Willson, Timothy M.
CORPORATE SOURCE: GlaxoSmithKline, Research Triangle Park, NC, 27709, USA
SOURCE: Journal of Medicinal Chemistry (2002), 45(10), 1963-1966
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A potent, selective, orally active liver x receptor (LXR) agonist was identified from focused libraries of tertiary amines. GW3965 recruits the steroid receptor coactivator 1 to human LXRα in a cell-free ligand-sensing assay with an EC50 of 125 nM and profiles as a full agonist on hLXRα and hLXRβ in cell-based reporter gene assays with EC50's of 190 and 30 nM, resp. After oral dosing at 10 mg/kg to C57BL/6 mice, GW3965 increased expression of the reverse cholesterol transporter ABCA1 in the small intestine and peripheral macrophages and increased the plasma concns. of HDL cholesterol by 30%. GW3965 will be a valuable chemical tool to investigate the role of LXR in the regulation of reverse cholesterol transport and lipid metabolism

IT 405910-80-7 405910-82-9 405910-84-1 405910-93-2 405910-99-8 405911-02-6 405911-05-9 405911-96-8 437991-36-1
RL: PAC (Pharmacological activity); BIOL (Biological study)
(tertiary amine as nonsteroidal liver X receptor agonist which increases expression of reverse cholesterol transporter ABCA1 and plasma concns. of HDL cholesterol and has good oral bioavailability)

RN 405910-80-7 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(4-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405910-82-9 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(2-fluoro-4-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405910-84-1 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,4-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405910-93-2 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(3-fluoro-4-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405910-99-8 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[[3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-02-6 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-05-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[(2,2-diphenylethyl)[(4-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-96-8 CAPLUS
CN Benzamide, 3-[3-[(3,4-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 437991-36-1 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



IT 437991-39-4
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tertiary amine as nonsteroidal liver X receptor agonist which increases expression of reverse cholesterol transporter ABCA1 and plasma concns. of HDL cholesterol and has good oral bioavailability)

RN 437991-39-4 CAPLUS
CN Benzeneacetic acid, 3-[3-[(2,2-diphenylethyl)[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 62 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:240713 CAPLUS
DOCUMENT NUMBER: 136:294650
TITLE: Preparation of substituted phenylacetamides and benzamides as agonists for Liver X receptors (LXR)
INVENTOR(S): Collins, Jon Loren; Fivush, Adam M.; Maloney, Patrick Reed; Stewart, Eugene L.; Willson, Timothy Mark
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

THIS IS THE CLOSEST PRIOR ART (102-e)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024632	A2	20020328	WO 2001-US27622	20010906
WO 2002024632	A3	20020711		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002011216	A5	20020402	AU 2002-11216	20010906
EP 1318976	A2	20030618	EP 2001-979230	20010906
EP 1318976	B1	20041124		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509161	T	20040325	JP 2002-528647	20010906
AT 283253	T	20041215	AT 2001-979230	20010906
ES 2233700	T3	20050616	ES 2001-979230	20010906
US 2004072868	A1	20040415	US 2003-380932	20030318
US 2005282908	A1	20051222	US 2005-154852	20050616
PRIORITY APPLN. INFO.:			US 2000-233144P	P 20000918
			WO 2001-US27622	W 20010906
			US 2003-380932	A1 20030318

OTHER SOURCE(S): MARPAT 136:294650
GI

AB The title compds. (I; X = OH, NH2; p = 0-6; R1, R2 = H, alkyl, alkoxy, thioalkyl; Z = CH, N; when Z = CH, k = 0-4; when Z = N, k = 0-3; R3 = halo, OH, alkyl, etc.; n = 2-8; q = 0-1; R4 = H, alkyl, alkenyl, alkenyloxy; A = cycloalkyl, aryl, 4-8 membered heterocycle, 5-6 membered heteroaryl; B = cycloalkyl, aryl) and their pharmaceutically acceptable salts, useful for the prevention or treatment of an LXR mediated disease and condition such as cardiovascular disease and atherosclerosis (no biol. data given), were prepared E.g., a solid phase synthesis of II was given.

IT 405910-78-3P 405910-80-7P 405910-82-9P
405910-84-1P 405910-86-3P 405910-88-5P
405910-90-9P 405910-93-2P 405910-96-5P
405910-99-8P 405911-02-6P 405911-05-9P
405911-09-3P 405911-13-9P 405911-17-3P
405911-22-0P 405911-26-4P 405911-37-7P
405911-39-9P 405911-41-3P 405911-42-4P
405911-45-7P 405911-48-0P 405911-50-4P
405911-52-6P 405911-54-8P 405911-57-1P
405911-60-6P 405911-63-9P 405911-65-1P
405911-68-4P 405911-70-8P 405911-72-0P
405911-75-3P 405911-78-6P 405911-81-1P
405911-84-4P 405911-87-7P 405911-90-2P
405911-92-4P 405911-94-6P 405911-96-8P
405911-97-9P 405911-98-0P 405911-99-1P
405912-00-7P 405912-01-8P 405912-02-9P
405912-03-0P 405912-04-1P 405912-05-2P
405912-06-3P 405912-07-4P 405912-08-5P
405912-09-6P 405912-10-9P 405912-11-0P
405912-12-1P 405912-13-2P 405912-14-3P
405912-15-4P 405912-17-6P 405912-18-7P
405912-20-1P 405912-22-3P 405912-23-4P
405912-24-5P 405912-25-6P 405912-26-7P
405912-27-8P 405912-28-9P 405912-29-0P
405912-30-3P 405912-31-4P 405912-32-5P
405912-33-6P 405912-34-7P 405912-35-8P
405912-36-9P 405912-37-0P 405912-38-1P
405912-39-2P 405912-40-5P 405912-41-6P
405912-42-7P 405912-43-8P 405912-44-9P
405912-45-0P 405912-46-1P 405912-48-3P
405912-49-4P 405912-50-7P 405912-51-8P
405912-52-9P 405912-53-0P 405912-54-1P
405912-55-2P 405912-56-3P 405912-57-4P
405912-58-5P 405912-59-6P 405912-60-9P
405912-61-0P 405912-62-1P 405912-64-3P
405912-65-4P 405912-66-5P 405912-67-6P
405912-68-7P 405912-69-8P 405912-70-1P
405912-71-2P 405912-73-4P 405912-74-5P
405912-75-6P 405912-76-7P 405912-78-9P
405912-80-3P 405912-81-4P 405912-82-5P
405912-83-6P 405912-84-7P 405912-85-8P
405912-86-9P 405912-87-0P 405912-88-1P
405912-89-2P 405912-90-5P 405912-91-6P
405912-93-8P 405912-94-9P 405912-95-0P
405912-96-1P 405912-97-2P 405912-98-3P
405912-99-4P 405913-00-0P 405913-01-1P
405913-02-2P 405913-03-3P 405913-04-4P
405913-05-5P 405913-06-6P 405913-07-7P
405913-08-8P 405913-09-9P 405913-10-2P
405913-11-3P 405913-12-4P 405913-13-5P
405913-14-6P 405913-15-7P 405913-16-8P
405913-18-0P 405913-19-1P 405913-20-4P
405913-21-5P 405913-22-6P 405913-23-7P
405913-24-8P 405913-26-0P 405913-27-1P
405913-28-2P 405913-29-3P 405913-31-7P
405913-32-8P 405913-33-9P 405913-34-0P
405913-35-1P 405913-36-2P 405913-37-3P
405913-38-4P 405913-39-5P 405913-42-0P
405913-43-1P 405913-44-2P 405913-45-3P
405913-46-4P 405913-47-5P 405913-50-0P
405913-51-1P 405913-53-3P 405913-54-4P
405913-55-5P 405913-56-6P 405913-57-7P
405913-58-8P 405913-59-9P 405913-60-2P
405913-62-4P 405913-63-5P 405913-64-6P
405913-66-8P 405913-67-9P 405913-68-0P
405913-69-1P 405913-71-5P 405913-72-6P
405913-73-7P 405913-74-8P 405913-76-0P
405913-78-2P 405913-79-3P 405913-80-6P
405913-81-7P 405913-82-8P 405913-83-9P
405913-85-1P 405913-86-2P 405913-87-3P
405913-88-4P 405913-89-5P 405913-90-8P
405913-91-9P 405913-92-0P 405913-93-1P
405913-94-2P 405913-95-3P 405913-96-4P
405913-97-5P 405913-98-6P 405913-99-7P
405914-00-3P 405914-02-5P 405914-03-6P
405914-04-7P 405914-05-8P 405914-06-9P
405914-07-0P 405914-09-2P 405914-10-5P
405914-11-6P 405914-12-7P 405914-13-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted phenylacetamides and benzamides as agonists for Liver X receptors (LXR))

RN 405910-78-3 CAPLUS
CN Benzeneacetamide, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405910-80-7 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(4-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405910-82-9 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(2-fluoro-4-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405910-84-1 CAPLUS
CN Benzeneacetamide, 3-[3-[[(2,4-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405910-86-3 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(4-fluoro-2-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405910-88-5 CAPLUS
CN Benzeneacetamide, 3-[3-[[(2,3-dichlorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)

ALL OF THE $H_2N-C(=O)-CH_2$ COMPOUNDS ARE NOT IN SCOPE OF THE INSTANT CLAIMS.



RN 405910-90-9 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[[3-(trifluoromethoxy)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405910-93-2 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(3-fluoro-4-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405910-96-5 CAPLUS
CN Benzeneacetamide, 3-[3-[[(2,5-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405910-99-8 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[[3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-02-6 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



● HCl

RN 405911-22-0 CAPLUS
CN Benzeneacetic acid, 3-[3-[(2,2-diphenylethyl)[(4-methoxyphenyl)methyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 405911-26-4 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 405911-37-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[3-(aminocarbonyl)phenoxy]propyl](2,2-diphenylethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405911-39-9 CAPLUS
CN Benzamide, 3-[3-[(1-benzoyl-4-piperidinyl)(2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-05-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[(2,2-diphenylethyl)[(4-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-09-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (CA INDEX NAME)



RN 405911-13-9 CAPLUS
CN Benzeneacetic acid, 3-[3-[(2,2-diphenylethyl)[(4-methoxyphenyl)methyl]amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 405911-17-3 CAPLUS
CN Benzeneacetic acid, 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-, hydrochloride (9CI) (CA INDEX NAME)

No good b/c W^1, W^2 can't be Ph and W^3 = -H when X = COOH, Y = -O-, etc.



RN 405911-41-3 CAPLUS
CN Benzamide, 3-[3-[(1-acetyl-4-piperidinyl)(2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-42-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[3-(aminocarbonyl)phenoxy]propyl](2,2-diphenylethyl)amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 405911-45-7 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[1-(2-phenylethyl)-4-piperidinyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-48-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[3-(aminocarbonyl)phenoxy]propyl](2-cyclohexyl-2-phenylethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405911-50-4 CAPLUS
CN Benzamide, 3-[3-[(1-benzoyl-4-piperidinyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-52-6 CAPLUS
CN Benzamide, 3-[3-[(1-acetyl-4-piperidinyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-54-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[3-(aminocarbonyl)phenoxy]propyl](2-cyclohexyl-2-phenylethyl)amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 405911-65-1 CAPLUS
CN Benzeneacetamide, 3-[3-[(1-benzoyl-4-piperidinyl)(2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-68-4 CAPLUS
CN Benzeneacetamide, 3-[3-[(1-acetyl-4-piperidinyl)(2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-70-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[3-(2-amino-2-oxoethyl)phenoxy]propyl](2,2-diphenylethyl)amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 405911-72-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[3-(2-amino-2-oxoethyl)phenoxy]propyl](2,2-diphenylethyl)amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 405911-57-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[3-(aminocarbonyl)phenoxy]propyl](2-cyclohexyl-2-phenylethyl)amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 405911-60-6 CAPLUS
CN Benzamide, 3-[3-[(2-cyclohexyl-2-phenylethyl)[1-(phenylmethyl)-4-piperidinyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-63-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[3-(2-amino-2-oxoethyl)phenoxy]propyl](2,2-diphenylethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 405911-75-3 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[1-(2-phenylethyl)-4-piperidinyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-78-6 CAPLUS
CN Benzeneacetamide, 3-[3-[(1-benzoyl-4-piperidinyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-81-1 CAPLUS
CN Benzeneacetamide, 3-[3-[(1-acetyl-4-piperidinyl)(2-cyclohexyl-2-phenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-84-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-[3-(2-amino-2-oxoethyl)phenoxy]propyl](2-cyclohexyl-2-phenylethyl)amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 405911-87-7 CAPLUS
CN Benzamide, 3-[3-[[(3-cyanophenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-90-2 CAPLUS
CN Benzamide, 3-[3-[cyclohexyl(2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-92-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[3-[3-(aminocarbonyl)phenoxy]propyl](2,2-diphenylethyl)amino]- (9CI) (CA INDEX NAME)



RN 405911-94-6 CAPLUS
CN Benzamide, 3-[3-[(1,3-benzodioxol-4-ylmethyl)(2,2-diphenylethyl)amino]propoxy]-. (9CI) (CA INDEX NAME)



RN 405911-99-1 CAPLUS
CN Benzeneacetamide, 3-[3-[[(3,4-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-00-7 CAPLUS
CN Benzamide, 3-[3-[(2-cyclohexyl-2-phenylethyl)[(3,4-dimethoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-01-8 CAPLUS
CN Benzamide, 3-[3-[[(2,6-dichlorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-02-9 CAPLUS
CN Benzoic acid, 3-[[3-[3-(aminocarbonyl)phenoxy]propyl](2,2-diphenylethyl)amino]methyl]- (9CI) (CA INDEX NAME)





RN 405911-96-8 CAPLUS
CN Benzamide, 3-[3-[[(3,4-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-97-9 CAPLUS
CN Benzamide, 3-[3-[[(4-cyanophenyl)methyl](2-cyclohexyl-2-phenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405911-98-0 CAPLUS
CN Benzeneacetamide, 3-[3-[cyclohexyl(2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-03-0 CAPLUS
CN Benzoic acid, 4-[[[3-[3-(aminocarbonyl)phenoxy]propyl](2,2-diphenylethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 405912-04-1 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[(5-methoxy-1H-indol-3-yl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-05-2 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[(4-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-06-3 CAPLUS
CN Benzamide, 3-[3-[[(1-acetyl-1H-indol-3-yl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-07-4 CAPLUS
CN Benzoic acid, 4-[[[3-[3-(aminocarbonyl)phenoxy]propyl](2,2-diphenylethyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 405912-08-5 CAPLUS
CN Benzamide, 3-[3-[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-09-6 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)(4-pyridinylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-10-9 CAPLUS
CN Benzeneacetamide, 3-[3-[(2-cyclohexyl-2-phenylethyl)[(3,4-difluorophenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-11-0 CAPLUS
CN Benzeneacetamide, 3-[3-[(cyclohexylmethyl)(2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-17-6 CAPLUS
CN Benzeneacetamide, 3-[3-[[(3,4-dihydro-2H-pyran-2-yl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-18-7 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(7-methoxy-1,3-benzodioxol-5-yl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-20-1 CAPLUS
CN Benzeneacetamide, 3-[3-[(3-cyclohexen-1-ylmethyl)(2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-22-3 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[[[3-[3-(2-amino-2-oxoethyl)phenoxy]propyl](2,2-diphenylethyl)amino]methyl]-, ethyl ester (9CI)* (CA INDEX NAME)



RN 405912-12-1 CAPLUS
CN Benzeneacetamide, 3-[3-[[(6-chloro-1,3-benzodioxol-5-yl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-13-2 CAPLUS
CN Benzeneacetamide, 3-[3-[[(1R,2S,4R)-bicyclo[2.2.1]hept-5-en-2-ylmethyl](2,2-diphenylethyl)amino]propoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 405912-14-3 CAPLUS
CN Benzeneacetamide, 3-[3-[[(2,4-dimethoxy-5-pyrimidinyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-15-4 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(3-methyl-5-(1-methylethyl)-4-isoxazolyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-23-4 CAPLUS
CN Benzeneacetamide, 3-[3-[(1-cyclohexen-1-ylmethyl)(2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-24-5 CAPLUS
CN Benzeneacetamide, 3-[3-[(1H-benzimidazol-2-ylmethyl)(2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-25-6 CAPLUS
CN Benzeneacetamide, 3-[3-[[(2,3-dihydro-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-26-7 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)(2-pyrrolidinylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-27-8 CAPLUS
CN Benzamide, 3-[3-[[(2,5-difluorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405912-28-9 CAPLUS
CN Benzamide, 3-[3-[[(3,4-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405912-29-0 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(4-ethylphenyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-30-3 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[(4-ethylphenyl)methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405912-31-4 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[(4-hydroxy-3-methoxyphenyl)methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405912-36-9 CAPLUS
CN Benzeneacetamide, 4-[3-[[[4-(dimethylamino)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-37-0 CAPLUS
CN Benzeneacetamide, 3-[3-[[(2,3-dihydro-5-benzofuranyl)methyl](2,2-diphenylethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405912-38-1 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(3-methyl-2-thienyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-39-2 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405912-32-5 CAPLUS
CN Benzenepropanamide, 4-[3-[(2-benzofuranylmethyl)(2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-33-6 CAPLUS
CN Benzamide, 4-[3-[[(2,4-dimethylphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-34-7 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[[4-(methylthio)phenyl]methyl]amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)



RN 405912-35-8 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(4-(methylthio)phenyl]methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-40-5 CAPLUS
CN Benzenepropanamide, 4-[3-[[(4-butoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-41-6 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)(1H-imidazol-4-ylmethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-42-7 CAPLUS
CN Benzeneacetamide, 3-[3-[[(2,3-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405912-43-8 CAPLUS
CN Benzeneacetamide, 4-[3-[(2-benzofuranylmethyl)(2,2-diphenylethyl)amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)



RN 405912-44-9 CAPLUS
CN Benzamide, 4-[3-[[(3,5-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-45-0 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(3-methyl-2-thienyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-46-1 CAPLUS
CN Benzamide, 3-[3-[[(4-chlorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405912-48-3 CAPLUS
CN Benzeneacetamide, 4-[3-[[(4-butoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-53-0 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(4-ethylphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-54-1 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)(2-thiazolylmethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-55-2 CAPLUS
CN Benzeneacetamide, 4-[3-[[(4-butoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)



RN 405912-56-3 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)(2-thiazolylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)





RN 405912-49-4 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)(phenylmethyl)amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)



RN 405912-50-7 CAPLUS
CN Benzeneacetamide, 3-[3-[[[4-(acetylamino)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-51-8 CAPLUS
CN Benzamide, 4-[3-[[(2,4-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-52-9 CAPLUS
CN Benzamide, 4-[3-[[[4-(difluoromethoxy)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)

RN 405912-57-4 CAPLUS
CN Benzamide, 4-[3-[[[4-(acetylamino)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-58-5 CAPLUS
CN Benzamide, 3-[3-[(2-benzofuranylmethyl)(2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-59-6 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[[3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405912-60-9 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[(4-methylphenyl)methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405912-61-0 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(4-ethylphenyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-62-1 CAPLUS
CN Benzeneacetamide, 4-[3-[(1,3-benzodioxol-5-ylmethyl)(2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-64-3 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)(phenylmethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405912-65-4 CAPLUS
CN Acetic acid, [2-[[[3-[4-(aminocarbonyl)-2-methoxyphenoxy]propyl](2,2-diphenylethyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 405912-66-5 CAPLUS
CN Benzeneacetamide, 4-[3-[[[4-(acetylamino)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-71-2 CAPLUS
CN Benzenepropanamide, 3-[3-[[(2,5-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-73-4 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)(2-pyridinylmethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405912-74-5 CAPLUS
CN Acetic acid, [2-[[[3-[5-(aminocarbonyl)-2-methoxyphenoxy]propyl](2,2-diphenylethyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 405912-75-6 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)(3-pyridinylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-67-6 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(4-nitrophenyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-68-7 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(4-methylphenyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-69-8 CAPLUS
CN Benzeneacetamide, 4-[3-[(2-benzofuranylmethyl)(2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-70-1 CAPLUS
CN Benzenepropanamide, 4-[3-[(2,2-diphenylethyl)[[3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-76-7 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)(4-pyridinylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-78-9 CAPLUS
CN Benzenepropanamide, 4-[3-[[(2,5-difluorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-80-3 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)(2-furanylmethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-81-4 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[(4-hydroxy-3-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-82-5 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(4-methoxy-3-methylphenyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-83-6 CAPLUS
CN Benzamide, 4-[3-[[(4-chlorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-84-7 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(4-fluorophenyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-85-8 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(3-methyl-2-thienyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-86-9 CAPLUS
CN Benzeneacetamide, 4-[3-[[(2-chlorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-91-6 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)(3-pyridinylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-93-8 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(4-(methylthio)phenyl]methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-94-9 CAPLUS
CN Benzenepropanamide, 4-[3-[[(2-chlorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-95-0 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[[3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)





RN 405912-87-0 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[[4-(methylsulfonyl)phenyl]methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-88-1 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-89-2 CAPLUS
CN Benzamide, 4-[3-[[(2-chloro-4-fluorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-90-5 CAPLUS
CN Benzeneacetamide, 3-chloro-4-[3-[(2,2-diphenylethyl)[(4-nitrophenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)

RN 405912-96-1 CAPLUS
CN Benzeneacetamide, 4-[3-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-97-2 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)(2-pyridinylmethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405912-98-3 CAPLUS
CN Benzenepropanamide, 4-[3-[(2,2-diphenylethyl)(4-pyridinylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405912-99-4 CAPLUS
CN Benzeneacetamide, 4-[3-[[(2,5-difluorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-00-0 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-01-1 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)(4-pyridinylmethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-02-2 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(2-fluoro-4-methoxyphenyl)methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-03-3 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[[5-(hydroxymethyl)-2-furanyl]methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-04-4 CAPLUS
CN Benzeneacetamide, 4-[3-[[(3,4-dichlorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-09-9 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(3-hydroxy-4-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-10-2 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(4-ethylphenyl)methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-11-3 CAPLUS
CN Benzamide, 3-chloro-4-[3-[(2,2-diphenylethyl)[(3-ethoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-12-4 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)(2-furanylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-05-5 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)(2-furanylmethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-06-6 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-07-7 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(3-methoxyphenyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-08-8 CAPLUS
CN Benzeneacetamide, 4-[3-[[[4-(acetylamino)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)



RN 405913-13-5 CAPLUS
CN Benzenepropanamide, 3-[3-[[(3,4-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-14-6 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)(3-pyridinylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-15-7 CAPLUS
CN Benzamide, 4-[3-[(2-benzofuranylmethyl)(2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-16-8 CAPLUS
CN Benzamide, 3-[3-[[(2-chlorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-18-0 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(3-fluoro-4-methoxyphenyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-19-1 CAPLUS
CN Benzenepropanamide, 3-[3-[[(4-butoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-20-4 CAPLUS
CN Acetic acid, [2-[[[3-[4-(2-amino-2-oxoethyl)-2-methoxyphenoxy]propyl](2,2-diphenylethyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 405913-21-5 CAPLUS
CN Benzeneacetamide, 4-[3-[[(2,4-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)



RN 405913-22-6 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(3-hydroxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-23-7 CAPLUS
CN Benzenepropanamide, 4-[3-[[(2,4-dimethylphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-24-8 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)(4-pyridinylmethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-26-0 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(4-iodophenyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-27-1 CAPLUS
CN Benzamide, 3-[3-[(2-benzofuranylmethyl)(2,2-diphenylethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-28-2 CAPLUS
CN Benzeneacetamide, 3-[3-[[(3,4-dichlorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-29-3 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[[4-(1-methylethoxy)phenyl]methyl]amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)



RN 405913-31-7 CAPLUS
CN Benzamide, 3-chloro-4-[3-[(2,2-diphenylethyl)[[4-[(trifluoromethyl)thio]phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-32-8 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)(2-pyridinylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-33-9 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(4-methylphenyl)methyl]amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)



RN 405913-34-0 CAPLUS
CN Benzeneacetamide, 3-[3-[[(4-butoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-35-1 CAPLUS
CN Benzamide, 3-[3-[[(4-butoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-36-2 CAPLUS
CN Benzeneacetamide, 4-[3-[(1,3-benzodioxol-5-ylmethyl)(2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-37-3 CAPLUS
CN Benzenepropanamide, 3-[3-[[(2-chloro-6-fluorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-38-4 CAPLUS
CN Benzenepropanamide, 4-[3-[(2,2-diphenylethyl)[(4-hydroxy-3-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-39-5 CAPLUS
CN Benzamide, 3-[3-[[(2,3-dihydro-5-benzofuranyl)methyl](2,2-diphenylethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-42-0 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(2-fluorophenyl)methyl]amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)



RN 405913-43-1 CAPLUS
CN Benzenepropanamide, 4-[3-[[(2,5-dimethylphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-50-0 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)(4-pyridinylmethyl)amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)



RN 405913-51-1 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(3-methyl-2-thienyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-53-3 CAPLUS
CN Acetic acid, [2-[[[3-[4-(aminocarbonyl)-2-chlorophenoxy]propyl](2,2-diphenylethyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 405913-54-4 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(4-ethoxyphenyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-44-2 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)(2-thiazolylmethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-45-3 CAPLUS
CN Benzeneacetamide, 3-[3-[[(3,5-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-46-4 CAPLUS
CN Benzenepropanamide, 4-[3-[(2,2-diphenylethyl)[(4-hydroxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-47-5 CAPLUS
CN Benzenepropanamide, 4-[3-[[(3,4-dimethylphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-55-5 CAPLUS
CN Benzeneacetamide, 3-chloro-4-[3-[(2,2-diphenylethyl)[(4-(methylsulfonyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-56-6 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(4-hydroxy-3-methoxyphenyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-57-7 CAPLUS
CN Benzeneacetamide, 4-[3-[(1,3-benzodioxol-5-ylmethyl)(2,2-diphenylethyl)amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)



RN 405913-58-8 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)(2-thiazolylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-59-9 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[(3-methyl-2-thienyl)methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-60-2 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[(3-hydroxy-4-methoxyphenyl)methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-62-4 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(4-methoxy-3-methylphenyl)methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-63-5 CAPLUS
CN Benzeneacetamide, 3-chloro-4-[3-[(2,2-diphenylethyl)(1H-imidazol-4-ylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-64-6 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(4-iodophenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-66-8 CAPLUS
CN Benzamide, 3-[3-[[[4-(acetylamino)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-67-9 CAPLUS
CN Benzeneacetamide, 4-[3-[[[4-(difluoromethoxy)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-68-0 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(4-methoxyphenyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-69-1 CAPLUS
CN Benzamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-71-5 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(2-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-72-6 CAPLUS
CN Benzenepropanamide, 3-[3-[[(2,3-dichlorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-73-7 CAPLUS
CN Benzeneacetamide, 3-chloro-4-[3-[(2,2-diphenylethyl)(4-pyridinylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-74-8 CAPLUS
CN Benzamide, 3-[3-[[(4-butoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-76-0 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-78-2 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-79-3 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(4-(trifluoromethyl)phenyl]methyl]amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)



RN 405913-80-6 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(3-hydroxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-81-7 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[(4-nitrophenyl)methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-82-8 CAPLUS
CN Benzeneacetamide, 3-chloro-4-[3-[(2,2-diphenylethyl)[(4-(methylthio)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-83-9 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-89-5 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)(3-pyridinylmethyl)amino]propoxy]-(9CI) (CA INDEX NAME)



RN 405913-90-8 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(3-hydroxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-91-9 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(4-methylphenyl)methyl]amino]propoxy]-(9CI) (CA INDEX NAME)



RN 405913-92-0 CAPLUS
CN Benzenepropanamide, 4-[3-[(2,2-diphenylethyl)[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)





RN 405913-85-1 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-86-2 CAPLUS
CN Benzeneacetamide, 4-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-87-3 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(4-propoxyphenyl)methyl]amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)



RN 405913-88-4 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(3-methyl-2-thienyl)methyl]amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)

RN 405913-93-1 CAPLUS
CN Benzeneacetamide, 3-chloro-4-[3-[(2,2-diphenylethyl)[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-94-2 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405913-95-3 CAPLUS
CN Benzenepropanamide, 3-[3-[(2,3-diphenylethyl)[(4-ethylphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-96-4 CAPLUS
CN Benzamide, 4-[3-[(1,3-benzodioxol-5-ylmethyl)(2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-97-5 CAPLUS
CN Benzeneacetamide, 3-chloro-4-[3-[(2,2-diphenylethyl)(2-thiazolylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405913-98-6 CAPLUS
CN Benzeneacetamide, 4-[3-[[(2,3-difluorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405913-99-7 CAPLUS
CN Benzamide, 4-[3-[[(3,4-dimethylphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-00-3 CAPLUS
CN Benzamide, 3-chloro-4-[3-[(2,2-diphenylethyl)[(2-fluorophenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-02-5 CAPLUS
CN Benzeneacetamide, 3-[3-[(2-cyclohexyl-2-phenylethyl)[(5-methoxy-1H-indol-3-yl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-07-0 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)[(3-hydroxy-4-methoxyphenyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405914-09-2 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[[3-(2-hydroxyethoxy)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-10-5 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(2-fluoro-4-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-11-6 CAPLUS
CN Benzeneacetamide, 3-chloro-4-[3-[(2,2-diphenylethyl)[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-03-6 CAPLUS
CN Benzenepropanamide, 3-[3-[(2,2-diphenylethyl)[[4-(2-hydroxyethoxy)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-04-7 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(3-methyl-2-thienyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-05-8 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(3-fluoro-4-methoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-06-9 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)(3-pyridinylmethyl)amino]propoxy]-3-fluoro- (9CI) (CA INDEX NAME)



RN 405914-12-7 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)(3-furanylmethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405914-13-8 CAPLUS
CN Benzamide, 3-chloro-4-[3-[(2,2-diphenylethyl)[(4-iodophenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



IT 405914-14-9P 405914-15-0P 405914-16-1P
405914-17-2P 405914-18-3P 405914-19-4P
405914-20-7P 405914-21-8P 405914-22-9P
405914-24-1P 405914-25-2P 405914-27-4P
405914-29-6P 405914-31-0P 405914-33-2P
405914-35-4P 406680-56-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted phenylacetamides and benzamides as agonists for Liver X receptors (LXR))

RN 405914-14-9 CAPLUS

CN Benzamide, 3-[3-[[(3,4-dimethylphenyl)methyl](2,2-diphenylethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405914-15-0 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[(3-ethoxyphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-16-1 CAPLUS
CN Benzenepropanamide, 3-[3-[(2,2-diphenylethyl)[[5-(hydroxymethyl)-2-furanyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-17-2 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(4-methoxy-3-methylphenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-18-3 CAPLUS
CN Benzeneacetamide, 4-[3-[(2,2-diphenylethyl)(1H-imidazol-4-ylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-19-4 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[[2-(trifluoromethyl)phenyl]methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405914-20-7 CAPLUS
CN Benzeneacetamide, 4-chloro-3-[3-[[(3,4-dimethoxyphenyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-21-8 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[(4-hydroxyphenyl)methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405914-22-9 CAPLUS
CN Benzeneacetamide, 4-[3-[[(3-chloro-4-fluorophenyl)methyl](2,2-diphenylethyl)amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405914-24-1 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-25-2 CAPLUS
CN Benzeneacetamide, 3-[3-[(2,2-diphenylethyl)[[4-(methylsulfonyl)phenyl]methyl]amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405914-27-4 CAPLUS
CN Benzamide, 3-[3-[[(2,3-dihydro-5-benzofuranyl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-29-6 CAPLUS
CN Benzamide, 4-[3-[(2,2-diphenylethyl)[(4-fluorophenyl)methyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 405914-31-0 CAPLUS
CN Benzamide, 3-[3-[(1,3-benzodioxol-5-ylmethyl)(2,2-diphenylethyl)amino]propoxy]-4-methoxy- (9CI) (CA INDEX NAME)



RN 405914-33-2 CAPLUS
CN Benzenepropanamide, 3-[3-[(2,2-diphenylethyl)[[4-(methylsulfonyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 405914-35-4 CAPLUS
CN Benzamide, 3-[3-[(2,2-diphenylethyl)[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 406680-56-6 CAPLUS
CN Benzeneacetamide, 3-[3-[[(4-chloro-1H-pyrazol-3-yl)methyl](2,2-diphenylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



L18 ANSWER 63 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:643416 CAPLUS
DOCUMENT NUMBER: 135:210826
TITLE: Preparation of arylaminoalkanols as cholesteryl ester transfer protein inhibitors.
INVENTOR(S): Sikorski, James A.; Durley, Richard C.; Grapperhaus, Margaret L.; Mischke, Deborah A.; Reinhard, Emily J.; Parnas, Barry L.; Rueppel, Melvin L.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: U.S. Pat. Appl. Publ., 80 pp., Cont. of U.S. Ser. No. 401,916, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001018446	A1	20010830	US 2001-760627	20010116
US 2003191306	A1	20031009	US 2002-320858	20021216
US 6787570	B2	20040907		
PRIORITY APPLN. INFO.:			US 1999-401916	B1 19990923
			US 2001-760627	A1 20010116

OTHER SOURCE(S): MARPAT 135:210826
GI



AB HOCR1R2(CHR3)nN(ZA)YQ [n = 1, 2; A, Q = CH2(CR37R38)v(CR33R34)uT(CR35R36)w H, I, II; T = bond, O, S, SO, SO2, CR33:CR35, C.tplbond.C; v = 0, 1; u, w = 0-6; A1 = CR30; D1, D2, J1, J2, K1 = C, N, O, S, bond; B1, B2, D3, D4, J3, J4, K2 = C, CR30, N, O, S, bond; B1D3, D3J3, J3K2, K2J4, J4D4, D4B2 = CR33:CR35, N:N; R1 = haloalkyl, haloalkoxymethyl; R2 = H, aryl, alkyl, alkenyl, haloalkyl, perhaloaryl, heteroaryl, etc.; R3 = H, aryl, alkyl, alkenyl, haloalkyl, haloalkoxyalkyl; Y, Z = bond, (CH2)q, (CH2)jO(CH2)k; q = 1, 2; j, k = 0, 1; R4, R8, R9, R13 = H, halo, haloalkyl, alkyl; R33, R34, R35, R36 = aryl, heteroaryl; R30 = spacer; R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R31, R32, R33, R34, R35, R36 = H, CO2H, heteroaralkylthio, heteroalkoxy, cycloalkylamino, acylalkyl, aroylalkoxy, cycloalkenyloxy, OH, amino, NO2, arylthio, etc.; with provisos], were prepared but the methods of preparation are not claimed. Thus, 4-methylcyclohexylamine and 3-trifluoromethylbenzaldehyde in CHCl3 were refluxed through a Dean-Stark trap to give 100% imine, which was stirred with NaBH4 in MeOH to give 68.4% N-(4-methylcyclohexyl)[[3-(trifluoromethyl)phenyl]methyl]amine. This was heated with 3,3,3-trifluoro-1,2-epoxypropane and ytterbium(III) trifluoroacetate in MeCN at 50° to give 77% 3-[(4-methylcyclohexyl)[[3-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol. The latter inhibited CETP with IC50 = 15 μM. The above compds. are claimed to be useful for treating atherosclerosis, dyslipidemia, and other coronary artery disease.

IT 263246-29-3P 263246-30-6P 263246-31-7P
263246-32-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylaminoalkanols as cholesteryl ester transfer protein inhibitors)

RN 263246-29-3 CAPLUS
CN 2-Propanol, 3-[[3-(4-chloro-3-ethylphenoxy)propyl][[3-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



RN 263246-30-6 CAPLUS
CN 2-Propanol, 3-[[3-(4-chloro-3-ethylphenoxy)propyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



RN 263246-31-7 CAPLUS
CN 2-Propanol, 3-[[3-(4-chloro-3-ethylphenoxy)propyl][[3-(trifluoromethoxy)phenyl]methyl]amino]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



RN 263246-32-8 CAPLUS
CN 2-Propanol, 3-[[3-(4-chloro-3-ethylphenoxy)propyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



L18 ANSWER 64 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:378601 CAPLUS
DOCUMENT NUMBER: 133:67684
TITLE: Design and synthesis of new models for diiron biosites
AUTHOR(S): Trukhan, V. M.; Gritsenko, O. N.; Nordlander, E.; Shteinman, A. A.
CORPORATE SOURCE: Institute of Problems of Chemical Physics, Russian Academy of Sciences, Chernogolovka, 142432, Russia
SOURCE: Journal of Inorganic Biochemistry (2000), 79(1-4), 41-46
CODEN: JIBIDJ; ISSN: 0162-0134
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB To mimic dinuclear active sites of some nonheme diiron proteins, ten new polydentate and potentially dinucleating ligands were synthesized. Each ligand contains a carboxylate moiety designed to bridge two metal atoms. These central carboxylate moieties are derived from substituted benzoic acids that in turn are linked to terminal nitrogen or oxygen donors by spacers so that framework-type polydentate ligands similar to the polypeptide frames in diiron metallobiosites are formed. Reaction of these ligands with Fe(ClO4)3·9H2O leads to ferric μ-oxo-μ-carboxylato iron complexes [Fe2O(L)2(H2O)2](ClO4)2 and [Fe2O(L)(BzO)](ClO4)2 (L = ligand), containing one or two immobilized bridging carboxylates, resp. While x-ray crystallog. shows that some of these complexes are dimers or network polymers in the solid state, electrospray ionization mass spectrometry (ESMS) and spectroscopic data (UV-visible, NMR, Moessbauer) indicate that they dissociate to monomeric Fe2O units in dilute CH3CN solns.

IT 219954-39-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reactant for preparation of iron oxo benzoato complex as nonheme diiron protein model)

RN 219954-39-9 CAPLUS
CN Benzoic acid, 2,6-bis[3-[bis(2-pyridinylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 65 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:227619 CAPLUS
DOCUMENT NUMBER: 132:264957
TITLE: Preparation of arylaminoalkanols as cholesteryl ester transfer protein inhibitors.
INVENTOR(S): Sikorski, James A.; Durley, Richard C.; Grapperhaus, Margaret L.; Mischke, Deborah A.; Reinhard, Emily J.; Parnas, Barry L.; Rueppel, Melvin L.
PATENT ASSIGNEE(S): Monsanto Company, USA
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000018723	A1	20000406	WO 1999-US22123	19990923
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2345108	A1	20000406	CA 1999-2345108	19990923
AU 9961610	A1	20000417	AU 1999-61610	19990923
EP 1115694	A1	20010718	EP 1999-948431	19990923
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002525350	T	20020813	JP 2000-572185	19990923
PRIORITY APPLN. INFO.:			US 1998-101660P	P 19980925
			WO 1999-US22123	W 19990923

OTHER SOURCE(S): MARPAT 132:264957
GI

AB HOCR1R2(CHR3)nN(ZA)YQ [n = 1, 2; A, Q = CH2(CR37R38)v(CR33R34)uT(CR35R36)w H, Q1, Q2; T = bond, O, S, SO, SO2, CR33:CR35, C.tplbond.C; v = 0, 1; u, w = 0-6; A1 = CR30; D1, D2, J1, J2, K1 = C, N, O, S, bond; B1, B2, D3, D4, J3, J4, K2 = C, CR30, N, O, S, bond; B1D3, D3J3, J3K2, K2J4, J4D4, D4B2 = CR33:CR35, N:N; R1 = haloalkyl, haloalkoxymethyl; R2 = H, aryl, alkyl, alkenyl, haloalkyl, perhaloaryl, heteroaryl, etc.; R3 = H, aryl, alkyl, alkenyl, haloalkyl, haloalkoxyalkyl; Y, Z = bond, (CH2)q, (CH2)jO(CH2)k; q = 1, 2; j, k = 0, 1; R4, R8, R9, R13 = H, halo, haloalkyl, alkyl; R33, R34, R35, R36 = aryl, heteroaryl; R30 = spacer; R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R31, R32, R33, R34, R35, R36 = H, CO2H, heteroaralkylthio, heteroalkoxy, cycloalkylamino, acylalkyl, aroylalkoxy, cycloalkenyloxy, OH, amino, NO2, arylthio, etc.; with provisos], were prepared Thus, 4-methylcyclohexylamine and 3-trifluoromethylbenzaldehyde in CHCl3 were refluxed through a Dean-Stark trap to give 100% imine, which

was stirred with NaBH4 in MeOH to give 68.4% N-(4-methylcyclohexyl)[[3-(trifluoromethyl)phenyl]methyl]amine. This was heated with 3,3,3-trifluoro-1,2-epoxypropane and ytterbium(III) trifluoroacetate in MeCN at 50° to give 77% 3-[(4-methylcyclohexyl)[[3-trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro-2-propanol. The latter inhibited CETP with IC50 = 15 μM.

IT 263246-29-3P 263246-30-6P 263246-31-7P
263246-32-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylaminoalkanols as cholesteryl ester transfer protein inhibitors)

RN 263246-29-3 CAPLUS
CN 2-Propanol, 3-[[3-(4-chloro-3-ethylphenoxy)propyl][[3-(trifluoromethyl)phenyl]methyl]amino]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



RN 263246-30-6 CAPLUS
CN 2-Propanol, 3-[[3-(4-chloro-3-ethylphenoxy)propyl][[3-(pentafluoroethyl)phenyl]methyl]amino]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



RN 263246-31-7 CAPLUS
CN 2-Propanol, 3-[[3-(4-chloro-3-ethylphenoxy)propyl][[3-(trifluoromethoxy)phenyl]methyl]amino]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



RN 263246-32-8 CAPLUS
CN 2-Propanol, 3-[[3-(4-chloro-3-ethylphenoxy)propyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]amino]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 66 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:522647 CAPLUS
DOCUMENT NUMBER: 131:286221
TITLE: New type of polydentate ligands for simulation of binuclear metallobiocenters
AUTHOR(S): Trukhan, V. M.; Norlander, E.; Shteinman, A. A.
CORPORATE SOURCE: Institute of Problems of Chemical Physics, Russian Academy of Sciences, Chernogolovka, Russia
SOURCE: Russian Journal of Organic Chemistry (Translation of Zhurnal Organicheskoi Khimii) (1999), 35(2), 315-317
CODEN: RJOCEQ; ISSN: 1070-4280
PUBLISHER: MAIK Nauka/Interperiodica Publishing
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Bispyridylalkoxybenzoates, e.g. I, have been prepared as polydentate ligands for simulation of binuclear metallobiocenters.

IT 219954-40-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn of pyridylbenzoic acid derivs. as polydentate ligands for simulation of binuclear metallobiocenters)

RN 219954-40-2 CAPLUS
CN Benzoic acid, 2,6-bis[3-[bis(2-pyridinylmethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT 219954-39-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn of pyridylbenzoic acid derivs. as polydentate ligands for simulation of binuclear metallobiocenters)

RN 219954-39-9 CAPLUS
CN Benzoic acid, 2,6-bis[3-[bis(2-pyridinylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 67 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:391238 CAPLUS
DOCUMENT NUMBER: 131:176871
TITLE: Synthesis and characterization of iron(III) complexes of a new ligand containing a potentially bridging carboxylate; structural characterization of a helical tetranuclear iron complex
AUTHOR(S): Trukhan, Vladimir M.; Shteinman, Albert A.; Pierpont, Cortlandt G.; Jensen, Kenneth B.; Nordlander, Ebbe
CORPORATE SOURCE: Institute of Chemical Physics, Chernogolovka, 142432, Russia
SOURCE: Chemical Communications (Cambridge) (1999), (13), 1193-1194
CODEN: CHCOFS; ISSN: 1359-7345
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Reaction of the new polydentate ligand 2,6-bis{3-[N,N-di(2-pyridylmethyl)amino]propoxy}benzoic acid (LH) with Fe(ClO4)3 followed by addition of chloroacetic acid gives tetranuclear [{Fe2OL(ClCH2CO2)2}2](ClO4)4, the crystal structure of which reveals that it consists of two FeIII2(μ-O)(μ-RCO2)2 cores that are linked via the two L ligands in a helical structure, with the carboxylate moieties of the two ligands forming a hydrogen-bonded pair at the center of the helix.

IT 219954-40-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction to give bis{[di(pyridylmethyl)amino]propoxy}benzoic acid and its iron complexes)

RN 219954-40-2 CAPLUS
CN Benzoic acid, 2,6-bis[3-[bis(2-pyridinylmethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT 219954-39-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction to give iron oxo bis{[di(pyridylmethyl)amino]propoxy}benzoato complexes)

RN 219954-39-9 CAPLUS
CN Benzoic acid, 2,6-bis[3-[bis(2-pyridinylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



IT 219954-39-9DP, iron aqua oxo complex
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with chloroacetic acid to give iron oxo bis{[di(pyridylmethyl)amino]propoxy}benzoato tetranuclear helical complex)

RN 219954-39-9 CAPLUS
CN Benzoic acid, 2,6-bis[3-[bis(2-pyridinylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 68 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:918 CAPLUS
DOCUMENT NUMBER: 130:133166
TITLE: First structural-functional model of methane

monooxygenase

AUTHOR(S): Trukhan, V. M.; Polukhov, V. V.; Sulimenkov, I. V.; Ovanesyan, N. S.; Koval'chuk, N. A.; Dodonov, A. F.; Shteinman, A. A.

CORPORATE SOURCE: Institute of Problems of Chemical Physics, Russian Academy of Sciences, Moscow, 142432, Russia

SOURCE: Kinetics and Catalysis (Translation of Kinetika i Kataliz) (1998), 39(6), 788-791
CODEN: KICAA8; ISSN: 0023-1584

PUBLISHER: MAIK Nauka/Interperiodica Publishing

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The {Fe2OL(OBz)}(ClO4)2 complex (1) was prepared by the interaction of the new polydentate ligand 2,6-bis[3-[N,N-di(2-pyridylmethyl)amino]propoxy]benzoic acid (LH) with Fe(ClO4)3 in the presence of NaOBz. 1 Is structurally similar to the binuclear unit of an active center of methane monooxygenase (MMO). In this structure, one bridging carboxylate (in L) becomes fixed, and the other (in OBz) remains mobile, retaining the capability for substitution reactions and occupying two labile coordination sites in the mol. (these sites are required for catalysis). The structure of 1 was supported by mass spectrometry and other spectroscopic data. 1 Catalyzes selective oxidation of methane to MeOH by H2O2.

IT 219954-40-2P, Methyl 2,6-bis[3-[N,N-di(2-pyridylmethyl)amino]propoxy]benzoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(for preparation of 2,6-bis[3-[N,N-di(2-pyridylmethyl)amino]propoxy]benzoic acid)

RN 219954-40-2 CAPLUS

CN Benzoic acid, 2,6-bis[3-[bis(2-pyridinylmethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT 219954-39-9P, 2,6-Bis[3-[N,N-di(2-pyridylmethyl)amino]propoxy]benzoic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and complexation with iron)

RN 219954-39-9 CAPLUS

CN Benzoic acid, 2,6-bis[3-[bis(2-pyridinylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 69 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:758050 CAPLUS

DOCUMENT NUMBER: 130:52236

TITLE: Preparation of dihydroxyphthalic acid diethers as squalene synthase inhibitors, their pharmaceutical uses, and their intermediates

INVENTOR(S): Ichikawa, Yuichiro; Niizuma, Setsuko; Abe, Masatoshi; Takahashi, Wataru; Ikeda, Tatsuji; Takashio, Kazutoshi

PATENT ASSIGNEE(S): Nippon Kayaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 64 pp.
CODEN: JKXXAP

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10316617	A	19981202	JP 1997-141169	19970516
PRIORITY APPLN. INFO.:			JP 1997-141169	19970516

OTHER SOURCE(S): MARPAT 130:52236

GI



AB The title derivs. I [R = OH; X1, X2 = (un)substituted linear or branched C1-20 (un)saturated aliphatic hydrocarbyl, (un)substituted C2-8 alkyloxyalkyl, alkenyloxyalkyl, YZ [Y = (un)substituted C1-8 (hydroxy)alkyl, (un)substituted C2-8 alkyloxyalkyl, (un)substituted C2-8 alkylaminoalkyl; Z = (un)substituted aryl] (II); except the case where X1 = X2 = C1-3 alkyl, benzyl] and/or their pharmaceutically acceptable salts are prepared by hydrolyzing I [R = OR1, NR2R3; R1-3 = C1-6 alkyl, (un)substituted C7-10 aralkyl; X1, X2 = same as in II). II and their salts are useful for treatment of infection, hypercholesterolemia, hyperlipemia, or atherosclerosis. IC50 of 3-farnesyloxy-4-[4-(3-phenoxyphenyl)butoxy]phthalic acid (preparation given) against Aspergillus fumigatus squalene synthase was 0.41 μg/mL. Antifungal activity against A. fumigatus and Candida albicans, and cholesterol formation-inhibiting action of II were also shown.

IT 217098-65-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydroxyphthalic acid diethers as squalene synthase inhibitors and pharmaceutical uses and intermediates)

RN 217098-65-2 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 5-[3-[[(3,4-dichlorophenyl)methyl][2-(2-naphthalenyl)ethyl]amino]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)



IT 217098-62-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dihydroxyphthalic acid diethers as squalene synthase inhibitors and pharmaceutical uses and intermediates)

RN 217098-62-9 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 5-[3-[[(3,4-dichlorophenyl)methyl][2-(2-naphthalenyl)ethyl]amino]propoxy]-3-methoxy-, dimethyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 70 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:621190 CAPLUS

DOCUMENT NUMBER: 129:230634

TITLE: Preparation of heteroaryl(aryl)-substituted alkanamides as LTB4 hydrolase inhibitors

INVENTOR(S): Penning, Thomas D.; Yu, Stella S.; Malecha, James; Liang, Chi-dean; Russell, Mark A.

PATENT ASSIGNEE(S): G.D. Searle and Co., USA

SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9840354	A1	19980917	WO 1998-US3928	19980306
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6162823	A	20001219	US 1997-815700	19970312
AU 9866733	A	19980929	AU 1998-66733	19980306
PRIORITY APPLN. INFO.:			US 1997-815700 A	19970312
			WO 1998-US3928 W	19980306

OTHER SOURCE(S): MARPAT 129:230634

GI



II



III

AB The title compds. Ar1-Q-Ar2-Y-(CH2)mN(R1)(CH2)nC(O)NHSO2R2 [I; Ar1 = (un)substituted Ph, 4-pyridyl, 2-thienyl, 3-thienyl, etc.; Ar2 = (un)substituted Ph, thiazolyl, pyridinyl, etc.; Q = O, CH2, OCH2, etc.; Y = O, S, NH, etc.; R1 = H, lower alkyl, lower alkoxy, cycloalkyl; R2 = lower alkyl, (un)substituted Ph; NR1CH2CONHSO2R = pyrrolidino, piperidino, piperazino substituted with (CH2)pCONHSO2R2; m = 2-4; n = 2-6; p = 1-3] and their pharmaceutically acceptable salts and stereoisomers, useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as psoriasis, ulcerative colitis, IBD, and asthma, were prepared Thus, reaction of carboxylic acid II with benzenesulfonamide in the presence of DMAP and EDC in CH2Cl2 afforded 8% the title compound III which showed IC50 of 0.079 μM against calcium ionophore-induced LTB4 production in human blood.

IT 212967-70-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl(aryl)-substituted alkanamides as LTB4 hydrolase inhibitors)

RN 212967-70-9 CAPLUS

CN Propanamide, 3-[cyclopropyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



IT 212967-83-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heteroaryl(aryl)-substituted alkanamides as LTB4 hydrolase inhibitors)
RN 212967-83-4 CAPLUS
CN β-Alanine, N-cyclopropyl-N-[3-[4-(phenylmethyl)phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 71 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:75334 CAPLUS
DOCUMENT NUMBER: 128:180389
TITLE: Synthesis and biological evaluation of phenylacetyl derivatives having low central nervous system permeability as potent and selective M2 muscarinic receptor antagonists
AUTHOR(S): Watanabe, Toshihiro; Kakefuda, Akio; Tanaka, Akihiro; Takizawa, Kenji; Hirano, Seiko; Shibata, Hiroshi; Yamagiwa, Yoko; Yanagisawa, Isao
CORPORATE SOURCE: Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, 305, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1998), 46(1), 53-68
CODEN: CPBTAL; ISSN: 0009-2363
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB A series of phenylacetyl derivs. containing the 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one or 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one skeleton was prepared and evaluated for their binding affinities to muscarinic receptors in vitro and for antagonism of bradycardia, salivation and tremor in vivo. Among them, dibenzodiazepinone compds. I and II had high affinity for M2 muscarinic receptors in the heart (pKi=8.7 and 8.9, resp.) with low affinity for M3 muscarinic receptors in the submandibular gland. A structure-activity relationship (SAR) study suggested that the high M2 selectivity over the M3 muscarinic receptors of I may be attributed to the direction of the carboxamide carbonyl group. In in vivo studies, I and II antagonized oxotremorine-induced bradycardia in rats on both i.v. and oral administration, and their heart rate increasing effect in dogs with nocturnal bradycardia was about 3-fold greater than that of AF-DX 116. Furthermore, they had almost no influence on oxotremorine-induced tremor in mice, presenting no evidence of central transfer.
IT 185801-64-3P 185801-68-7P 185801-71-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, muscarinic receptor antagonist activity, and structure activity relationship of phenylacetyl pyridobenzodiazepinones and dibenzodiazepinones)
RN 185801-64-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-[ethyl[[4-(4-ethyl-1-piperazinyl)phenyl]methyl]amino]propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 185801-68-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(cyclohexylethylamino)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 185801-71-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-[ethyl(phenylmethyl)amino]propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 72 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:85185 CAPLUS
DOCUMENT NUMBER: 126:104108
TITLE: Preparation of fused benzodiazepinone derivatives for the treatment of heart diseases
INVENTOR(S): Watanabe, Toshihiro; Kakefuda, Akio; Tanaka, Akihiro
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9638422	A1	19961205	WO 1996-JP1462		19960530
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM					
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9658447	A	19961218	AU 1996-58447		19960530
CN 1180350	A	19980429	CN 1996-193058		19960530
PRIORITY APPLN. INFO.:			JP 1995-133609	A	19950531
			WO 1996-JP1462	W	19960530

OTHER SOURCE(S): MARPAT 126:104108
GI



I

AB Fused benzodiazepinone derivs. represented by general formula I [X represents CH or N; Y represents oxygen, NR4, S(O)n or NR5CO, wherein R4 and R5 are the same or different and each represents hydrogen or lower alkyl; and n is an integer of from 0 to 2; A represents lower alkylene; R1 and R2 are the same or different and each represents hydrogen, lower alkyl, cycloalkyl, optionally substituted aryl or optionally substituted aralkyl, or R1 and R2 together with the nitrogen atom to which they are bonded may form a 4- to 9-membered nitrogen-containing saturated heterocycle optionally further containing one of oxygen, sulfur and nitrogen atoms and optionally having substituent(s); and R3 represents hydrogen, optionally substituted lower alkyl, hydroxy, lower alkoxy, nitro, halogeno, lower acyl or optionally substituted amino] are prepared I have medicinal effects, in particular, preventive or therapeutic effects on heart diseases in which muscarinic M2 receptors participate. I show high affinity for the muscarinic M2 receptors.

IT 185801-64-3P 185801-69-8P 185801-72-3P
185801-74-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused benzodiazepinone derivs. for the treatment of heart diseases)

RN 185801-64-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-[ethyl[[4-(4-ethyl-1-piperazinyl)phenyl]methyl]amino]propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 185801-69-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(cyclohexylethylamino)propoxy]phenyl]acetyl]-5,10-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 185801-68-7
CMF C32 H37 N3 O3

PAGE 1-A



PAGE 2-A

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 185801-72-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-[ethyl(phenylmethyl)amino]propoxy]phenyl]acetyl]-5,10-dihydro-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 185801-71-2
CMF C33 H33 N3 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 185801-74-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-[3-[ethyl(phenylmethyl)amino]propoxy]phenyl]acetyl]-5,10-dihydro-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 185801-73-4
CMF C33 H33 N3 O3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L18 ANSWER 73 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:466897 CAPLUS
DOCUMENT NUMBER: 125:142545
TITLE: Preparation of heterocyclic LTA4 hydrolase inhibitors
INVENTOR(S): Chandrakumar,, Nizal Samuel; Chen, Barbara Baosheng; Clare, Michael; Desai, Bipinchandra Nanubhai; Djuric, Steven Wakefield; Docter, Stephan Hermann; Gasiecki, Alan Frank; Haack, Richard Arthur; Liang, Chi-Dean; et al.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: PCT Int. Appl., 342 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9611192	A1	19960418	WO 1995-US12365	19951010
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5585492	A	19961217	US 1994-321183	19941011
US 5719306	A	19980217	US 1995-466010	19950606
CA 2202371	A1	19960418	CA 1995-2202371	19951010
AU 9536865	A	19960502	AU 1995-36865	19951010
EP 804427	A1	19971105	EP 1995-934554	19951010
EP 804427	B1	20020918		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
JP 10512848	T	19981208	JP 1996-512608	19951010
EP 1221441	A2	20020710	EP 2002-6764	19951010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 224381	T	20021015	AT 1995-934554	19951010
PT 804427	T	20030131	PT 1995-934554	19951010
ES 2183886	T3	20030401	ES 1995-934554	19951010

PRIORITY APPLN. INFO.: US 1994-321183 A1 19941011
EP 1995-934554 A3 19951010
WO 1995-US12365 W 19951010
OTHER SOURCE(S): MARPAT 125:142545
GI



AB The title compds. Ar1QAr2YRZ [Ar1, Ar2 = (un)substituted aryl; Z = (un)substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or (an) (un)substituted monocyclic or bicyclic nitrogen-containing heteroarom. moiety; Q, Y = linking group; R = alkylene], useful in the treatment of inflammatory diseases which are mediated by LTB4 production (e.g., psoriasis (no data), ulcerative colitis (no data), irritable bowel syndrome (no data), and asthma (no data)], are prepared Thus, 4-phenoxyphenol was condensed with 1-(2-chloroethyl)pyrrolidine hydrochloride, producing pyrrolidine I, which demonstrated a IC50 of 30 nM in a recombinant human LTA4 hydrolase assay.
IT 179021-87-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic LTA4 hydrolase inhibitors)
RN 179021-87-5 CAPLUS
CN β-Alanine, N-[3-[4-(phenylmethyl)phenoxy]propyl]-N-(3-pyridinylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 74 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:452004 CAPLUS
DOCUMENT NUMBER: 125:142725
TITLE: LTA4-Hydrolase inhibitors, pharmaceutical compositions, and methods of use
INVENTOR(S): Chandrakumar, Nizal Samuel; Chen, Barbara Baosheng; Clare, Michael; Desai, Bipinchandra Nanubhai; Djuric, Steven Wakefield; Docter, Stephan Hermann; Gasiecki, Alan Frank; Haack, Richard Arthur; Liang, Chi-Dean; et al.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: PCT Int. Appl., 362 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9610999	A2	19960418	WO 1995-US12367	19951010
WO 9610999	A3	19960919		
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6506876	B1	20030114	US 1994-321184	19941011
US 5723492	A	19980303	US 1995-469606	19950606
CA 2202368	A1	19960418	CA 1995-2202368	19951010
AU 9536866	A	19960502	AU 1995-36866	19951010
EP 786992	A2	19970806	EP 1995-934555	19951010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 10512542	T	19981202	JP 1995-512609	19951010

PRIORITY APPLN. INFO.: US 1994-321184 A1 19941011
WO 1995-US12367 W 19951010
OTHER SOURCE(S): MARPAT 125:142725
GI



II



• HCl III

AB The invention provides compds. Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof [wherein Ar1 and Ar2 = (un)substituted (hetero)aryl moieties; Z = (un)substituted N-containing moiety which may be an acyclic, cyclic, or bicyclic amine, or an (un)substituted monocyclic or bicyclic, N-containing, heteroarom. moiety; Q = O, CH2, OCH2, CH2O, NH, NHCH2, CH2NH, CF2, CH:CH, CH2CH2, or bond; R = alkylene moiety; Y = O, S, NH, S(O), S(O)2; Z is bound to R through a N atom]. I and their pharmaceutical compns. are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as psoriasis, ulcerative colitis, inflammatory bowel disease, and asthma. Over 500 examples cover syntheses of various I and precursors, plus results of 3 bioassays. For instance, etherification of 1-(2-hydroxyethyl)pyrrolidine with 2-bromothiazole and NaH gave 74% 2-(2-pyrrolidinoethoxy)thiazole, which was lithiated with BuLi and treated with PhCHO to give the 5-(α-hydroxybenzyl) derivative in 66% yield. This was reduced with Et3SiH and CF3CO2H to give 74% title compound II. In a recombinant human LTA4 hydrolase assay, title compound III had IC50 of 2 nM.

IT 179021-87-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hetero)aryloxyalkylamines and analogs as LTA4 hydrolase inhibitors)
RN 179021-87-5 CAPLUS
CN β-Alanine, N-[3-[4-(phenylmethyl)phenoxy]propyl]-N-(3-pyridinylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 75 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:881345 CAPLUS
DOCUMENT NUMBER: 123:286522
TITLE: Preparation of methyl 6-acylamino-6-deoxy-α-D-glucopyranoside derivatives increasing leukocyte count and preventing infection
INVENTOR(S): Kurita, Hiroki; Sofugawa, Masao; Sugawara, Kazutoshi; Onda, Tokio; Oohashi, Motoaki
PATENT ASSIGNEE(S): Tanabe Seiyaku Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07126279	A	19950516	JP 1993-269343	19931028

PRIORITY APPLN. INFO.: JP 1993-269343 19931028
OTHER SOURCE(S): MARPAT 123:286522
GI



I II

AB The title compds. [I; R = COR2; Q = S, O, (un)substituted NH; R1 = alkyl, alkenyl, alkynyl, (un)substituted aryl, mono- or bicyclic heterocyclyl containing 1-2 heteroatoms selected from N, O, and S; R2 = group selected from (1) alkyl, alkenyl, or alkynyl optionally substituted with aryl or mono- or bicyclic heterocyclyl containing 1-2 heteroatoms selected from N, O, and S and (2) tricycloalkyl; Alk = lower alkylene], having preventive effect

against infection with bacteria and fungi and useful for the treatment of infectious diseases of humans and animals and congenital or acquired immunodeficiency, particularly acquired immunodeficiency caused by temporal abnormal symptoms after radiotherapy or therapy using immunosuppressant substances (no data), are prepared by acylation of I (R = H; R1, Q, Alk = same as above) with R2CO2H (R2 = same as above) or a salt or reactive derivative thereof. Thus, 3-phenylthiopropylamine was added to a solution of Me 6-O-tosyl-α-D-glucopyranoside in toluene and refluxed for 4 h to give Me 6-deoxy-6-(3-phenylthiopropyl)amino- α-D-glucopyranoside. The latter glucoside was dissolved in THF and after adding an aqueous solution of K2CO3, treated dropwise with a solution of octadecanoyl chloride in THF, and the resulting mixture was stirred overnight, treated MeOH , and stirred for 1 h to give a title compound (II).

IT 169465-61-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of Me acylaminodeoxy-α-D-glucopyranoside derivs. increasing leukocyte count and preventing bacterial and fungal infection)

RN 169465-61-6 CAPLUS

CN α-D-Glucopyranoside, methyl 6-deoxy-6-[[3-(3,4-dimethylphenoxy)propyl](1-oxooctadecyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 76 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:881294 CAPLUS
DOCUMENT NUMBER: 123:285534
TITLE: Preparation of phenylcarboxylate derivatives as phospholipase A2 inhibitors.
INVENTOR(S): Ohtani, Mitsuaki; Kato, Toshiyuki; Hori, Yozo
PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 66 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 646569	A1	19950405	EP 1994-307136	19940929
EP 646569	B1	19980107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2133115	A1	19950402	CA 1994-2133115	19940928
AU 9474285	A	19950413	AU 1994-74285	19940928
AU 674779	B2	19970109		
US 5534533	A	19960709	US 1994-313890	19940928
AT 161820	T	19980115	AT 1994-307136	19940929
ES 2112489	T3	19980401	ES 1994-307136	19940929
CN 1107337	A	19950823	CN 1994-118648	19940930
CN 1071738	B	20010926		
JP 08073404	A	19960319	JP 1994-236824	19940930
JP 3714978	B2	20051109		
WO 9519773	A1	19950727	WO 1994-US847	19940119
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1992-957491	19921007
			JP 1993-246732	A 19931001
			JP 1994-154937	A 19940706

OTHER SOURCE(S): MARPAT 123:285534
GI



AB A method of inhibiting oxytocin from acting at its receptor site by administering oxytocin receptor antagonist compds. of the formula I wherein X is oxygen or sulfur; Y is hydrogen or lower alkyl; RA is II. IC50 (nM) values were determined for both [3H]oxytocin and [3H]vasopressin: 560-2500 and 39-320, resp. Pharmaceutical formulations were given.

IT 131631-90-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(carbostyril oxytocin receptor antagonists)

RN 131631-90-8 CAPLUS

CN Piperidine, 4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-[4-[3-[(phenylmethyl)propylamino]propoxy]benzoyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 78 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:549521 CAPLUS
DOCUMENT NUMBER: 119:149521
TITLE: Recording material useful for pressure-sensitive and heat-sensitive recording
INVENTOR(S): Araki, Katsumi; Takashima, Masanobu; Azuma, Shunsaku
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 30 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I (A = HO, H2N, alkylamino; R1-12 = H, Me, MeO, HO, provided that all of R1-12 are not H; G1 = a single bond, (CH2)xO(CH2)y wherein x and y = 0-5; G2 = a single bond, O, S, CO, etc.; G3 = alkyl, aryl, (substituted)amino or heterocyclyl) or a salt thereof, are prepared To a terephthalic ester derivative in DMF was added NaH and 4-(3-BrPrO)C6H4CF3 to give the appropriate trifluoromethyl derivative to which in CH2Cl2 was added anisole and trifluoroacetic acid to give after workup the title compound II. Phospholipase A2 inhibitory activity was demonstrated. Inhibition of exptl. adjuvant arthritis of selective I are given.

IT 169450-42-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylcarboxylate derivs. as phospholipase A2 inhibitors)

RN 169450-42-4 CAPLUS

CN Benzoic acid, 4-[3-[bis(phenylmethyl)amino]propoxy]-2-methoxy-3,5,6-trimethyl-, 4-carboxy-3-methoxy-2,5,6-trimethylphenyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 77 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:227441 CAPLUS
DOCUMENT NUMBER: 122:105695
TITLE: Carbostyril oxytocin receptor antagonists
INVENTOR(S): Freidinger, Roger M.; Pawluczyk, Joseph M.; Pettibone, Douglas J.; Williams, Peter D.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 177 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5356904	A	19941018	US 1992-957491	19921007
JP 04347682	A	19921202	JP 1991-120210	19910524
JP 2720231	B2	19980304		
PRIORITY APPLN. INFO.:			JP 1991-120210	19910524

GI



AB A recording material using a colorless electron-donating dye and an electron-accepting compound contains ≥1 compound represented by I [R1-3 = H, halo, hydroxy, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, aryloxy, arylthio, amino, acyl, alkoxycarbonyl, carboxy, carbamoyl, sulfamoyl, cyano, nitro, isocyanate, heterocyclyl residue; A1 = aromatic; X = S, SO, SO2, O, CO, CO2, alkylene, cycloalkylene, aralkylene, arylene; and A2 = aromatic ring or heterocyclyl without OH]. This recording material gives excellent color-forming d. and storage stabilities for non-image and images regions.

IT 139332-53-9
RL: USES (Uses)
(colorless electron-donating dye, material containing, for pressure-sensitive and heat-sensitive recording)

RN 139332-53-9 CAPLUS

CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[ethyl[3-(4-ethylphenoxy)propyl]amino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)



L18 ANSWER 79 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:408837 CAPLUS
DOCUMENT NUMBER: 119:8837
TITLE: Preparation of 1,2,4-benzothiadiazine-1,1-dioxide derivatives for treatment of peptic ulcer
INVENTOR(S): Ohno, Tomoyasu; Yano, Shingo; Fujiwara, Kosuke; Ajioka, Hirofusa; Yamamoto, Noriyuki; Yamada, Shozo; Kajitani, Makoto
PATENT ASSIGNEE(S): Taiho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9220666	A1	19921126	WO 1992-JP672	19920522
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2109723	A1	19921126	CA 1992-2109723	19920522
CA 2109723	C	19990720		
AU 9217923	A	19921230	AU 1992-17923	19920522
AU 655986	B2	19950119		
EP 641789	A1	19950308	EP 1992-910342	19920522
EP 641789	B1	19971203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
AT 160776	T	19971215	AT 1992-910342	19920522
ES 2111637	T3	19980316	ES 1992-910342	19920522
US 5401739	A	19950328	US 1993-142307	19931123
KR 9702467	B1	19970305	KR 1993-73587	19931124
PRIORITY APPLN. INFO.:			JP 1991-149927 A	19910524
			WO 1992-JP672 A	19920522

OTHER SOURCE(S): MARPAT 119:8837
GI



I



II

AB The title compds. (I; X = CH2, (alkyl-substituted) NH; Z = CH2, CO; A = (MeO2C-substituted) phenylene; B = alkylene, alkenylene; R1 = H, AcOCH2CO, cyclohexylmethyl, (un)substituted PhCH2 or PhCH2O; R2 = alkyl, Ph; R3 = H, halo, alkoxy; excluding a case where X = Y = Z = CH2, A = phenylene, B = lower alkylene, and R1 = H) are prepared Thus, treatment of 3-(1-piperidinomethyl)phenol with NaH in DMF followed by etherification with N-(3-bromopropyl)phthalimide and deprotection with hydrazine hydrate in MeOH at 70° gave 78% 3-[3-(1-piperidinomethyl)phenoxy]propylamin e. Reductive alkylation of this amine with p-anisaldehyde and NaBH4 in EtOH to N-[3-[3-(piperidinomethyl)phenoxy]propyl]-4'-methoxybenzylamine followed by cyclocondensation with 3-chloro-4-methyl-1,2,4-benzothadiazine-1,1-dioxide in CHCl3 gave, after salt formation with 4N HCl in EtOAc, title compound II.HCl.2H2O which at 30 and 100 mg/kg p.o. inhibited 85.0 and 94.5% 0.6N HCl-induced stomach ulcer in rats. A total of 34 I were prepared, some of which also reduced the stomach acid secretion in rats. A tablet formulation containing II.HCl.2H2O was given.

IT 147181-01-9P 147192-66-3P 147192-71-0P
147192-72-1P 147661-70-9P 147661-72-1P
147661-74-3P 147661-76-5P 147661-78-7P
147661-80-1P 147661-82-3P 147661-84-5P
147661-86-7P 147661-88-9P 147661-90-3P
147661-91-4P 147661-93-6P 147661-95-8P
147661-97-0P 147661-99-2P 147662-01-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as peptic ulcer inhibitor)

RN 147181-01-9 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, N-[(4-methoxyphenyl)methyl]-4-methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 147192-66-3 CAPLUS
CN Phenol, 3-[[(4-methyl-1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 147192-71-0 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, N-[(4-methoxyphenyl)methyl]-4-methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 147192-72-1 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, 4-ethyl-N-[(4-methoxyphenyl)methyl]-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide (9CI). (CA INDEX NAME)



RN 147661-70-9 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, N-[(4-methoxyphenyl)methyl]-4-methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147192-71-0
CMF C31 H38 N4 O4 S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 147661-72-1 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, 4-methyl-N-(phenylmethyl)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147661-71-0
CMF C30 H36 N4 O3 S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 147661-74-3 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, N-[(4-chlorophenyl)methyl]-4-methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147661-73-2
CMF C30 H35 Cl N4 O3 S



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 147661-76-5 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, 4-methyl-N-[(4-nitrophenyl)methyl]-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147661-75-4
CMF C30 H35 N5 O5 S



CM 2

CRN 144-62-7
CMF C2 H2 O4

CRN 144-62-7
CMF C2 H2 O4

RN 147661-82-3 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, N-[(2-methoxyphenyl)methyl]-4-methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147661-81-2
CMF C31 H38 N4 O4 S



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 147661-84-5 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, 4-methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-N-[(3,4,5-trimethoxyphenyl)methyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147661-83-4
CMF C33 H42 N4 O6 S

RN 147661-78-7 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, 4-methyl-N-[(4-methylphenyl)methyl]-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147661-77-6
CMF C31 H38 N4 O3 S



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 147661-80-1 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, N-[(3-methoxyphenyl)methyl]-4-methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147661-79-8
CMF C31 H38 N4 O4 S



CM 2



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 147661-86-7 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, N-(1,3-benzodioxol-5-ylmethyl)-4-methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147661-85-6
CMF C31 H36 N4 O5 S



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 147661-88-9 CAPLUS
CN Phenol, 4-[[(4-methyl-1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]methyl]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 147661-87-8
CMF C30 H36 N4 O4 S



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 147661-90-3 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, N-(cyclohexylmethyl)-4-methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147661-89-0
CMF C30 H42 N4 O3 S



CM 2



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 147661-95-8 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, 4-butyl-N-[(4-methoxyphenyl)methyl]-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 147661-94-7
CMF C34 H44 N4 O4 S



CM 2

CRN 144-62-7
CMF C2 H2 O4

CRN 144-62-7
CMF C2 H2 O4

RN 147661-91-4 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, 4-ethyl-N-[(4-methoxyphenyl)methyl]-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147192-72-1
CMF C32 H40 N4 O4 S



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 147661-93-6 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, N-[(4-methoxyphenyl)methyl]-4-(1-methylethyl)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147661-92-5
CMF C33 H42 N4 O4 S

RN 147661-97-0 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, N-[(4-methoxyphenyl)methyl]-4-phenyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147661-96-9
CMF C36 H40 N4 O4 S



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 147661-99-2 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, 7-chloro-N-[(4-methoxyphenyl)methyl]-4-methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147661-98-1
CMF C31 H37 Cl N4 O4 S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 147662-01-9 CAPLUS
CN 4H-1,2,4-Benzothiadiazin-3-amine, 6-chloro-N-[(4-methoxyphenyl)methyl]-4-methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147662-00-8
CMF C31 H37 Cl N4 O4 S.



CM 2

CRN 144-62-7
CMF C2 H2 O4



L18 ANSWER 80 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:244677 CAPLUS
DOCUMENT NUMBER: 118:244677
TITLE: Recording material using electron donor colorless dye and electron acceptor compound
INVENTOR(S): Araki, Katsumi; Takashima, Masanobu; Azuma, Shunsaku; Satomura, Masato
PATENT ASSIGNEE(S): Fuji Shashin Film K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04312587	A	19921104	JP 1991-76550	19910409
PRIORITY APPLN. INFO.:			JP 1991-76550	19910409
OTHER SOURCE(S):	MARPAT 118:170999			

GI



I

AB Fluorans I (Ar = 2-ethylphenoxy, 4-ethylphenoxy, 4-methoxyphenoxy, 2-fluorophenoxy; R = Pr, iso-Pr) and 2-anilino-6-[ethyl[2-(3-methylphenoxy)ethyl]amino]-3-methylfluoran (II) are useful as electron-donating leuco dyes for recording materials. Thus, a mixture of 2-[4-[ethyl[2-(3-methylphenoxy)ethyl]amino]-2-hydroxybenzoyl]benzoic acid and 4-methoxy-2-methyldiphenylamine in 97% H2SO4 was stirred for 24 h at room temperature to give II.
IT 146563-82-8P 146563-83-9P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of, as leuco dye for recording materials)
RN 146563-82-8 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[[3-(2-ethylphenoxy)propyl]propylamino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)



RN 146563-83-9 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[[3-(4-ethylphenoxy)propyl]propylamino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04082776	A	19920316	JP 1990-196974	19900725
PRIORITY APPLN. INFO.:			JP 1990-196974	19900725

AB The title recording material with good color-forming properties contains ≥2 fluoran compds., wherein ≥1 fluoran compound has aryloxy- or arylthio-substituted alkylamino at the 6th position. This recording material may be used for a pressure-sensitive paper, a heat-sensitive paper, a photo- and pressure-sensitive paper, an electrothermal-transfer paper, a thermal-transfer paper, etc.
IT 139332-53-9 139478-15-2
RL: USES (Uses)
(recording material containing)
RN 139332-53-9 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[ethyl[3-(4-ethylphenoxy)propyl]amino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)



RN 139478-15-2 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[ethyl[3-(2-ethylphenoxy)propyl]amino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)



L18 ANSWER 81 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:170999 CAPLUS
DOCUMENT NUMBER: 118:170999
TITLE: Fluorans
INVENTOR(S): Araki, Katsumi; Yanagihara, Naoto; Takashima, Masanobu; Satomura, Masato
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1



L18 ANSWER 82 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:30088 CAPLUS
DOCUMENT NUMBER: 118:30088
TITLE: Thermal recording paper
INVENTOR(S): Azuma, Shunsaku; Araki, Katsumi
PATENT ASSIGNEE(S): Fuji Shashin Film K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04086286	A	19920318	JP 1990-203213	19900731
PRIORITY APPLN. INFO.:			JP 1990-203213	19900731

AB In the title thermal recording medium employing an electron-donor leuco dye and an electron-acceptor compound, the above leuco dye is a fluoran derivative having at its 6-position an alkylamino group containing an aryloxy or arylthio group, and the heat-sensitive coloring layers is formed on a support having a smoothness specified by JIS-P-8119 of ≥ 500 s.
IT 139332-53-9 139478-15-2
RL: USES (Uses)
(leuco dye, thermal recording medium containing)
RN 139332-53-9 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[ethyl[3-(4-ethylphenoxy)propyl]amino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)



RN 139478-15-2 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[ethyl[3-(2-ethylphenoxy)propyl]amino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)



L18 ANSWER 83 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:30087 CAPLUS
DOCUMENT NUMBER: 118:30087
TITLE: Thermal recording paper
INVENTOR(S): Azuma, Shunsaku; Araki, Katsumi
PATENT ASSIGNEE(S): Fuji Shashin Film K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04086287	A	19920318	JP 1990-203214	19900731
PRIORITY APPLN. INFO.:			JP 1990-203214	19900731

AB In the title thermal recording medium employing an electron-donor leuco dye and an electron-acceptor compound, the leuco dye is a fluoran derivative having at its deposition on alkylamino group having an aryloxy or arylthio substituent, and a paraffin wax (m.p. 40-120°(in incorporated in the recording medium. The recording medium shows good solvent resistances.
IT 139332-53-9 139478-15-2
RL: USES (Uses)
(color-former, thermal recording sheet containing)
RN 139332-53-9 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[ethyl[3-(4-ethylphenoxy)propyl]amino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)



RN 139478-15-2 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[ethyl[3-(2-ethylphenoxy)propyl]amino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)

DOCUMENT NUMBER: 117:235156
TITLE: Light-resistant polymer compositions
INVENTOR(S): Allen, N. S.; Haque, E.; Yoshikawa, Kazumi; Yamanoi, Hiroshi
PATENT ASSIGNEE(S): Asahi Denka Kogyo K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04117461	A	19920417	JP 1990-237820	19900907
PRIORITY APPLN. INFO.:			JP 1990-237820	19900907

AB The title compns. contain 100 parts polymers and 0.001-5 parts 2-hydroxybenzophenones such as 2-hydroxy-4-(3-morpholinopropyl)benzophenone (I), and 2-hydroxy-4-(4-(2,2,6,6-tetramethyl-4-piperidinylamino)butoxy]benzophenone. Thus, a composition contained Profax 6501 100, stearyl (3,5-di-tert-butyl-4-hydroxyphenyl)propionate 0.15, Ca stearate 0.1, and I 0.25 parts.
IT 144556-99-0
RL: USES (Uses)
(light stabilizer, for polymers)
RN 144556-99-0 CAPLUS
CN Methanone, [[(2,2,6,6-tetramethyl-4-piperidinyl)imino]bis[3,1-propanediyloxy(2-hydroxy-4,1-phenylene)]]bis[phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



L18 ANSWER 86 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:436679 CAPLUS
DOCUMENT NUMBER: 117:36679
TITLE: Pressure- and heat-sensitive recording material
INVENTOR(S): Araki, Katsumi; Yanagihara, Naoto; Takashima, Masanobu; Azuma, Shunsaku; Satomura, Masato
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:



L18 ANSWER 84 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:30086 CAPLUS
DOCUMENT NUMBER: 118:30086
TITLE: Thermal recording paper
INVENTOR(S): Azuma, Shunsaku; Kawakami, Hiroshi; Araki, Katsumi
PATENT ASSIGNEE(S): Fuji Shashin Film K. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04086288	A	19920318	JP 1990-203216	19900731
PRIORITY APPLN. INFO.:			JP 1990-203216	19900731

AB In a thermal recording medium employing an electron-donor leuco dye and an electron-acceptor compound the leuco dye is a fluoran derivative with the 6-position substituted by an alkylamine group containing aryloxy or arylthio groups, and the recording medium contains ≥1 compds. selected from the hydrolysis product(s) of olefin-maleic acid anhydrides copolymer and(or), alkylnaphthalenesulfonic acid salt(s), and alkyl di-Ph ether disulfonic acid salt(s). The recording medium has good coloring characteristics and possess good solvent resistances.
IT 139478-15-2
RL: USES (Uses)
(leuco dye, thermal recording medium using)
RN 139478-15-2 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[ethyl[3-(2-ethylphenoxy)propyl]amino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)



L18 ANSWER 85 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:635156 CAPLUS

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03205180	A	19910906	JP 1990-71179	19900320
PRIORITY APPLN. INFO.:			JP 1989-276528 A1	19891024

AB In the title recording material utilizing an electron donor-type leuco dye and an electron acceptor compound, the leuco dye is a fluoran derivative with the 6 position substituted by a divalent amino group. The recording material shows good color rendition and produces stable color images.
IT 142234-22-8 142234-23-9 142234-24-0
RL: USES (Uses)
(pressure- and heat-sensitive recording materials containing)
RN 142234-22-8 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 3',3'''-[(1-methylethylidene)bis[4,1-phenyleneoxy-3,1-propanediyl(ethylimino)]]bis[6'-methyl-7'-(phenylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 142234-23-9 CAPLUS
CN Benzoic acid, 4-[3-[ethyl[6'-methyl-3-oxo-7'-(phenylamino)spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3'-yl]amino]propoxy]-, 1,2-ethanediyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 142234-24-0 CAPLUS
CN Benzoic acid, 4-[3-[ethyl[6'-methyl-3-oxo-7'-(phenylamino)spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3'-yl]amino]propoxy]-, 1,4-phenylenebis(methylene) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B





IT 140374-66-9
RL: USES (Uses)
(recording material using)
RN 140374-66-9 CAPLUS
CN Benzoic acid, 4-[3-[ethyl[6'-methyl-3-oxo-7'-(phenylamino)spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3'-yl]amino]propoxy]-, phenylmethyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 88 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:131169 CAPLUS
DOCUMENT NUMBER: 116:131169
TITLE: Fluoran compounds as leuco dyes for recording materials
INVENTOR(S): Araki, Katsumi; Satomura, Masato; Takashima, Masanobu; Yanagihara, Naoto
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 2 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03264587	A	19911125	JP 1990-63875	19900314
PRIORITY APPLN. INFO.:			JP 1990-63875	19900314

AB 2-Anilino-3-methyl-6-[ethyl[3-(2-ethylphenoxy)- and -(3,5-difluorophenoxy)propyl]amino]fluoran are prepared as leuco dyes. Thus, treating o-ethylphenol with 2-anilino-6-[(3-bromopropyl)ethylamino]-3-methylfluoran in sulfolane containing K2CO3 gave 2-anilino-6-[ethyl[3-(2-ethylphenoxy)propyl]amino]-3-methylfluoran, for which NMR and TLC data are given.
IT 139478-15-2P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of, as leuco dye for recording materials)

L18 ANSWER 87 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:184659 CAPLUS
DOCUMENT NUMBER: 116:184659
TITLE: Recording materials using fluoran derivative color former
INVENTOR(S): Araki, Katsumi; Yanagihara, Naoto; Takashima, Masanobu; Azuma, Shunsaku; Satomura, Masato
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03227289	A	19911008	JP 1990-22681	19900201
PRIORITY APPLN. INFO.:			JP 1990-22681	19900201

OTHER SOURCE(S): MARPAT 116:184659
GI



I

AB The title materials comprise fluoran derivs. containing alkylamino groups substituted for alkoxy-, aralkyloxy-, or aryloxy-carbonylaryloxy groups in their 6-positions as electron-donating colorless dyes, and electron-accepting compds. A pressure-sensitive copying set prepared from a color former sheet using I-containing microcapsules and a color developer sheet using Zn 3,5-bis(α-methylbenzyl)salicylate gave high d. images.
IT 140374-65-8P
RL: PREP (Preparation)
(preparation of, recording material using)
RN 140374-65-8 CAPLUS
CN Benzoic acid, 4-[3-[ethyl[6'-methyl-3-oxo-7'-(phenylamino)spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3'-yl]amino]propoxy]-, ethyl ester (9CI) (CA INDEX NAME)

RN 139478-15-2 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[ethyl[3-(2-ethylphenoxy)propyl]amino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)



L18 ANSWER 89 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:108315 CAPLUS
DOCUMENT NUMBER: 116:108315
TITLE: Fluoran compounds for electron-donor colorless dyes
INVENTOR(S): Araki, Katsumi; Yanagihara, Naoto; Takashima, Masanobu; Satomura, Masato
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03255086	A	19911113	JP 1990-178445	19900705
PRIORITY APPLN. INFO.:			JP 1990-15794	A1 19900125

OTHER SOURCE(S): MARPAT 116:108315
AB 2-Anilino-3-methyl-6-N-alkyl-N-[3-(aryloxy)propyl]aminofluorans, useful for electron-donor colorless dyes, are prepared Thus, 1.23 g p-EtC6H4OH was stirred with K2CO3 and sulfolane, then heated with 5.7 g 2-anilino-3-methyl-6-N-ethyl-N-(3-bromopropyl)aminofluoran at 80° under stirring to give 2-anilino-3-methyl-6-N-ethyl-N-[3-(4-ethylphenoxy)propyl]aminofluoran.
IT 139332-53-9P 139332-54-0P 139332-56-2P
139359-52-7P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of, as electron-donor colorless dye)
RN 139332-53-9 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[ethyl[3-(4-ethylphenoxy)propyl]amino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)



RN 139332-54-0 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[ethyl[3-(3-ethylphenoxy)propyl]amino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)



RN 139332-56-2 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[[3-(3,5-dimethylphenoxy)propyl]ethylamino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)



RN 139359-52-7 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[ethyl[3-(4-propylphenoxy)propyl]amino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)

L18 ANSWER 91 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:451863 CAPLUS
DOCUMENT NUMBER: 115:51863
TITLE: Manufacture of fluoran leuco dyes
INVENTOR(S): Yanagihara, Naoto; Iwakura, Ken; Satomura, Masato; Yamada, Hisao
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03014583	A	19910123	JP 1989-148690	19890612

PRIORITY APPLN. INFO.: JP 1989-148690 19890612

AB Fluoran leuco dyes, useful for pressure-sensitive copying papers and thermal papers, are manufactured by treating halo-containing fluorans with phenols.
Thus, 2-anilino-3-methyl-6-[N-ethyl-N-(3-bromopropyl)amino]fluoran and 4-MeSC6H4OH were stirred in AcNMe2 in presence of K2CO3 to give 2-anilino-3-methyl-6-[N-ethyl-N-[3-(4-methylthiophenoxy)propyl]amino]fluoran, black on silica gel.

IT 134992-61-3P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of, leuco dye, for pressure-sensitive copying and thermal printing)

RN 134992-61-3 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[ethyl[3-(3-methylphenoxy)propyl]amino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)



L18 ANSWER 92 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:104531 CAPLUS
DOCUMENT NUMBER: 114:104531
TITLE: Jet-printing with inks containing aniline azo magenta dyes
INVENTOR(S): Tanaka, Mitsugi; Sakai, Takeo
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE



L18 ANSWER 90 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:644169 CAPLUS
DOCUMENT NUMBER: 115:244169
TITLE: Recording material using fluoran derivative as color former
INVENTOR(S): Araki, Katsumi; Yanagihara, Naoto; Takashima, Masanobu; Azuma, Shunsaku; Satomura, Masato; Iwakura, Ken; Yamada, Hisao
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03087287	A	19910412	JP 1990-103376	19900419

PRIORITY APPLN. INFO.: JP 1989-147656 A1 19890609

AB Title material contains a fluoran derivative having an aryloxy- or arylthio-substituted alkylamino group at position 6 as an electron-donating colorless dye precursor, and an electron-accepting compound The recording material provides high d. images with good storage stability. Thus, a pressure-sensitive copying set was prepared by using a color-former sheet containing microencapsulated 2-anilino-3-methyl-6-N-ethyl-N-(4-methylthiophenoxypropyl)aminofluoran, and a color-developer sheet containing Zn 3,5-bis-(α-methylbenzyl)salicylate.

IT 134992-61-3
RL: USES (Uses)
(color-former, recording material using)

RN 134992-61-3 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 6'-[ethyl[3-(3-methylphenoxy)propyl]amino]-3'-methyl-2'-(phenylamino)- (9CI) (CA INDEX NAME)



JP 02212566	A	19900823	JP 1989-31599	19890210

PRIORITY APPLN. INFO.: JP 1989-31599 19890210
OTHER SOURCE(S): MARPAT 114:104531
GI For diagram(s), see printed CA Issue.

AB Images with good color and light resistance are formed by jet-printing with inks containing title dyes I [R1 = heterocyclic group; R2 = halo, alkyl, alkoxy, aryl, aryloxy, CN, amido, sulfonamido, alkoxycarbonylamino, ureido, alkylthio, arylthio, alkoxycarbonyl, carbamoyl, sulfamoyl, sulfonyl, acyl, NH2, OH, R3,R4 = H, alkyl, aryl, or cyclic groups; n = 0-3]. Thus, paper coated with SBR, styrene-acrylic hollow particles, PHMA particles, and poly(vinyl acetate) was jet-printed with an ink containing I [R' = 3-methyl-4-cyanoisothiazolyl, R2 = NHCOCH3, R3 = 4-[2,4-bis(tert-pentyl)phenoxy]butyl, R4 = Et] to give images with good water resistance (10 min in H2O) and light resistance (3 mo).

IT 132122-65-7
RL: USES (Uses)
(magenta dyes, light-resistant, for jet-printing inks)

RN 132122-65-7 CAPLUS
CN Acetamide, N-[2-[(4-cyano-3-methyl-5-isothiazolyl)azo]-5-[ethyl[3-[4-(2,2,4,4-tetramethylpentyl)phenoxy]propyl]amino]phenyl]- (9CI) (CA INDEX NAME)





L18 ANSWER 93 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:81619 CAPLUS
DOCUMENT NUMBER: 114:81619
TITLE: Preparation of carbostyril derivatives as vasopressin antagonists
INVENTOR(S): Ogawa, Hidenori; Miyamoto, Hisashi; Kondo, Kazumi; Yamashita, Hiroshi; Nakaya, Kenji; Tominaga, Michiaki; Yabuuchi, Yoichi
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 364 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 382185	A2	19900816	EP 1990-102404	19900207
EP 382185	A3	19910918		
EP 382185	B1	19940615		
R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
ES 2056259	T3	19941001	ES 1990-102404	19900207
JP 03173870	A	19910729	JP 1990-31360	19900208
JP 07068218	B	19950726		
CN 1046529	A	19901031	CN 1990-100657	19900210
CN 1036394	B	19971112		
KR 9711153	B1	19970707	KR 1990-1705	19900210
US 5225402	A	19930706	US 1991-762736	19910918
US 5436254	A	19950725	US 1993-125667	19931102
US 5652247	A	19970729	US 1994-359081	19941214
PRIORITY APPLN. INFO.:			JP 1989-31580 A	19890210
			JP 1989-102699 A	19890421
			JP 1989-181440 A	19890713
			JP 1989-232333 A	19890907
			US 1990-478181 B1	19900209
			US 1991-762736 A3	19910918
			US 1992-846941 A1	19920306

OTHER SOURCE(S): MARPAT 114:81619
GI



AB The title compds. I [R1 = H, NO2, alkoxy, alkoxycarbonyl, alkyl, etc.; t = 1-3; R = Q, (substituted) Ph, etc.; R2 = H, alkoxycarbonyl, (substituted) phenoxycarbonyl, etc.; n = 1,2; m = 0-3; R3 = alkyl; dotted line indicates single or double bond] were prepared I are useful as vasodilators and antihypertensives. A mixture of N-(1-benzoyl-4-piperidinyl)-2-(2-carbamolyethyl)aniline and 5% HCl was refluxed for 5 h to give dihydrocarbostyril II. In an in vitro test using rat liver plasma membrane prepns. and H3-vasopressin, the compound 1-[1-(4-methylaminobenzoyl)-4-piperidinyl]-3,4-dihydrostyril showed IC50 of 0.4 μM. Formulations containing I were given.
IT 131631-90-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as vasopressin antagonist)
RN 131631-90-8 CAPLUS
CN Piperidine, 4-(3,4-dihydro-2-oxo-1(2H)-quinolinyl)-1-[4-[3-[(phenylmethyl)propylamino]propoxy]benzoyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 94 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:42272 CAPLUS
DOCUMENT NUMBER: 114:42272
TITLE: Preparation of (aminoalkoxy)benzenes and pharmaceuticals containing them for treatment of dysuria
INVENTOR(S): Kimura, Kiyoshi; Shimomura, Suetaka; Kise, Masahiro; Murase, Masao; Shirochi, Yoshiaki
PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02202857	A	19900810	JP 1989-23460	19890131
JP 08016086	B	19960221		
PRIORITY APPLN. INFO.:			JP 1989-23460	19890131

OTHER SOURCE(S): CASREACT 114:42272; MARPAT 114:42272
GI



AB Dysuria-controlling pharmaceuticals, which do not show hypotensive effect, contain title compds. I [R1 = H, OH, MeO, Ac, AcO, isopropoxycarboxy, (2-imidazolin-2-yl)methoxy, guanidino, thioureido, AcNH, halo; Z = Q, Q1; R2 = alkyl, cycloalkyl, aryl, aromatic heterocyclyl; R3 = H, alkyl, alkoxy, halo; m = 0-2; n = 2, 3] or their pharmacol. acceptable salts as active ingredients. Treatment of 100 g 2-acetyl-5-(2-bromoethoxy)-p-cymene (preparation given) with CF3CO2H and m-chloroperbenzoic acid in MePh at <15° for 16 h gave 89 g 2-acetoxy-5-(2-bromoethoxy)-p-cymene. Refluxing 40 g the acetoxy derivative with 17 g N-ethylbenzylamine and Et3N in EtOH for 20 h afforded 23 g I (R1 = AcO, Z = N-benzyl-N-ethylamino, n = 2), which was converted into I.maleate (II). II inhibited specific binding of prazosin or yohimbine to α-adrenergic receptor with IC50 of 5.4 + 10-8 and 6.7 + 10-7 M, resp.
IT 130994-46-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treatment of dysuria)
RN 130994-46-6 CAPLUS
CN Ethanone, 1-[4-[3-[ethyl(phenylmethyl)amino]propoxy]-2-methyl-5-(1-methylethyl)phenyl]-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 130994-45-5
CMF C24 H33 N O2



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



L18 ANSWER 95 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:55245 CAPLUS
DOCUMENT NUMBER: 112:55245
TITLE: Preparation of [(aminoalkoxy)phenyl]benzoates and analogs as hypolipemics
INVENTOR(S): Fujii, Setsuro; Kawamura, Hiroyuki; Watanabe, Shinichi
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8903819	A1	19890505	WO 1988-JP1065	19881020
W: DK, KR, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
JP 02056452	A	19900226	JP 1988-265829	19881020
JP 06067882	B	19940831		
EP 394440	A1	19901031	EP 1988-909127	19881020
EP 394440	B1	19940511		
R: CH, DE, FR, GB, IT, LI, NL, SE				
DK 8903043	A	19890620	DK 1989-3043	19890620
US 4999378	A	19910312	US 1989-372336	19890620
KR 9706890	B1	19970430	KR 1989-71126	19890620
PRIORITY APPLN. INFO.:			JP 1987-264744 A	19871020
			JP 1988-45339 A	19880226
			WO 1988-JP1065 W	19881020

OTHER SOURCE(S): CASREACT 112:55245; MARPAT 112:55245
GI



AB Title compds. I [R1, R2 = H, halo, alkyl, haloalkyl, alkanoyl, cycloalkyl, NO2, NH2, (halo- or alkyl-substituted)PhO, etc.; R3 = H, R5E (R5 = H, CO2H, cyano, etc. E = alkylene), R6GCO (R6 = H, CO2H, halo-substituted phenylcarbamoyl; G = alkylene), etc.; R4 = H, alkyl; A = alkylene, cycloalkylene, alkenylene; Z = alkylene, alkenylene; l = 0, 1] are prepared A mixture of p-ClC6H4NH2, 4-[Cl(CH2)3O]C6H4CO2Me (preparation given), and NaHCO3 in DMF was heated at 100° to give I.HCl [R1 = p-Cl; R2 = R3 = H; A = (CH2)3; l = 0; R4 = Me] which was converted to the corresponding acid (II). II showed IC50 of 3.88 μM and 2.40 μM against syntheses of sterol and fatty acid. An injection was formulated containing 200 mg I.HCl [R1 = 4-F; R2 = R3 = H; A = (CH2)3; l = 0; R4 = Me], 250 mg glucose, and H2O 5 mL q.s.
IT 124062-88-0P 124063-28-1P 124063-29-2P

124063-31-6P 124063-32-7P 124063-35-0P
124063-73-6P 124063-74-7P 124063-75-8P
124063-76-9P 124063-77-0P 124063-78-1P
124063-79-2P 124063-80-5P 124063-81-6P
124063-86-1P 124063-87-2P 124063-88-3P
124063-89-4P 124063-90-7P 124063-93-0P
124063-94-1P 124063-95-2P 124063-96-3P
124092-81-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as hypolipemic)

RN 124062-88-0 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)(1-methylethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 124063-28-1 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)ethylamino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 124063-29-2 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)ethylamino]propoxy]- (9CI) (CA INDEX NAME)



RN 124063-31-6 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)(1-methylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 124063-32-7 CAPLUS

methyl ester (9CI) (CA INDEX NAME)



RN 124063-76-9 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)-2-propenylamino]propoxy]- (9CI) (CA INDEX NAME)



RN 124063-77-0 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)(2-methyl-2-propenyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 124063-78-1 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)[(4-chlorophenyl)methyl]amino]propoxy]-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)

CN Benzoic acid, 4-[3-[(4-chlorophenyl)(2-ethoxy-2-oxoethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 124063-35-0 CAPLUS
CN Benzoic acid, 4-[3-[(3-carboxy-1-oxopropyl)(4-chlorophenyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 124063-73-6 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)(2-methylpropyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 124063-74-7 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)-2-propenylamino]propoxy]-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 124063-75-8 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)(2-methyl-2-propenyl)amino]propoxy]-,



● HCl

RN 124063-79-2 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)[(4-chlorophenyl)methyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 124063-80-5 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)(cyanomethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 124063-81-6 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)(cyanomethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 124063-86-1 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)[2-(phenylmethoxy)ethyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 124063-87-2 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)[2-(phenylmethoxy)ethyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 124063-88-3 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)(2-hydroxyethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 124063-89-4 CAPLUS
CN Benzoic acid, 4-[3-[(2-carboxyethyl)(4-chlorophenyl)amino]propoxy]-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 124063-90-7 CAPLUS
CN Benzoic acid, 4-[3-[(2-carboxyethyl)(4-chlorophenyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 124063-93-0 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)[4-[(4-chlorophenyl)amino]-1,4-dioxobutyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 124063-94-1 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)[4-[(4-chlorophenyl)amino]-1,4-dioxobutyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 124063-95-2 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)[3-[(4-chlorophenyl)amino]-3-oxopropyl]amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 124063-96-3 CAPLUS
CN Benzoic acid, 4-[3-[(4-chlorophenyl)[3-[(4-chlorophenyl)amino]-3-oxopropyl]amino]propoxy]- (9CI) (CA INDEX NAME)



RN 124092-81-5 CAPLUS
CN Benzoic acid, 4-[3-[(3-carboxy-1-oxopropyl)(4-chlorophenyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 96 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1988:204623 CAPLUS
DOCUMENT NUMBER: 108:204623
TITLE: Preparation of (aryloxyalkyl)carbamolylazoles as agrochemical fungicides
INVENTOR(S): Rentzea, Costin; Sauter, Hubert; Ammermann, Eberhard; Pommer, Ernst Heinrich
PATENT ASSIGNEE(S): BASF A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 11 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 3614608	A1	19871105	DE 1986-3614608		19860430
EP 243842	A1	19871104	EP 1987-105795		19870418
EP 243842	B1	19910130			
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE					
AT 60588	T	19910215	AT 1987-105795		19870418
PRIORITY APPLN. INFO.:			DE 1986-3614608	A	19860430
			EP 1987-105795	A	19870418

OTHER SOURCE(S): CASREACT 108:204623
GI



I

AB The title compds. (I; R1 = F-, Cl-, or Br-substituted alkyl; R2, R3 = H, alkyl; R4 = halo-, CF3- alkyl-, alkoxy, NO2-, or cyano-substituted Ph; A = C1-10 hydrocarbyl; Y = CH, N) were prepared as agrochem. fungicides. 4-Phenoxybutyl bromide was stirred 16 h in pyrrolidine at 25° and the resulting N-(4-phenoxybutyl)pyrrolidine was added together with COCl2 to EtOAc at 10° to give N-chlorocarbonyl-N-4-(chlorobutyl)-N-(4-phenoxybutyl)amine. The latter was added to imidazole in THF at 25° and the mixture was stirred at 70° for 6 h to give I (R1 = Cl(CH2)4, R2 = R3 = H, R4 = Ph, A = (CH2)4, Y = CH) (II). A spray was prepared containing 90 weight % II and 10 weight % N-methylpyrrolidone. II as a 0.0025% spray gave 97% control of wheat mildew on wheat.
IT 112879-61-5P 112879-62-6P 112879-93-3P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as agrochem. fungicide)
RN 112879-61-5 CAPLUS
CN 1H-1,2,4-Triazole-1-carboxamide, N-(4-chlorobutyl)-N-[3-(2,4,6-trimethylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 112879-62-6 CAPLUS
CN 1H-Imidazole-1-carboxamide, N-(4-chlorobutyl)-N-[3-(2,4,6-trimethylphenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 112879-93-3 CAPLUS
CN 1H-Imidazole-1-carboxamide, N-(4-chlorobutyl)-N-[3-(2-methylphenoxy)propyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 97 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1987:590365 CAPLUS
DOCUMENT NUMBER: 107:190365
TITLE: Structural modification of H2-receptor antagonists provide post-H2-receptor gastric antisecretory activity
AUTHOR(S): Nielsen, S. T.; Dove, P. A.; Strike, D. P.; Schiehser, G. A.
CORPORATE SOURCE: Wyeth Lab., Inc., Philadelphia, PA, 19101, USA
SOURCE: Drugs under Experimental and Clinical Research (1987), 13(5), 297-304
CODEN: DECRDP; ISSN: 0378-6501
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



RN 111128-26-8 CAPLUS
CN 1,2-Benzisothiazol-3-amine, N-(3-furanylmethyl)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



IT 104221-86-5
RL: BIOL (Biological study)
(gastric antisecretory and antihistaminic activity of, structure in relation to)
RN 104221-86-5 CAPLUS
CN Thieno[3,4-d]isothiazol-3-amine, N-(phenylmethyl)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



L18 ANSWER 98 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1986:533763 CAPLUS
DOCUMENT NUMBER: 105:133763
TITLE: N-Alkylated benzo- and hetero-fused aminopropoxybenzylpiperidine antisecretory agents
INVENTOR(S): Schiehser, Guy A.; Nielsen, Susan T.; Strike, Donald P.
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4595757	A	19860617	US 1984-681169	19841213
PRIORITY APPLN. INFO.:			US 1984-681169	19841213
OTHER SOURCE(S):	CASREACT 105:133763; MARPAT 105:133763			



I

AB Structural analogs of Wy 45,662 were found to inhibit acid secretion in the pylorus ligated rat and to block forskolin and DBcAMP-stimulated [14C]aminopyrine (AP) uptake by rat isolated gastric mucosal cell prepns. Wy 45,662 (N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]thieno[3,4-d]isothiazol-3-amine 1,1-dioxide), a very potent histamine H2-antagonist and antisecretory agent in the rat (ED50 = 0.3 mg-kg), had no effect in vitro at 1 μM on forskolin-induced [14C]AP uptake while 10 nM Wy-45,662 completely suppressed histamine-stimulated [14C]AP uptake. In contrast, the N-benzylated form of Wy 45,662, Wy 46,499 (I), dose-dependently (1 + 10-7 - 3 + 10-6M) suppressed forskolin-stimulated [14C]AP uptake while retaining modest antisecretory activity (ED50 = 8 mg/kg) in vivo. Wy 46,499's modest antisecretory activity was thus attributable to inhibition via a post-histamine H2-receptor mechanism.
IT 104221-88-7 104221-89-8 104221-91-2
111128-26-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(gastric antisecretory activity of, structure in relation to)
RN 104221-88-7 CAPLUS
CN 1,2-Benzisothiazol-3-amine, N-(phenylmethyl)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 104221-89-8 CAPLUS
CN Thieno[3,4-d]isothiazol-3-amine, N-(1,3-benzodioxol-5-ylmethyl)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 104221-91-2 CAPLUS
CN 3-Cyclobutene-1,2-dione, 3-amino-4-[(1,3-benzodioxol-5-ylmethyl)[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)

GI For diagram(s), see printed CA Issue.
AB The title compds. (I; R1 = Q, Q1; R2 = Ph, 1,3-benzodioxol-5-yl; X = SO2, SO, S, CO; Z = atoms needed to complete substituted benzo- or thieno-fused ring) were prepared as antiulcer agents. Thus, 3-[3-(1-piperidinylmethyl)phenoxy]propylamine was iminated with PhCHO and hydrogenated to give I (R1 = H, R2 = Ph). This was condensed with 3-(methylthio)thieno[3,4-d]isothiazole 1,1-dioxide to give I (R1 = Q2, R2 = Ph) (II). In rats, II inhibited gastric secretion and ulcerogenesis with ED50 of 8 and 6 mg/kg, resp., compared to 6 and 12 mg/kg for omeprazole.
IT 104221-86-5P 104221-87-6P 104221-88-7P
104221-89-8P 104221-90-1P 104221-91-2P
104221-92-3P 104249-16-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as ulcer inhibitor)
RN 104221-86-5 CAPLUS
CN Thieno[3,4-d]isothiazol-3-amine, N-(phenylmethyl)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 104221-87-6 CAPLUS
CN Thieno[3,4-d]isothiazol-3-amine, N-(phenylmethyl)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 104221-86-5
CMF C27 H31 N3 O3 S2



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 104221-88-7 CAPLUS
CN 1,2-Benzisothiazol-3-amine, N-(phenylmethyl)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 104221-89-8 CAPLUS
CN Thieno[3,4-d]isothiazol-3-amine, N-(1,3-benzodioxol-5-ylmethyl)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 104221-90-1 CAPLUS
CN Thieno[3,4-d]isothiazol-3-amine, N-(1,3-benzodioxol-5-ylmethyl)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 104221-89-8
CMF C28 H31 N3 O5 S2



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 104221-91-2 CAPLUS
CN 3-Cyclobutene-1,2-dione, 3-amino-4-[(1,3-benzodioxol-5-ylmethyl)[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)

CM 2

CRN 144-62-7
CMF C2 H2 O4

L18 ANSWER 99 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1984:630158 CAPLUS
DOCUMENT NUMBER: 101:230158
TITLE: N-Alkylated amino alcohols and their pharmaceutical compositions useful for the treatment of cardiac insufficiency
INVENTOR(S): Ostermayer, Franz; Zimmermann, Markus
PATENT ASSIGNEE(S): Ciba-Geigy Corp., USA
SOURCE: U.S., 18 pp. Cont.-in-part of U.S. Ser. No. 316,263, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4460580	A	19840717	US 1982-391814	19820624
PRIORITY APPLN. INFO.:			CH 1978-6136	A 19780605
			US 1979-41570	A2 19790523
			US 1979-95688	A2 19791119
			US 1981-316263	A2 19811029

GI



AB About 30 title compds. I [R = unsubstituted or hydroxy substituted Ph and pyridyl; X = C2-5 alkylene; n = 0, 1], useful as cardioselective β-stimulators (no data) were prepared. Thus 2,5-(HO)2C6H3CONH2 underwent cyclocondensation with Me2CO to give benzoxazinone II (R1 = H), which was alkylated with ClCH2COMe to give II (R1 = CH2COMe). The last reacted with H2NCH2CHPhOH and H to give II [R1 = CH2CMe(OH)NHCH2CHPhOH], which gave diastereomeric 3,4-(H2NCO)(HO)C6H3OCH2CHMeNHCH2CHPhOH on hydrolysis.
IT 92990-35-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)
RN 92990-35-7 CAPLUS
CN Benzamide, 2-hydroxy-4-[3-[(2-hydroxy-2-phenylethyl)(phenylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



RN 104221-92-3 CAPLUS
CN 3-Cyclobutene-1,2-dione, 3-amino-4-[(1,3-benzodioxol-5-ylmethyl)[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 104221-91-2
CMF C27 H31 N3 O5



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 104249-16-3 CAPLUS
CN 1,2-Benzisothiazol-3-amine, N-(phenylmethyl)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, 1,1-dioxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 104221-88-7
CMF C29 H33 N3 O3 S





L18 ANSWER 100 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1981:121135 CAPLUS
DOCUMENT NUMBER: 94:121135
TITLE: 3-Amino-1,2-propane diol derivatives and pharmaceutical compositions containing them
INVENTOR(S): Ostermayer, Franz; Zimmermann, Markus
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 92 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 15505	A1	19800917	EP 1980-100991	19800228
EP 15505	B1	19840808		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
DD 150456	A5	19810902	DD 1980-219248	19800225
FI 8000582	A	19800902	FI 1980-582	19800227
ES 489031	A1	19810216	ES 1980-489031	19800228
CA 1134843	A1	19821102	CA 1980-346595	19800228
IL 59487	A	19830515	IL 1980-59487	19800228
AT 8876	T	19840815	AT 1980-100991	19800228
DK 8000878	A	19800902	DK 1980-878	19800229
DK 153940	B	19880926		
DK 153940	C	19890522		
NO 8000586	A	19800902	NO 1980-586	19800229
NO 151743	B	19850218		
NO 151743	C	19850529		
AU 8056022	A	19800904	AU 1980-56022	19800229
AU 540060	B2	19841101		
ZA 8001165	A	19810225	ZA 1980-1165	19800229
HU 24122	A2	19821228	HU 1980-476	19800229
HU 181697	B	19831128		
JP 55167263	A	19801226	JP 1980-24668	19800301
ES 495882	A1	19810916	ES 1980-495882	19801013
ES 495879	A1	19811001	ES 1980-495879	19801013
ES 495880	A1	19820801	ES 1980-495880	19801013
ES 495881	A1	19830201	ES 1980-495881	19801013
PRIORITY APPLN. INFO.:			CH 1979-2037	A 19790301
			EP 1980-100991	A 19800228

GI



I



II



III

AB Propanediols I [R = (un)substituted aryl; R1, R2 = H, alkyl; R1R2 = alkylene, oxaalkylene, thiaalkylene, azaalkylene, N-alkylazaalkylene; Z = C2-5 alkylene, n = 0, 1], useful in treating angina pectoris, arrhythmia, and hypertension (no data), were prepared Thus, aminopropanol II was prepared in 6 steps from 2,5-(HO)2C6H3CONH2 and Me2CO via benzoxazinone III and 5,2-(MeCOCH2O)(HO)C6H3CONH2 which underwent reductive amination with PhCH2NH2 and ring cleavage reaction with 1-(2,3-epoxypropoxy)-4-(2-methoxyethoxy)benzene to give the N-benzyl derivative of II.

IT 76823-33-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debenzylation of)

RN 76823-33-1 CAPLUS

CN Benzamide, 2-hydroxy-5-[3-[[2-hydroxy-3-[4-(2-methoxyethoxy)phenoxy]propyl](phenylmethyl)amino]propoxy]- (9CI) (CA INDEX NAME)



L18 ANSWER 101 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1980:620465 CAPLUS
DOCUMENT NUMBER: 93:220465
TITLE: N-Alkylated aminoalcohols and their salts
INVENTOR(S): Ostermayer, Franz; Zimmermann, Markus
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: Eur. Pat. Appl., 63 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 5848	A1	19791212	EP 1979-101724	19790601
EP 5848	B1	19811230		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
FI 7901727	A	19791206	FI 1979-1727	19790530
DD 144050	A5	19800924	DD 1979-213267	19790530
DK 7902298	A	19791206	DK 1979-2298	19790601
NO 7901841	A	19791206	NO 1979-1841	19790601
NO 149034	B	19831024		
NO 149034	C	19840201		
AT 511	T	19820115	AT 1979-101724	19790601
CA 1124241	A1	19820525	CA 1979-328929	19790601
AU 7947736	A	19791213	AU 1979-47736	19790604
AU 522483	B2	19820610		
GB 2026474	A	19800206	GB 1979-19470	19790604
GB 2026474	B	19820714		
ES 481238	A1	19800216	ES 1979-481238	19790604
ZA 7902748	A	19800625	ZA 1979-2748	19790604
PL 116529	B1	19810630	PL 1979-216090	19790604
PL 116612	B1	19810630	PL 1979-222399	19790604
PL 116597	B1	19810630	PL 1979-222400	19790604
PL 117155	B1	19810731	PL 1979-222397	19790604
PL 117158	B1	19810731	PL 1979-222398	19790604
IL 57471	A	19821130	IL 1979-57471	19790604
HU 24847	A2	19830428	HU 1979-CI1940	19790604
HU 182019	B	19831228		
JP 54163543	A	19791226	JP 1979-69524	19790605
PRIORITY APPLN. INFO.:			CH 1978-6136	19780605
			EP 1979-101724 A	19790601

OTHER SOURCE(S): MARPAT 93:220465
GI



I

II



III

AB A wide range of I (Ar = unsubstituted or hydroxy-substituted phenyl, heterocyclic, Q = C2-5-alkylene, n = 0,1) was prepared as β-sympathomimetics. Thus, 2,5-(HO)2C6H3CONH2 was treated with Me2CO to give II, which was etherified with MeCOCH2Cl, subjected to reductive amination with PhCH(CH2NH2)OH, and solvolyzed with Me2CHNH2-Me2CHOH to give I (Ar = Ph, Q = CHMeCH2, n = 1, 5-position of benzamide ring). Other I prepared included, e.g., III fumarate.

IT 92990-35-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debenzylation of)

RN 92990-35-7 CAPLUS

CN Benzamide, 2-hydroxy-4-[3-[(2-hydroxy-2-phenylethyl)(phenylmethyl)amino]pr

opoxy]- (9CI) (CA INDEX NAME)



L18 ANSWER 102 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1980:198403 CAPLUS
DOCUMENT NUMBER: 92:198403
TITLE: Di-N-substituted carbamoyltriazoles
INVENTOR(S): Birchmore, Richard John; Brookes, Robert Frederick; Copping, Leonard George; Wells, Wilfred Hase
PATENT ASSIGNEE(S): Boots Co. Ltd., UK
SOURCE: Brit. UK Pat. Appl., 7 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2011414	A	19790711	GB 1979-2279	19790122
GB 2011414	B	19830223		
PRIORITY APPLN. INFO.:			GB 1977-48531 A	19771122

GI

I

AB Triazoles I (R = optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, Ph, phenylalkyl, phenylalkenyl, phenoxyalkyl, phenylthioalkyl; R1 = optionally substituted Ph, phenylalkyl, phenylalkenyl, phenoxyalkyl, phenylthioalkyl), useful as fungicides, were prepared Thus, I (R = Pr, R1 = 2,4,6-Cl3C6H2O(CH2)2] was prepared from 2,4,6-Cl3C6H2O(CH2)2NHPr by sequential treatment with COCl2 (refluxing EtOAc, 1.5 h) and 1,2,4-triazole Na salt in THF (reflux, 16 h, anhydrous conditions). The fungicidal activities of I against mildew on oats were assessed; 2000 ppm of each test compound gave >50% control of Erysiphe graminis infections.

IT 73616-04-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as fungicide)

RN 73616-04-3 CAPLUS

CN 1H-1,2,4-Triazole-1-carboxamide, N-butyl-N-[3-(2,4-dichloro-6-methylphenoxy)propyl]- (9CI) (CA INDEX NAME)



L18 ANSWER 103 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1978:529403 CAPLUS
DOCUMENT NUMBER: 89:129403
TITLE: Chromone derivatives
PATENT ASSIGNEE(S): THEA (Therapeutique et Applications) S. A., Fr.
SOURCE: Ger. Offen., 24 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2800015	A1	19780713	DE 1978-2800015	19780102
FR 2376145	A1	19780728	FR 1977-10	19770103
FR 2376145	B1	19800328		
JP 53084976	A	19780726	JP 1977-157571	19771228
JP 61021234	B	19860526		
US 4220645	A	19800902	US 1977-865573	19771229
BE 862569	A1	19780630	BE 1977-184052	19771230
GB 1569529	A	19810903	GB 1977-54223	19771230
DK 7800008	A	19780704	DK 1978-8	19780102
SE 7800033	A	19780704	SE 1978-33	19780102
SE 438857	B	19850513		
SE 438857	C	19850822		
NL 7800001	A	19780705	NL 1978-1	19780102
ES 466168	A1	19790701	ES 1978-466168	19780102
ZA 7800002	A	19781025	ZA 1978-2	19780103
AU 7832117	A	19790712	AU 1978-32117	19780103
AU 518897	B2	19811029		
CA 1129875	A1	19820817	CA 1978-294226	19780103
CH 631713	A5	19820831	CH 1978-13	19780103
PRIORITY APPLN. INFO.:			FR 1977-10 A	19770103

OTHER SOURCE(S): MARPAT 89:129403
GI

STOPPED HERE...

(02(b) ⟹

(CHIBRET etal)



I



II

AB The benzoylchromones I (R = R1 = R2 = H, lower alkyl; R3 = R4 = H, alkyl, cycloalkyl, hydroxyalkyl; NR3R4 = heterocycle; n = 1-5) were prepared for treatment heart diseases. Thus, acylating 2,6-Me2C6H4OH with 2-(chlorocarbonyl)chromone and AlCl3, and then treating with Bu2N(CH2)3Cl gave 80% II, which showed antiarrhythmic, sympathicoinhibiting, and bradykinin activity in dogs.

IT 67652-42-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 67652-42-0 CAPLUS

CN 4H-1-Benzopyran-4-one, 2-[4-[3-[cyclohexyl(1-methylethyl)amino]propoxy]-3,5-dimethylbenzoyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L18 ANSWER 104 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1960:34666 CAPLUS
DOCUMENT NUMBER: 54:34666
ORIGINAL REFERENCE NO.: 54:6863h-i
TITLE: Relations between the antibacterial activity and molecular structure in a series of quaternary ammonia derivatives
AUTHOR(S): Tommasini, R.
CORPORATE SOURCE: Univ. Milan
SOURCE: Giorn. ital. chemioterap (1958), 5, 151-9
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB A series of mono(alkylammonium) derivs. of 1-(p-hydroxyphenyl)-2-phenylethane [p-(PhCH2CH2)C6H4OXNRR'R''Y-, where X = (CH2)2, (CH2)3, or CHMe- CH2, R, R', R'' is alkyl or N, R, and R' form a heterocyclic group, and Y is halogen] are studied for the relation between structure and bactericidal activity against Escherichia coli and Staphylococcus aureus as well as against Candida albicans and Aspergillus niger. The activity of the derivs. is influenced by the nature and mol. weight of the quaternary N derivs

IT 120970-90-3, Ammonium, benzyldiethyl[3-(p-phenethylphenoxy)propyl]-, bromides
(bactericidal action of)

RN 120970-90-3 CAPLUS

CN Benzyldiethyl[3-(p-phenethylphenoxy)propyl]ammonium bromide (6CI) (CA INDEX NAME)



● Br⁻

L18 ANSWER 105 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1960:34665 CAPLUS
DOCUMENT NUMBER: 54:34665
ORIGINAL REFERENCE NO.: 54:6863g-h
TITLE: Interaction of phenolic compounds with bacteria. III. Evaluation of the antibacterial activity of hexylresorcinol against Escherichia coli
AUTHOR(S): Beckett, A. H.; Patki, S. J.; Robinson, Ann E.
SOURCE: Journal of Pharmacy and Pharmacology (1959), 11, 421-6
CODEN: JPPMAB; ISSN: 0022-3573
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB cf. C.A. 53, 18159e. The antibacterial activity of hexylresorcinol solns. with and without cetomacrogol and NaCl was determined by using E. coli. The extent of drug binding, light-scattering change, and release of cell exudate as related to bactericidal activity was studied

IT 120970-90-3, Ammonium, benzyldiethyl[3-(p-phenethylphenoxy)propyl]-, bromides
(bactericidal action of)

RN 120970-90-3 CAPLUS

CN Benzyldiethyl[3-(p-phenethylphenoxy)propyl]ammonium bromide (6CI) (CA INDEX NAME)



● Br⁻

L18 ANSWER 106 OF 106 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1955:64705 CAPLUS
DOCUMENT NUMBER: 49:64705
ORIGINAL REFERENCE NO.: 49:12400a-c
TITLE: Biphenyl, stilbene and diphenylethane derivatives. IV. New ganglioplegic synthetics
AUTHOR(S): Cavallini, G.; Massarani, E.
CORPORATE SOURCE: Lab. Maggioni, Milan
SOURCE: Farmaco, Edizione Scientifica (1954), 9, 416-37
CODEN: FRPSAX; ISSN: 0430-0920
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB Refluxing I with 2 moles of the appropriate alkyl halides gives the following I.MeI (IA), I.EtI (IB), and I.PhCH2Br (IC) [R, followed by the serial number (in parentheses) and the m.p. and % yield of IA, IB, and IC, resp., given]. Me2NCH2CH2: (1) 283-5°, 98, soluble in hot MeOH, insol. in H2O, EtOH, Et2O, Me2CO, C6H6, and CHCl3; (2) 249-51°. 96; (3) 187-8°, 76°. Me2N(CH2)3: (4) 244-6°, 70; (5) 214-16°, 68; (6) 172-5°, 49. Et2N(CH2)3: (7) 211-12, 77; (8) 195-6°, 81; (9) 154-5°, 87. Me2NCH2CHMe: (10), 249-50°, 92; (11), 206-8°, 87; (12) 179-80°, 90. Et2NCH2CHMe: (13) 187°, 93; (14) 203-4°, 38; (15) 165°, 56. Bu2NCH2CH2: (16) 147-9°, 50; (17) 147-9°, 64°; (18) 110-11°, 67. 2-Piperidinoethyl: (19) -, 76; (20) 200-1°, 48; (21) 204-5°, 94. 2-Morpholinoethyl: (22) 232-3°, 84; (23) 191-3°, 31; (24) 201-2°, 79. The m.p. and % yield of the corresponding II derivs., given in the same serial order as above, are: (1) 218°, 97; (2) 113-14°, 61; (3) 124-5°, 95°; (4) 210°, 92; (5) 153°, 97; (6) 111°, 72; (7) 138.5-9.5°, 86; (8) 128°, 90; (9) 85-6°, 95; (10) 148-50°, 96; (11) 149-50°, 40; (12) 108-10°, 33; (13) 144°, 56; (14) 113°, 51; (15) 112-14°, 70; (16) 85-6°, 30; (17) 116°, 74; (18) 114-15°, 46; (19) 168-9°, 95; (20) 163-5°, 65; (21) 147-8°, 96; (22) 163-5°, 44; (23) 163-5°, 37; (24) 185°, 93. Also prepared from II (R = Et2NCH2CH2): II.MeI, 132°, 85; II.EtI, 136°, 55; and II.PhCH2Br, 155-6°, 52.

IT 806647-73-4, Ammonium, benzyldiethyl[3-(p-phenethylphenoxy)propyl]-857164-20-6, Ammonium, benzyldiethyl[3-p-styrylphenoxypropyl]-(bromides)

RN 806647-73-4 CAPLUS

CN Benzenemethanaminium, N,N-diethyl-N-[3-[4-(2-phenylethyl)phenoxy]propyl]-(9CI) (CA INDEX NAME)



RN 857164-20-6 CAPLUS

CN Ammonium, benzyldiethyl[3-p-styrylphenoxypropyl]- (5CI) (CA INDEX NAME)



=> LOG HOLD

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	380.74	1200.51
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-43.68	-51.48

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:52:30 ON 10 JUL 2007